<?xml version='1.0' encoding='UTF-8'?>
<?xml-stylesheet type="text/xsl" href="static/xsl/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-11-03T07:36:57Z</responseDate>
  <request verb="ListRecords" metadataPrefix="oai_dc">https://sonar.ch/oai2d</request>
  <ListRecords>
    <record>
      <header>
        <identifier>oai:sonar.ch:5235</identifier>
        <datestamp>2025-10-24T20:14:22Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bellée V</dc:creator>
          <dc:creator>Pais P</dc:creator>
          <dc:creator>Puig Navarro A</dc:creator>
          <dc:creator>Blanc F</dc:creator>
          <dc:creator>Schneider O</dc:creator>
          <dc:creator>Trabelsi K</dc:creator>
          <dc:creator>Veneziano G</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">A method is proposed to measure the photon polarisation parameter   in   transitions using an amplitude analysis of   decays. Simplified models of the   system are used to simulate     and     decays, validate the amplitude analysis method, and demonstrate the feasibility of a measurement of the   parameter irrespective of the model parameters. Similar sensitivities to   are obtained with both the charged and neutral hadronic systems. In the absence of any background and distortion due to experimental effects, the statistical uncertainty expected from an analysis of     decays in an LHCb data set corresponding to an integrated luminosity of 9    is estimated to be 0.009. A similar measurement using     decays in a Belle II data sample corresponding to an integrated luminosity of 5    would lead to a statistical uncertainty of 0.018.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5235</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1140/epjc/s10052-019-7127-3</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31402844</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The European physical journal. C, Particles and fields. - 2019</dc:source>
          <dc:subject xml:lang="en">Physics and Astronomy (miscellaneous)</dc:subject>
          <dc:subject xml:lang="en">Engineering (miscellaneous)</dc:subject>
          <dc:title xml:lang="en">Using an amplitude analysis to measure the photon polarisation in   decays.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5277</identifier>
        <datestamp>2025-10-24T20:14:23Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Okonska A</dc:creator>
          <dc:creator>Bühler S</dc:creator>
          <dc:creator>Rao V</dc:creator>
          <dc:creator>Ronner M</dc:creator>
          <dc:creator>Blijlevens M</dc:creator>
          <dc:creator>van der Meulen-Muileman IH</dc:creator>
          <dc:creator>de Menezes RX</dc:creator>
          <dc:creator>Wipplinger M</dc:creator>
          <dc:creator>Oehl K</dc:creator>
          <dc:creator>Smit EF</dc:creator>
          <dc:creator>Weder W</dc:creator>
          <dc:creator>Stahel RA</dc:creator>
          <dc:creator>Penengo L</dc:creator>
          <dc:creator>van Beusechem VW</dc:creator>
          <dc:creator>Felley-Bosco E</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">Loss of function of BRCA1-associated protein 1 (BAP1) is observed in about 50% of malignant pleural mesothelioma (MPM) cases. The aim of this study was to investigate whether this aspect could be exploited for targeted therapy. A genetically engineered model was established expressing either functional or nonfunctional BAP1, and whole-genome siRNA synthetic lethality screens were performed assessing differentially impaired survival between the two cell lines. The whole-genome siRNA screen unexpectedly revealed 11 hits (FDR &lt; 0.05) that were more cytotoxic to BAP1-proficient cells. Two actionable targets, ribonucleotide reductase (RNR) catalytic subunit M1 (RRM1) and RNR regulatory subunit M2 (RRM2), were validated. In line with the screen results, primary mesothelioma (BAP1 +/-) overexpressing BAP1 C91A (catalytically dead mutant) was more resistant to RNR inhibition, while BAP1 knockdown in the BAP1-proficient cell lines rescued the cells from their vulnerability to RNR depletion. Gemcitabine and hydroxyurea were more cytotoxic in BAP1-proficient cell line-derived spheroids compared with BAP1 deficient. Upregulation of RRM2 upon gemcitabine and hydroxyurea treatment was more profound in BAP1 mut/del cell lines. Increased lethality mediated by RNR inhibition was observed in NCI-H2452 cells reconstituted with BAP1-WT but not with BAP1 C91A. Upregulation of RRM2 in NCI-H2452-BAP1 WT spheroids was modest compared with control or C91A mutant. Together, we found that BAP1 is involved in the regulation of RNR levels during replication stress. Our observations reveal a potential clinical application where BAP1 status could serve as predictive or stratification biomarker for RNR inhibition-based therapy in MPM.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5277</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1158/1535-7163.MCT-19-0356</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31619462</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Molecular cancer therapeutics. - 2020</dc:source>
          <dc:subject xml:lang="en">Cancer Research</dc:subject>
          <dc:subject xml:lang="en">Oncology</dc:subject>
          <dc:title xml:lang="en">Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5312</identifier>
        <datestamp>2025-10-24T20:14:23Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Felley-Bosco E</dc:creator>
          <dc:date>2019</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5312</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3389/fgene.2019.01121</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31788004</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Frontiers in genetics. - 2019</dc:source>
          <dc:subject xml:lang="en">Gli-1 inhibition</dc:subject>
          <dc:subject xml:lang="en">hedgehog inhibition</dc:subject>
          <dc:subject xml:lang="en">hedgehog signaling</dc:subject>
          <dc:subject xml:lang="en">macrophage differentiation</dc:subject>
          <dc:subject xml:lang="en">malignant pleural mesothelioma</dc:subject>
          <dc:subject xml:lang="en">personalized medicine</dc:subject>
          <dc:subject xml:lang="en">tumor-stroma cross talk</dc:subject>
          <dc:title xml:lang="en">Hedgehog Signaling in Mesothelioma: 2019 Status.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5387</identifier>
        <datestamp>2025-10-24T20:14:25Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Martin-Isla C</dc:creator>
          <dc:creator>Campello VM</dc:creator>
          <dc:creator>Izquierdo C</dc:creator>
          <dc:creator>Raisi-Estabragh Z</dc:creator>
          <dc:creator>Baeßler B</dc:creator>
          <dc:creator>Petersen SE</dc:creator>
          <dc:creator>Lekadir K</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">Cardiac imaging plays an important role in the diagnosis of cardiovascular disease (CVD). Until now, its role has been limited to visual and quantitative assessment of cardiac structure and function. However, with the advent of big data and machine learning, new opportunities are emerging to build artificial intelligence tools that will directly assist the clinician in the diagnosis of CVDs. This paper presents a thorough review of recent works in this field and provide the reader with a detailed presentation of the machine learning methods that can be further exploited to enable more automated, precise and early diagnosis of most CVDs.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5387</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3389/fcvm.2020.00001</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32039241</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Frontiers in cardiovascular medicine. - 2020</dc:source>
          <dc:subject xml:lang="en">artificial intelligence</dc:subject>
          <dc:subject xml:lang="en">automated diagnosis</dc:subject>
          <dc:subject xml:lang="en">cardiac imaging</dc:subject>
          <dc:subject xml:lang="en">cardiovascular disease</dc:subject>
          <dc:subject xml:lang="en">deep learning</dc:subject>
          <dc:subject xml:lang="en">machine learning</dc:subject>
          <dc:subject xml:lang="en">radiomics</dc:subject>
          <dc:title xml:lang="en">Image-Based Cardiac Diagnosis With Machine Learning: A Review.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:4967</identifier>
        <datestamp>2025-10-24T20:14:26Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kishore S</dc:creator>
          <dc:creator>Jaskiewicz L</dc:creator>
          <dc:creator>Burger L</dc:creator>
          <dc:creator>Hausser J</dc:creator>
          <dc:creator>Khorshid M</dc:creator>
          <dc:creator>Zavolan M</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/4967</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/nmeth.1608</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21572407</dc:relation>
          <dc:source>Nature methods. - 2011</dc:source>
          <dc:subject xml:lang="en">Binding Sites</dc:subject>
          <dc:subject xml:lang="en">Cross-Linking Reagents</dc:subject>
          <dc:subject xml:lang="en">Immunoprecipitation</dc:subject>
          <dc:subject xml:lang="en">RNA-Binding Proteins</dc:subject>
          <dc:title xml:lang="en">A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:4995</identifier>
        <datestamp>2025-10-24T20:14:29Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Abel S</dc:creator>
          <dc:creator>Chien P</dc:creator>
          <dc:creator>Wassmann P</dc:creator>
          <dc:creator>Schirmer T</dc:creator>
          <dc:creator>Kaever V</dc:creator>
          <dc:creator>Laub MT</dc:creator>
          <dc:creator>Baker TA</dc:creator>
          <dc:creator>Jenal U</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">In Caulobacter crescentus, phosphorylation of key regulators is coordinated with the second messenger cyclic di-GMP to drive cell-cycle progression and differentiation. The diguanylate cyclase PleD directs pole morphogenesis, while the c-di-GMP effector PopA initiates degradation of the replication inhibitor CtrA by the AAA+ protease ClpXP to license S phase entry. Here, we establish a direct link between PleD and PopA reliant on the phosphodiesterase PdeA and the diguanylate cyclase DgcB. PdeA antagonizes DgcB activity until the G1-S transition, when PdeA is degraded by the ClpXP protease. The unopposed DgcB activity, together with PleD activation, upshifts c-di-GMP to drive PopA-dependent CtrA degradation and S phase entry. PdeA degradation requires CpdR, a response regulator that delivers PdeA to the ClpXP protease in a phosphorylation-dependent manner. Thus, CpdR serves as a crucial link between phosphorylation pathways and c-di-GMP metabolism to mediate protein degradation events that irreversibly and coordinately drive bacterial cell-cycle progression and development.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/4995</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.molcel.2011.07.018</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21855795</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Molecular cell. - 2011</dc:source>
          <dc:subject xml:lang="en">Bacterial Proteins</dc:subject>
          <dc:subject xml:lang="en">Caulobacter crescentus</dc:subject>
          <dc:subject xml:lang="en">Cell Cycle</dc:subject>
          <dc:subject xml:lang="en">Cell Polarity</dc:subject>
          <dc:subject xml:lang="en">Models, Biological</dc:subject>
          <dc:subject xml:lang="en">Phosphoric Diester Hydrolases</dc:subject>
          <dc:subject xml:lang="en">Phosphorylation</dc:subject>
          <dc:subject xml:lang="en">Second Messenger Systems</dc:subject>
          <dc:title xml:lang="en">Regulatory cohesion of cell cycle and cell differentiation through interlinked phosphorylation and second messenger networks.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5008</identifier>
        <datestamp>2025-10-24T20:14:30Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kossowsky J</dc:creator>
          <dc:creator>Wilhelm FH</dc:creator>
          <dc:creator>Roth WT</dc:creator>
          <dc:creator>Schneider S</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Separation anxiety disorder (SAD) is one of the most common anxiety disorders in childhood and is predictive of adult anxiety disorders, especially panic disorder. However, the disorder has seldom been studied and the attempt to distinguish SAD from other anxiety disorders with regard to psychophysiology has not been made. We expected exaggerated anxiety as well as sympathetic and respiratory reactivity in SAD during separation from the mother.


METHOD
Participants were 49 children with a principal diagnosis of SAD, 21 clinical controls (CC) with a principal diagnosis of anxiety disorder other than SAD, and 39 healthy controls (HC) not meeting criteria for any current diagnosis. Analyses of covariance controlling for age were used to assess sympathetic and parasympathetic activation (preejection period and respiratory sinus arrhythmia) as well as cardiovascular (heart rate, mean arterial pressure, total peripheral resistance), respiratory (total breath time, minute ventilation, tidal volume, end-tidal CO(2) , respiratory variability), electrodermal, and self-report (anxiety, cognitions, symptoms) variables during baseline, 4-min separation from, and reunion with the mother.


RESULTS
Children with a diagnosis of SAD were characterized by elevated self-reported anxiety responses to separation and increased sympathetic reactivity compared with CC and HC groups. The SAD group also displayed greater vagal withdrawal and higher reactivity in multiple cardiovascular, respiratory, and electrodermal measures compared with the HC group, while corresponding responses were less in the CC group and not significantly different from the other groups.


CONCLUSIONS
Separation from the mother elicits greater autonomic, respiratory, and experiential responses in children with SAD. Our findings based on brief experimental separation demonstrate differential subjective and physiological manifestations of specific anxiety diagnoses, thus supporting the validity of the diagnostic category of SAD.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5008</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1469-7610.2011.02465.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21923807</dc:relation>
          <dc:source>Journal of child psychology and psychiatry, and allied disciplines. - 2012</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Anxiety Disorders</dc:subject>
          <dc:subject xml:lang="en">Anxiety, Separation</dc:subject>
          <dc:subject xml:lang="en">Autonomic Nervous System</dc:subject>
          <dc:subject xml:lang="en">Blood Pressure</dc:subject>
          <dc:subject xml:lang="en">Capnography</dc:subject>
          <dc:subject xml:lang="en">Child</dc:subject>
          <dc:subject xml:lang="en">Child, Preschool</dc:subject>
          <dc:subject xml:lang="en">Electrocardiography</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Galvanic Skin Response</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Mothers</dc:subject>
          <dc:subject xml:lang="en">Psychiatric Status Rating Scales</dc:subject>
          <dc:subject xml:lang="en">Respiration</dc:subject>
          <dc:subject xml:lang="en">Self Report</dc:subject>
          <dc:subject xml:lang="en">Stress, Psychological</dc:subject>
          <dc:title xml:lang="en">Separation anxiety disorder in children: disorder-specific responses to experimental separation from the mother.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5014</identifier>
        <datestamp>2025-10-24T20:14:31Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Flicker F</dc:creator>
          <dc:creator>Betz G</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">UNLABELLED
The aim of this study was to develop a high-dose tablet formulation of the poorly soluble carbamazepine (CBZ) with sufficient tablet hardness and immediate drug release. A further aim was to investigate the influence of various commercial CBZ raw materials on the optimized tablet formulation.


MATERIALS AND METHODS
Hydroxypropyl cellulose (HPC-SL) was selected as a dry binder and crospovidone (CrosPVP) as a superdisintegrant. A direct compacted tablet formulation of 70% CBZ was optimized by a 3² full factorial design with two input variables, HPC (0--10%) and CrosPVP (0--5%). Response variables included disintegration time, amount of drug released at 15 and 60 min, and tablet hardness, all analyzed according to USP 31.


RESULTS AND DISCUSSION
Increasing HPC-SL together with CrosPVP not only increased tablet hardness but also reduced disintegration time. Optimal condition was achieved in the range of 5--9% HPC and 3--5% CrosPVP, where tablet properties were at least 70 N tablet hardness, less than 1 min disintegration, and within the USP requirements for drug release. Testing the optimized formulation with four different commercial CBZ samples, their variability was still observed. Nonetheless, all formulations conformed to the USP specifications.


CONCLUSIONS
With the excipients CrosPVP and HPC-SL an immediate release tablet formulation was successfully formulated for high-dose CBZ of various commercial sources.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5014</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3109/03639045.2011.623166</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22010838</dc:relation>
          <dc:source>Drug development and industrial pharmacy. - 2012</dc:source>
          <dc:subject xml:lang="en">Analysis of Variance</dc:subject>
          <dc:subject xml:lang="en">Anticonvulsants</dc:subject>
          <dc:subject xml:lang="en">Carbamazepine</dc:subject>
          <dc:subject xml:lang="en">Cellulose</dc:subject>
          <dc:subject xml:lang="en">Excipients</dc:subject>
          <dc:subject xml:lang="en">Hardness</dc:subject>
          <dc:subject xml:lang="en">Particle Size</dc:subject>
          <dc:subject xml:lang="en">Povidone</dc:subject>
          <dc:subject xml:lang="en">Solubility</dc:subject>
          <dc:subject xml:lang="en">Tablets</dc:subject>
          <dc:title xml:lang="en">Effect of crospovidone and hydroxypropyl cellulose on carbamazepine in high-dose tablet formulation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5016</identifier>
        <datestamp>2025-10-24T20:14:31Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Scherer K</dc:creator>
          <dc:creator>Schindler C</dc:creator>
          <dc:creator>Arnold A</dc:creator>
          <dc:creator>Bach S</dc:creator>
          <dc:creator>Bircher AJ</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">Systemic reactions to subcutaneous immunotherapy occur despite all necessary precautions and experienced staff and should prompt a search for causative factors. We present an analysis of 11 reactions, 8 of them within a short period. The patients and reactions were evaluated regarding extract errors (composition, concentration), dosing errors, ignored contraindications to specific subcutaneous immunotherapy, introductions versus maintenance phase and accidental intravascular injection. No single or common cause could be identified. Statistical analysis suggests that exceptional clusters of systemic reactions such as these may be just random cumulations without identifiable cause.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5016</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1159/000328753</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22056648</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>International archives of allergy and immunology. - 2012</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Allergens</dc:subject>
          <dc:subject xml:lang="en">Desensitization, Immunologic</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypersensitivity, Immediate</dc:subject>
          <dc:subject xml:lang="en">Injections, Subcutaneous</dc:subject>
          <dc:subject xml:lang="en">Logistic Models</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Plant Extracts</dc:subject>
          <dc:subject xml:lang="en">Respiratory Hypersensitivity</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Vaccines</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Analysis of an unusual cluster of systemic reactions to subcutaneous specific immunotherapy with respiratory allergens in one allergy center.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5020</identifier>
        <datestamp>2025-10-24T20:14:32Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Brand Y</dc:creator>
          <dc:creator>Setz C</dc:creator>
          <dc:creator>Levano S</dc:creator>
          <dc:creator>Listyo A</dc:creator>
          <dc:creator>Chavez E</dc:creator>
          <dc:creator>Pak K</dc:creator>
          <dc:creator>Sung M</dc:creator>
          <dc:creator>Radojevic V</dc:creator>
          <dc:creator>Ryan AF</dc:creator>
          <dc:creator>Bodmer D</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, known as statins, are commonly used as cholesterol-lowering drugs. During the past decade, evidence has emerged that statins also have neuroprotective effects. Research in the retina has shown that simvastatin, a commonly used statin, increases Akt phosphorylation in vivo, indicating that the PI3K/Akt pathway contributes to the protective effects achieved. While research about neuroprotective effects have been conducted in several systems, the effects of statins on the inner ear are largely unknown.


RESULTS
We evaluated whether the 3-hydroxy-3-methylglutaryl-coenzyme A reductase is present within the rat cochlea and whether simvastatin is able to protect auditory hair cells from gentamicin-induced apoptotic cell death in a in vitro mouse model. Furthermore, we evaluated whether simvastatin increases Akt phosphorylation in the organ of Corti. We detected 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in organ of Corti, spiral ganglion, and stria vascularis by reverse transcriptase-polymerase chain reaction (RT-PCR). Moreover, we observed a dose-dependent and significant reduction of hair cell loss in organs of Corti treated with simvastatin in addition to gentamicin, as compared to samples treated with gentamicin alone. The protective effect of simvastatin was reversed by addition of mevalonate, a downstream metabolite blocked by simvastatin, demonstrating the specificity of protection. Finally, Western blotting showed an increase in organ of Corti Akt phosphorylation after simvastatin treatment in vitro.


CONCLUSION
These results suggest a neuroprotective effect of statins in the inner ear, mediated by reduced 3-hydroxy-3-methylglutaryl-coenzyme A reductase metabolism and Akt activation.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5020</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2202-12-114</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22082490</dc:relation>
          <dc:source>BMC neuroscience. - 2011</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Animals, Newborn</dc:subject>
          <dc:subject xml:lang="en">Disease Models, Animal</dc:subject>
          <dc:subject xml:lang="en">Gentamicins</dc:subject>
          <dc:subject xml:lang="en">Hair Cells, Auditory</dc:subject>
          <dc:subject xml:lang="en">Hearing Loss, Sensorineural</dc:subject>
          <dc:subject xml:lang="en">Hydroxymethylglutaryl-CoA Reductase Inhibitors</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Transgenic</dc:subject>
          <dc:subject xml:lang="en">Nerve Degeneration</dc:subject>
          <dc:subject xml:lang="en">Neuroprotective Agents</dc:subject>
          <dc:subject xml:lang="en">Primary Cell Culture</dc:subject>
          <dc:subject xml:lang="en">Proto-Oncogene Proteins c-akt</dc:subject>
          <dc:subject xml:lang="en">Rats</dc:subject>
          <dc:subject xml:lang="en">Rats, Wistar</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:subject xml:lang="en">Simvastatin</dc:subject>
          <dc:title xml:lang="en">Simvastatin protects auditory hair cells from gentamicin-induced toxicity and activates Akt signaling in vitro.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5038</identifier>
        <datestamp>2025-10-24T20:14:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kind F</dc:creator>
          <dc:creator>Scherer K</dc:creator>
          <dc:creator>Bircher AJ</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">BACKGROUND
The increased frequency of case reports of allergic contact dermatitis from non-permanent black henna tattoos in recent years shows the popularity of this form of body painting.


PATIENTS AND METHODS
Seven patients presented with allergic contact dermatitis after initial hair or eyelash dyeing. They all had a history of a previous reaction from a black henna tattoo. All were patch tested with the European standard patch test series and the standard supplemental series, as well as special series for dyes and hairdressers.


RESULTS
All seven patients showed a positive reaction in patch testing with para-phenylenediamine (PPD) (0.3 % and/or 1.0 % in pet.). Five patients also had positive reactions to other dyes such as aminophenol, para-toluene diamine, disperse orange and yellow and four patients reacted to benzocaine. These were interpreted as cross-reactions. The time from sensitization by the black henna tattoo to the onset of allergic contact dermatitis after hair dyeing was an average of 6.2 years.


CONCLUSIONS
The most common cause of allergic contact dermatitis after black henna tattoos is PPD. Both the long skin contact and the high concentrations of PPD increase the risk of sensitization. Allergic contact dermatitis may be followed by post-inflammatory hyper- or hypopigmentation, scarring and lifelong sensitization, which can have occupational impact, especially for hair dressers and cosmeticians.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5038</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1610-0387.2011.07882.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22299643</dc:relation>
          <dc:source>Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. - 2012</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Dermatitis, Allergic Contact</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Hair Dyes</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Naphthoquinones</dc:subject>
          <dc:subject xml:lang="en">Phenylenediamines</dc:subject>
          <dc:subject xml:lang="en">Tattooing</dc:subject>
          <dc:title xml:lang="en">Contact dermatitis to para-phenylenediamine in hair dye following sensitization to black henna tattoos - an ongoing problem.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5068</identifier>
        <datestamp>2025-10-24T20:14:37Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Broz P</dc:creator>
          <dc:creator>Jaeger KA</dc:creator>
          <dc:date>2012</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/5068</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1177/1358863X12442265</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22556152</dc:relation>
          <dc:source>Vascular medicine (London, England). - 2012</dc:source>
          <dc:subject xml:lang="en">Fingers</dc:subject>
          <dc:subject xml:lang="en">Gangrene</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Marijuana Smoking</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:subject xml:lang="en">Smoking</dc:subject>
          <dc:subject xml:lang="en">Thromboangiitis Obliterans</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">Vasodilator Agents</dc:subject>
          <dc:subject xml:lang="en">Wound Healing</dc:subject>
          <dc:title xml:lang="en">Images in vascular medicine. Buerger's disease.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5069</identifier>
        <datestamp>2025-10-24T20:14:37Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Hynes NE</dc:creator>
          <dc:creator>Smirnova T</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">Ling and colleagues demonstrated that loss of the conditional 14-3-3σ allele results in accelerated HER2/ERBB2-driven mammary tumorigenesis and metastasis. This study underscores the role of 14-3-3σ as a potent tumor suppressor in ERBB2-driven tumor initiation and progression.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5069</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1158/2159-8290.CD-11-0317</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22585164</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Cancer discovery. - 2012</dc:source>
          <dc:subject xml:lang="en">14-3-3 Proteins</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Mammary Neoplasms, Experimental</dc:subject>
          <dc:subject xml:lang="en">Receptor, ErbB-2</dc:subject>
          <dc:title xml:lang="en">The 14-3-3σ tumor suppressor has multiple functions in ErbB2-induced breast cancer.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5026</identifier>
        <datestamp>2025-10-24T20:14:40Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gaillard RC</dc:creator>
          <dc:creator>Abeywickrama K</dc:creator>
          <dc:creator>Brownell J</dc:creator>
          <dc:creator>Muller AF</dc:creator>
          <dc:date>1989</dc:date>
          <dc:description xml:lang="en">CV 205-502, an octahydrobenzo[g]quinoline, is a dopamine agonist compound that is not an ergot or ergoline derivative. To investigate the site of action of CV 205-502, three groups of five men were given single daily doses of CV 205-502 (0.04, 0.06, or 0.08 mg/day, doses that suppress plasma PRL by 60-80% for 24 h) for 5 days; on day 6 a combined anterior pituitary function test using iv administration of four hypothalamic releasing hormones (TRH, 200 micrograms; GHRH, 100 micrograms; CRH, 100 micrograms; LHRH, 100 micrograms) was performed. One month later the challenge tests were repeated to obtain control values. The following hormones were measured by RIA in plasma: TSH, ACTH, cortisol, PRL, GH, LH, FSH, and testosterone. With the exception of plasma PRL levels, basal and releasing hormone-stimulated values were similar after CV 205-502 administration and after the 1-month washout period. Basal plasma PRL was lower after CV 205-502 administration, and the response to TRH was attenuated by all three doses of CV 205-502 (the mean percent inhibition values were 76%, 93%, and 94%, respectively). All three doses of CV 205-502 were well tolerated, and another group of men well tolerated 0.1 mg daily. The results confirm that CV 205-502 is a potent dopamine agonist, which directly inhibits lactotropic cells but has no effect on other pituitary cell types.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5026</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1210/jcem-68-2-329</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/2563733</dc:relation>
          <dc:source>The Journal of clinical endocrinology and metabolism. - 1989</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aminoquinolines</dc:subject>
          <dc:subject xml:lang="en">Binding Sites</dc:subject>
          <dc:subject xml:lang="en">Corticotropin-Releasing Hormone</dc:subject>
          <dc:subject xml:lang="en">Dopamine Agents</dc:subject>
          <dc:subject xml:lang="en">Dose-Response Relationship, Drug</dc:subject>
          <dc:subject xml:lang="en">Gonadotropin-Releasing Hormone</dc:subject>
          <dc:subject xml:lang="en">Growth Hormone-Releasing Hormone</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypothalamus</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Pituitary Function Tests</dc:subject>
          <dc:subject xml:lang="en">Pituitary Gland, Anterior</dc:subject>
          <dc:subject xml:lang="en">Pituitary Hormones, Anterior</dc:subject>
          <dc:subject xml:lang="en">Prolactin</dc:subject>
          <dc:subject xml:lang="en">Receptors, Dopamine</dc:subject>
          <dc:subject xml:lang="en">Testosterone</dc:subject>
          <dc:subject xml:lang="en">Thyrotropin-Releasing Hormone</dc:subject>
          <dc:title xml:lang="en">Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5059</identifier>
        <datestamp>2025-10-24T20:14:45Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Golaz O</dc:creator>
          <dc:creator>Sanchez JC</dc:creator>
          <dc:creator>James RW</dc:creator>
          <dc:creator>Hochstrasser DF</dc:creator>
          <dc:date>1995</dc:date>
          <dc:description xml:lang="en">Apolipoprotein E (apo E) is a normal component of several classes of plasma lipoproteins. Apo E phenotypes are closely related to total cholesterol, low density lipoprotein (LDL)-cholesterol and apo B concentration. The apo E 2/2 phenotype is related to the type III hyperlipoproteinemia due to the defective binding of apo E-2 to the hepatic receptors. The apo E 4/4 phenotype has been reported to be present in most elderly people suffering from the Alzheimer disease, and is associated with increased risk of coronary heart disease and Creutzfeld-Jakob disease. Therefore, apo E phenotyping is essential. The method described here uses a precast immobilized pH gradient, avoids time-consuming separation of lipoproteins from plasma, needs no pretreatment with neuraminidase and involves highly sensitive enhanced chemiluminescence for visualization. Therefore it has many advantages over previously published methods.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5059</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/elps.11501601196</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/7498163</dc:relation>
          <dc:source>Electrophoresis. - 1995</dc:source>
          <dc:subject xml:lang="en">Apolipoproteins E</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Gel, Two-Dimensional</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Polyacrylamide Gel</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hydrogen-Ion Concentration</dc:subject>
          <dc:subject xml:lang="en">Phenotype</dc:subject>
          <dc:title xml:lang="en">Phenotyping of apolipoprotein E using immobilized pH gradient gels for one-dimensional and two-dimensional separations.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5072</identifier>
        <datestamp>2025-10-24T20:14:49Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Imbach P</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">Since 1946 the development of fractionation and purification methods of human plasma led to biologic immunoglobulin for intravenous use (IVIG). In 1980 a child with refractory immune thrombocytopenia (ITP), bleeding and secondary hypogammaglobulinaemia due to long term immunosuppressive treatment got IVIG. His platelet counts dramatically increased. In 13 consecutive children with ITP, but without hypogammaglobulinaemia, similar rapid platelet increases were observed and confirmed in a controlled, multicentre study. During the past three decades this biologic treatment modality evoked clinical and laboratory research on the mechanisms of action and in disorders with similar immune pathogenesis. It was recognised that IVIG modulates the disturbed immune response in multiple, synergistic ways between the different components of the immune system. Beside other immune hematologic disorders other inflammatory and autoimmune diseases, mainly in the field of neurology and dermatology, IVIG showed beneficial effects. The worldwide consumption of IVIG increased from 300 kg per year in 1980 to 100 tonnes per year in 2010. Due to the heterogeneity of immunopathological mechanisms of autoimmune diseases evidence based indications of IVIG remain rare and off label use high. Registries of large numbers of patients and first endpoints of defining less heterogenous subgroups in immune related disorders are the next steps toward establishment of evidence based IVIG indications.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5072</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2012.13593</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22653800</dc:relation>
          <dc:source>Swiss medical weekly. - 2012</dc:source>
          <dc:subject xml:lang="en">Autoimmune Diseases</dc:subject>
          <dc:subject xml:lang="en">History, 20th Century</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunoglobulins, Intravenous</dc:subject>
          <dc:subject xml:lang="en">Purpura, Thrombocytopenic, Idiopathic</dc:subject>
          <dc:title xml:lang="en">Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5090</identifier>
        <datestamp>2025-10-24T20:14:52Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kantengwa S</dc:creator>
          <dc:creator>Müller I</dc:creator>
          <dc:creator>Louis J</dc:creator>
          <dc:creator>Polla BS</dc:creator>
          <dc:date>1995</dc:date>
          <dc:description xml:lang="en">Heat shock/stress proteins (HSP) represent the most conserved proteins expressed in prokaryotes and eukaryotes. These constitutive and inducible proteins function as molecular chaperones and are part of virulence factors. They participate in self/non-self discrimination and may protect phagocytes from the toxic effects of the reactive oxygen species generated by these cells during bacterial phagocytosis and infection. In this study, we investigated the early stress response of host cells [either human alveolar macrophages (AM) or murine peritoneal macrophages (PM)] during infection by an obligate intracellular parasite (Leishmania major), which lives within phagolysosomes. Immunoblotting with specific antibodies demonstrated that L. major had no effect on host stress protein synthesis, but synthesized high levels of its own stress proteins within AM and PM. The lack of induction of a host cell stress response may relate to the failure of L. major to activate the respiratory burst in these cells, whereas the upshift of L. major HSP within macrophages is part of an adaptive response of the parasite to the host.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5090</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/icb.1995.12</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/7768547</dc:relation>
          <dc:source>Immunology and cell biology. - 1995</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Heat-Shock Proteins</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Interferon-gamma</dc:subject>
          <dc:subject xml:lang="en">Leishmania major</dc:subject>
          <dc:subject xml:lang="en">Macrophages</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred BALB C</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred DBA</dc:subject>
          <dc:subject xml:lang="en">Protozoan Proteins</dc:subject>
          <dc:subject xml:lang="en">Superoxides</dc:subject>
          <dc:title xml:lang="en">Infection of human and murine macrophages with Leishmania major is associated with early parasite heat shock protein synthesis but fails to induce a host cell stress response.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5093</identifier>
        <datestamp>2025-10-24T20:14:52Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Marti MC</dc:creator>
          <dc:creator>Roche B</dc:creator>
          <dc:creator>Gumener RG</dc:creator>
          <dc:date>1994</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/5093</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/bf00290195</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/7814992</dc:relation>
          <dc:source>International journal of colorectal disease. - 1994</dc:source>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Perineum</dc:subject>
          <dc:subject xml:lang="en">Surgical Flaps</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Skin cover of perineal defects using V-Y flaps.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5105</identifier>
        <datestamp>2025-10-24T20:14:55Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kahlen JP</dc:creator>
          <dc:creator>Carlberg C</dc:creator>
          <dc:date>1994</dc:date>
          <dc:description xml:lang="en">Calcitriol (1,25-dihydroxyvitamin D3, VD) controls multiple aspects of homeostasis, cell growth and differentiation by the action of its nuclear receptor (VDR), which binds to, and activates transcription from, response elements in the promoter region of its target genes. One of these target genes is calcitriol 24-hydroxylase, an enzyme that initiates the degradation of 25-dihydroxyvitamin D3 (calcidiol) and calcitriol. We screened the promoter of rat calcitriol 24-hydroxylase for potential VDR binding sites and identified a functional VD response element, between positions -250 and -233. This response element consists of two directly repeated hexameric core binding motifs spaced by six nucleotides and confers VD-dependent transactivation mediated by VDR homodimers or alternatively by heterodimers formed by VDR and retinoic acid receptor (RAR). Its structure and function are very similar to those of the homodimer-type response element of the human osteocalcin promoter.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5105</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1006/bbrc.1994.2081</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/8060315</dc:relation>
          <dc:source>Biochemical and biophysical research communications. - 1994</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Base Sequence</dc:subject>
          <dc:subject xml:lang="en">Binding Sites</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Cytochrome P-450 Enzyme System</dc:subject>
          <dc:subject xml:lang="en">Drosophila</dc:subject>
          <dc:subject xml:lang="en">Molecular Sequence Data</dc:subject>
          <dc:subject xml:lang="en">Oligodeoxyribonucleotides</dc:subject>
          <dc:subject xml:lang="en">Promoter Regions, Genetic</dc:subject>
          <dc:subject xml:lang="en">Rats</dc:subject>
          <dc:subject xml:lang="en">Receptors, Calcitriol</dc:subject>
          <dc:subject xml:lang="en">Sequence Alignment</dc:subject>
          <dc:subject xml:lang="en">Steroid Hydroxylases</dc:subject>
          <dc:subject xml:lang="en">Tumor Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Vitamin D3 24-Hydroxylase</dc:subject>
          <dc:title xml:lang="en">Identification of a vitamin D receptor homodimer-type response element in the rat calcitriol 24-hydroxylase gene promoter.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5116</identifier>
        <datestamp>2025-10-24T20:14:56Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Brosi R</dc:creator>
          <dc:creator>Gröning K</dc:creator>
          <dc:creator>Behrens SE</dc:creator>
          <dc:creator>Lührmann R</dc:creator>
          <dc:creator>Krämer A</dc:creator>
          <dc:date>1993</dc:date>
          <dc:description xml:lang="en">In the assembly of a prespliceosome, U2 small nuclear ribonucleoprotein (snRNP) functions in pre-messenger RNA (mRNA) splicing together with splicing factors (SFs) 3a, SF3b, and several other proteins. The 17S but not the 12S form of U2 snRNP is active in splicing-complex formation. Here it is shown that the SF3a subunits correspond to three of the 17S U2 snRNP-specific polypeptides. SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome. Furthermore, the 60-kilodalton subunit of SF3a is related to the yeast splicing protein PRP9.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5116</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1126/science.8211112</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/8211112</dc:relation>
          <dc:source>Science (New York, N.Y.). - 1993</dc:source>
          <dc:subject xml:lang="en">Adenosine Triphosphate</dc:subject>
          <dc:subject xml:lang="en">Cross Reactions</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Polyacrylamide Gel</dc:subject>
          <dc:subject xml:lang="en">Fungal Proteins</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Nuclear Proteins</dc:subject>
          <dc:subject xml:lang="en">RNA Splicing</dc:subject>
          <dc:subject xml:lang="en">RNA Splicing Factors</dc:subject>
          <dc:subject xml:lang="en">RNA-Binding Proteins</dc:subject>
          <dc:subject xml:lang="en">Ribonucleoprotein, U2 Small Nuclear</dc:subject>
          <dc:subject xml:lang="en">Saccharomyces cerevisiae Proteins</dc:subject>
          <dc:subject xml:lang="en">Spliceosomes</dc:subject>
          <dc:title xml:lang="en">Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast PRP9.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5137</identifier>
        <datestamp>2025-10-24T20:14:59Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kiss JZ</dc:creator>
          <dc:creator>Wang C</dc:creator>
          <dc:creator>Rougon G</dc:creator>
          <dc:date>1993</dc:date>
          <dc:description xml:lang="en">The adult hypothalamo-neurohypophysial system of the rat retains the capacity to express highly polysialylated isoforms of neural cell adhesion molecule normally expressed in developing tissues. Here we report that the expression of these isoforms in neurohypophysial astrocytes (pituicytes) may be regulated by neurosecretory cells. In the intact neurohypophysis a strong and homogeneously distributed immunostaining for the "embryonic", highly sialylated form of neural cell adhesion molecules was detected by light-microscopic immunocytochemistry. By electron-microscopy, both neurosecretory axons and pituicytes were immunoreactive for this isoform. However, in contrast to the rather uniform staining on nerve fibres, polysialic acid immunolabelling on glial surfaces was uneven: immunostaining could be observed on glial surfaces facing neuronal elements, but not at contact sites between pituicytes. In addition, most glial and neuronal elements were heavily and evenly labelled with the polyclonal antibody recognizing "total" neural cell adhesion molecule. Surgical transection of the hypophysial stalk, a procedure that eliminates descending neurosecretory axons from the neurohypophysis, resulted in the complete disappearance of polysialic immunoreactivity from the neurohypophysis. The electron-microscopic analysis confirmed that cell surfaces of pituicytes lacked this immunoreactivity after the lesion. When residual neurosecretory axons were observed following an incomplete lesion, immunoreactivity on axons and glial processes was maintained. Transection did not affect the distribution of "total" neural cell adhesion molecule. We postulate that the presence of neurosecretory axons in the neurohypophysis is necessary to maintain the capacity of pituicytes to express immunoreactivity for the polysialylated isoforms of neural cell adhesion molecule but not the neural cell adhesion molecule itself since immunoreactivity for "total" neural cell adhesion molecule was unaltered after hypophysial stalk transection.(ABSTRACT TRUNCATED AT 250 WORDS)</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5137</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/0306-4522(93)90299-u</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/8469308</dc:relation>
          <dc:source>Neuroscience. - 1993</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Astrocytes</dc:subject>
          <dc:subject xml:lang="en">Axons</dc:subject>
          <dc:subject xml:lang="en">Cell Adhesion Molecules, Neuronal</dc:subject>
          <dc:subject xml:lang="en">Immunohistochemistry</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Microscopy, Immunoelectron</dc:subject>
          <dc:subject xml:lang="en">Neuronal Plasticity</dc:subject>
          <dc:subject xml:lang="en">Pituitary Gland</dc:subject>
          <dc:subject xml:lang="en">Pituitary Gland, Posterior</dc:subject>
          <dc:subject xml:lang="en">Rats</dc:subject>
          <dc:subject xml:lang="en">Rats, Sprague-Dawley</dc:subject>
          <dc:subject xml:lang="en">Sialic Acids</dc:subject>
          <dc:title xml:lang="en">Nerve-dependent expression of high polysialic acid neural cell adhesion molecule in neurohypophysial astrocytes of adult rats.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5144</identifier>
        <datestamp>2025-10-24T20:15:01Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Galetto-Lacour A</dc:creator>
          <dc:creator>Yerly S</dc:creator>
          <dc:creator>Perneger TV</dc:creator>
          <dc:creator>Baumberger C</dc:creator>
          <dc:creator>Hirschel B</dc:creator>
          <dc:creator>Perrin L</dc:creator>
          <dc:date>1996</dc:date>
          <dc:description xml:lang="en">Human immunodeficiency virus (HIV) viremia was evaluated in 73 patients with long-standing infection to investigate its relationship with clinical or biologic parameters and to assess its use as a predictor of clinical progression and death. After adjustment for other parameters, baseline HIV RNA level was significantly associated with baseline clinical stage and CD4 cell count. During follow-up (mean, 14.6 months), 16 patients died; 34 others had clinical progression of disease. In multivariate analysis, mortality was better predicted by baseline CD4 cell count (relative hazard [RH] for 100-cell decrease, 3.5; 95% confidence interval [CI], 1.5-8.2; P = .003) than by HIV RNA (P = .28) or clinical stage. HIV RNA level was the best predictor of clinical progression (RH for 1 log increase, 2.8; 95% CI, 1.6-4.9; P &lt; .001). Monitoring of HIV RNA level may help to identify patients who might benefit from antiretroviral or prophylactic therapy.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5144</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/infdis/173.6.1388</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/8648210</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The Journal of infectious diseases. - 1996</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">CD4 Lymphocyte Count</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Disease Progression</dc:subject>
          <dc:subject xml:lang="en">Disease-Free Survival</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">HIV</dc:subject>
          <dc:subject xml:lang="en">HIV Infections</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Predictive Value of Tests</dc:subject>
          <dc:subject xml:lang="en">Prognosis</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">RNA, Viral</dc:subject>
          <dc:subject xml:lang="en">Viremia</dc:subject>
          <dc:title xml:lang="en">Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5159</identifier>
        <datestamp>2025-10-24T20:15:02Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Golaz O</dc:creator>
          <dc:creator>Wilkins MR</dc:creator>
          <dc:creator>Sanchez JC</dc:creator>
          <dc:creator>Appel RD</dc:creator>
          <dc:creator>Hochstrasser DF</dc:creator>
          <dc:creator>Williams KL</dc:creator>
          <dc:date>1996</dc:date>
          <dc:description xml:lang="en">Expression of different genomes can be studied by high-resolution two-dimensional electrophoresis (2-D PAGE). To help these studies, two-dimensional reference maps of different biological tissues and fluids have been built and can be found in the SWISS-2DPAGE database, accessible via the World Wide Web network on the ExPASy molecular biology server. Different techniques were used to identify the polypeptides. At the present time, the method considered to be the fastest and the most cost-effective is amino acid composition analysis (AAC). Proteins, transferred onto polyvinylidene (PVDF) membranes, were submitted to vapor-phase hydrolysis, derivatized with 9-fluorenylmethyl chloroformate (FMOC) and separated on an ODS-Hypersil column. Identification was obtained by using the program 'AACompIdent' available from ExPASy. In this work, different experimental parameters, such as contamination, reproducibility and accuracy, have been assessed. First, it has been found that a major source of contamination was human keratin. Next, amino acids have been classified into 'reliable' and 'nonreliable'. Accordingly, 'bias' and 'weights' were defined for each amino acid, which could be set in the 'AACompIdent' program. Finally, examples of identification, including the use of Edman degradation sequence tagging, are described.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5159</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/elps.1150170328</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/8740182</dc:relation>
          <dc:source>Electrophoresis. - 1996</dc:source>
          <dc:subject xml:lang="en">Amino Acid Sequence</dc:subject>
          <dc:subject xml:lang="en">Databases, Factual</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Gel, Two-Dimensional</dc:subject>
          <dc:subject xml:lang="en">Evaluation Studies as Topic</dc:subject>
          <dc:subject xml:lang="en">Hydrolysis</dc:subject>
          <dc:subject xml:lang="en">Molecular Sequence Data</dc:subject>
          <dc:subject xml:lang="en">Proteins</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Software</dc:subject>
          <dc:title xml:lang="en">Identification of proteins by their amino acid composition: an evaluation of the method.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5125</identifier>
        <datestamp>2025-10-24T20:15:04Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>François P</dc:creator>
          <dc:creator>Vaudaux P</dc:creator>
          <dc:creator>Lew PD</dc:creator>
          <dc:date>1998</dc:date>
          <dc:description xml:lang="en">Foreign body implants are highly susceptible to microorganism infection. The infectious agents may be of low pathogenicity (such as S. epidermidis) or involve more virulent strains (such as S. aureus). The common denominator for the three main elements that play a role in the physiopathology of such infections (bacteria, neutrophils, and different biomaterials) are host proteins deposited over the surface of the devices immediately after their implantation. These proteins modulate that host cells response but can also promote Staphylococcus adhesion to the biomaterial. Neutrophils and other cells such as fibroblasts adhere to several extracellular matrix proteins such as fibronectin, fibrinogen, collagen, vitronectin, via specific cell surface receptor. The evolution of the technology and the increasing numbers of long-term artificial implants require a better understanding of fundamental mechanisms of foreign body infections to reduce their incidence and optimize their treatment.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5125</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s100169900112</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9451994</dc:relation>
          <dc:source>Annals of vascular surgery. - 1998</dc:source>
          <dc:subject xml:lang="en">Bacterial Adhesion</dc:subject>
          <dc:subject xml:lang="en">Blood Proteins</dc:subject>
          <dc:subject xml:lang="en">Catheterization, Central Venous</dc:subject>
          <dc:subject xml:lang="en">Extracellular Matrix Proteins</dc:subject>
          <dc:subject xml:lang="en">Foreign-Body Reaction</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Neutrophils</dc:subject>
          <dc:subject xml:lang="en">Staphylococcal Infections</dc:subject>
          <dc:title xml:lang="en">Role of plasma and extracellular matrix proteins in the physiopathology of foreign body infections.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5148</identifier>
        <datestamp>2025-10-24T20:15:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Allaz AF</dc:creator>
          <dc:creator>Vannotti M</dc:creator>
          <dc:creator>Desmeules J</dc:creator>
          <dc:creator>Piguet V</dc:creator>
          <dc:creator>Celik Y</dc:creator>
          <dc:creator>Pyroth O</dc:creator>
          <dc:creator>Guez P</dc:creator>
          <dc:creator>Dayer P</dc:creator>
          <dc:date>1998</dc:date>
          <dc:description xml:lang="en">The use of the term "litigation neurosis"--a condition with controversial clinical significance--might correspond to the expression for a difficult physician-patient relationship. The characteristics of patients with a DSM-III-R diagnosis of somatoform pain disorder who had been labeled "litigation neurosis" by their physicians were explored. Among 74 patients referred to a pain clinic, 30% had been labeled litigation neurosis, and among 81 patients referred while claiming disability benefits, 19% had been thus categorized. The attribution of this label was neither correlated to actually being involved in a claim for disability benefits nor to involvement in legal action. Patients who had been designated with litigation neurosis were characterized by a lower educational level, a higher rate of DSM-III-R major depression, and a much higher frequency of personality disorders than patients who were not thus labeled. We postulate that the communication style of patients with this constellation of characteristics, in particular the presence of psychiatric comorbidity, may have engendered a difficult doctor-patient relationship, leading physicians to use the label in the absence of objective evidence of litigation or involvement in legal action. We agree that the inappropriate use of labels such as "litigation neurosis" should be questioned.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5148</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/s0163-8343(97)00127-8</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9582593</dc:relation>
          <dc:source>General hospital psychiatry. - 1998</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Attitude of Health Personnel</dc:subject>
          <dc:subject xml:lang="en">Chi-Square Distribution</dc:subject>
          <dc:subject xml:lang="en">Chronic Disease</dc:subject>
          <dc:subject xml:lang="en">Comorbidity</dc:subject>
          <dc:subject xml:lang="en">Disability Evaluation</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Neurotic Disorders</dc:subject>
          <dc:subject xml:lang="en">Pain</dc:subject>
          <dc:subject xml:lang="en">Personality Disorders</dc:subject>
          <dc:subject xml:lang="en">Physician-Patient Relations</dc:subject>
          <dc:subject xml:lang="en">Prevalence</dc:subject>
          <dc:subject xml:lang="en">Socioeconomic Factors</dc:subject>
          <dc:subject xml:lang="en">Somatoform Disorders</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:subject xml:lang="en">Terminology as Topic</dc:subject>
          <dc:title xml:lang="en">Use of the label "litigation neurosis" in patients with somatoform pain disorder.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5197</identifier>
        <datestamp>2025-10-24T20:15:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Fabre-Jonca N</dc:creator>
          <dc:creator>Viard I</dc:creator>
          <dc:creator>French LE</dc:creator>
          <dc:creator>Masson D</dc:creator>
          <dc:date>1999</dc:date>
          <dc:description xml:lang="en">Microtubules are involved in the positioning and movement of organelles and vesicles and therefore play fundamental roles in cell polarization and differentiation. Their organization and properties are cell-type specific and are controlled by microtubule-associated proteins (MAP). E-MAP-115 (epithelial microtubule-associated protein of 115 kDa) has been identified as a microtubule-stabilizing protein predominantly expressed in epithelial cells. We have used human skin and primary keratinocytes as a model to assess a putative function of E-MAP-115 in stabilizing and reorganizing the microtubule network during epithelial cell differentiation. Immunolabeling of skin sections indicated that E-MAP-115 is predominantly expressed in the suprabasal layers of the normal epidermis and, in agreement with this observation, is relatively abundant in squamous cell carcinomas but barely detectable in basal cell carcinomas. In primary keratinocytes whose terminal differentiation was induced by increasing the Ca2+ concentration of the medium, E-MAP-115 expression significantly increased during the first day, as observed by northern and western blot analysis. Parallel immunofluorescence studies showed an early redistribution of E-MAP-115 from microtubules with a paranuclear localization to cortical microtubules organized in spike-like bundles facing intercellular contacts. This phenomenon is transient and can be reversed by Ca2+ depletion. Treatment of cells with cytoskeleton-active drugs after raising the Ca2+ concentration indicated that E-MAP-115 is associated with a subset of stable microtubules and that the cortical localization of these microtubules is dependent on other microtubules but not on strong interactions with the actin cytoskeleton or the plasma membrane. The mechanism whereby E-MAP-115 would redistribute to and stabilize cortical microtubules used for the polarized transport of vesicles towards the plasma membrane, where important reorganizations take place upon stratification, is discussed.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5197</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1046/j.1523-1747.1999.00500.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9989799</dc:relation>
          <dc:source>The Journal of investigative dermatology. - 1999</dc:source>
          <dc:subject xml:lang="en">Cytochalasin D</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intracellular Fluid</dc:subject>
          <dc:subject xml:lang="en">Keratinocytes</dc:subject>
          <dc:subject xml:lang="en">Microtubule-Associated Proteins</dc:subject>
          <dc:subject xml:lang="en">Skin Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Up-Regulation</dc:subject>
          <dc:title xml:lang="en">Upregulation and redistribution of E-MAP-115 (epithelial microtubule-associated protein of 115 kDa) in terminally differentiating keratinocytes is coincident with the formation of intercellular contacts.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5208</identifier>
        <datestamp>2025-10-24T20:15:13Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Par M</dc:creator>
          <dc:creator>Spanovic N</dc:creator>
          <dc:creator>Tauböck TT</dc:creator>
          <dc:creator>Attin T</dc:creator>
          <dc:creator>Tarle Z</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">Resin composites containing reinforcing inert glass fillers combined with bioactive glass (BG) can aid in the prevention of secondary caries, which is a major cause of failure of contemporary composite restorations. A series of previous studies on experimental resin composites filled with BG 45S5 has demonstrated that methacrylate resin polymerization can be impaired by the addition of unsilanized BG, leading to lower degrees of conversion (DC). In order to distinguish whether the polymerization inhibition is caused by a direct (temperature-independent) effect of BG or an indirect (temperature-dependent) effect of restricted mobility of reactive species, this study used Raman spectroscopy to evaluate the DC values of experimental composites post-cured at 37 °C and 150 °C. The potential of BG to adversely affect DC was highly dependent on the resin system. The highest DC reduction was observed in the resin system based on ethoxylated bisphenol A dimethacrylate (Bis-EMA), followed by bisphenol A glycidyl methacrylate (Bis-GMA). In contrast, the DC for urethane dimethacrylate (UDMA) was not compromised by BG. Increasing the mobility of reactive species by heating at 150 °C showed limited potential for increasing the DC in the Bis-EMA and Bis-GMA resin systems, indicating a direct inhibitory effect of BG on polymerization.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5208</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-019-54035-y</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31754180</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Scientific reports. - 2019</dc:source>
          <dc:subject xml:lang="en">Multidisciplinary</dc:subject>
          <dc:title xml:lang="en">Degree of conversion of experimental resin composites containing bioactive glass 45S5: the effect of post-cure heating.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5182</identifier>
        <datestamp>2025-10-24T20:15:20Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Baeyens V</dc:creator>
          <dc:creator>Varesio E</dc:creator>
          <dc:creator>Veuthey JL</dc:creator>
          <dc:creator>Gurny R</dc:creator>
          <dc:date>1997</dc:date>
          <dc:description xml:lang="en">A selective capillary zone electrophoresis (CZE) microassay was developed for the simultaneous determination of dexamethasone phosphate and its major metabolite, dexamethasone, in tears. The calibration was carried out in the biological matrix with indoprofen as an internal standard which allowed the separation of dexamethasone phosphate and dexamethasone from the tear constituents. The limits of detection and quantification of the assay were 0.5 and 2.0 microg ml(-1), respectively. This quantification method is essential for the in vivo determination of dexamethasone concentration-time profiles in tears after application of the antiinflammatory drug.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5182</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/s0378-4347(96)00494-x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9187404</dc:relation>
          <dc:source>Journal of chromatography. B, Biomedical sciences and applications. - 1997</dc:source>
          <dc:subject xml:lang="en">Administration, Topical</dc:subject>
          <dc:subject xml:lang="en">Anti-Inflammatory Agents</dc:subject>
          <dc:subject xml:lang="en">Dexamethasone</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Capillary</dc:subject>
          <dc:subject xml:lang="en">Glucocorticoids</dc:subject>
          <dc:subject xml:lang="en">Sensitivity and Specificity</dc:subject>
          <dc:subject xml:lang="en">Tears</dc:subject>
          <dc:title xml:lang="en">Determination of dexamethasone in tears by capillary electrophoresis.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5219</identifier>
        <datestamp>2025-10-24T20:15:23Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Barazzone Argiroffo C</dc:creator>
          <dc:creator>Donati YR</dc:creator>
          <dc:creator>Boccard J</dc:creator>
          <dc:creator>Rochat AF</dc:creator>
          <dc:creator>Vesin C</dc:creator>
          <dc:creator>Kan CD</dc:creator>
          <dc:creator>Piguet PF</dc:creator>
          <dc:date>2002</dc:date>
          <dc:description xml:lang="en">Recent studies suggest that apoptosis plays a role in oxygen-induced injury, although the activation pathways and the executioner proteases that lead to cleavage of lung cell proteins and DNA, are not yet identified. We explored previously the tumor necrosis factor/tumor necrosis factor receptor and the Fas/FasL, belonging to the intrinsic pathway, and could not demonstrate any protective effect by interfering with these cell receptors. Lately, it has been shown that interacting with the CD40 system, also known to promote cell death, by administering anti-CD40 ligand (L) antibody was beneficial in several diseases and, in particular, in hyperoxia-induced injury. Using CD40- and CD40L-deficient mice (-/-) as well as administering anti-CD40L antibody, we examined the extent of lung injury in oxygen-breathing mice by several ways (lung weight, histology, inflammatory mediators, and DNA ladder) as well as the mortality. The development of lung injury was similar in wild-type, CD40-/-, CD40L-/-, or in wild-type mice treated with anti-CD40L antibody. Apoptosis was present in all conditions at 72 hours of oxygen exposure. These results show that oxygen-induced injury does not require CD40-CD40L interaction and that apoptosis of lung cells does not involve this pathway.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/5219</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/S0002-9440(10)64350-7</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/11786400</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The American journal of pathology. - 2002</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Antibodies</dc:subject>
          <dc:subject xml:lang="en">Apoptosis</dc:subject>
          <dc:subject xml:lang="en">Bronchoalveolar Lavage Fluid</dc:subject>
          <dc:subject xml:lang="en">CD40 Antigens</dc:subject>
          <dc:subject xml:lang="en">CD40 Ligand</dc:subject>
          <dc:subject xml:lang="en">Cytokines</dc:subject>
          <dc:subject xml:lang="en">Hyperoxia</dc:subject>
          <dc:subject xml:lang="en">Lung</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">Mice, Knockout</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Time Factors</dc:subject>
          <dc:title xml:lang="en">CD40-CD40 ligand disruption does not prevent hyperoxia-induced injury.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5259</identifier>
        <datestamp>2025-10-24T20:15:26Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Loubeyre P</dc:creator>
          <dc:creator>Debard I</dc:creator>
          <dc:creator>Nemoz C</dc:creator>
          <dc:creator>Minh VA</dc:creator>
          <dc:date>2002</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
The main goal of this study was to determine whether in thoracic helical CT for general indications a high opacification of hilar pulmonary vessels could be obtained using a small amount of nonionic contrast medium.


SUBJECTS AND METHODS
Two hundred consecutive patients referred for contrast-enhanced thoracic CT for malignancies or infections prospectively entered the study. They were randomly assigned to one of two simple bolus injection protocols (100 patients in each protocol): 60 mL of a nonionic contrast agent (250 mg I/mL) injected at a 3 mL/sec flow rate, or 80 mL of the same contrast agent injected at a 4 mL/sec flow rate. No saline flush or bolus triggering system was used. Hilar and mediastinal vessel enhancement was qualitatively (using a 4-point scale) and quantitatively (arterial attenuation values) assessed. Perivenous artifacts were also assessed.


RESULTS
No extensive perivenous artifacts were noted. No significant difference was noted regarding pulmonary venous enhancement. Excellent opacification of the pulmonary veins was observed in 66% of patients injected at 3 mL/sec and in 56% of patients injected at 4 mL/sec (p &gt; 0.192). A highly significant difference was noted for pulmonary artery enhancement. Excellent opacification of the pulmonary arteries was noted in 83% of patients injected with a 3mL/sec flow rate and in 61% of patients injected with a 4 mL/sec flow rate (p = 0.001).


CONCLUSION
A high level of opacification of hilar pulmonary vessels, with no major perivenous artifacts, can be obtained with a small amount of nonionic contrast medium using a simple bolus injection.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5259</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.2214/ajr.178.6.1781377</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/12034600</dc:relation>
          <dc:source>AJR. American journal of roentgenology. - 2002</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Contrast Media</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Radiography, Thoracic</dc:subject>
          <dc:subject xml:lang="en">Tomography, X-Ray Computed</dc:subject>
          <dc:title xml:lang="en">High opacification of hilar pulmonary vessels with a small amount of nonionic contrast medium for general thoracic CT: a prospective study.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5237</identifier>
        <datestamp>2025-10-24T20:15:28Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bernasconi L</dc:creator>
          <dc:creator>Şen S</dc:creator>
          <dc:creator>Angerame L</dc:creator>
          <dc:creator>Balyegisawa AP</dc:creator>
          <dc:creator>Hong Yew Hui D</dc:creator>
          <dc:creator>Hotter M</dc:creator>
          <dc:creator>Hsu CY</dc:creator>
          <dc:creator>Ito T</dc:creator>
          <dc:creator>Jörger F</dc:creator>
          <dc:creator>Krassnitzer W</dc:creator>
          <dc:creator>Phillips AT</dc:creator>
          <dc:creator>Li R</dc:creator>
          <dc:creator>Stockley L</dc:creator>
          <dc:creator>Tay F</dc:creator>
          <dc:creator>von Heijne Widlund C</dc:creator>
          <dc:creator>Wan M</dc:creator>
          <dc:creator>Wong C</dc:creator>
          <dc:creator>Yau H</dc:creator>
          <dc:creator>Hiemstra TF</dc:creator>
          <dc:creator>Uresin Y</dc:creator>
          <dc:creator>Senti G</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">BACKGROUND
The progress of electronic health technologies and biobanks holds enormous promise for efficient research. Evidence shows that studies based on sharing and secondary use of data/samples have the potential to significantly advance medical knowledge. However, sharing of such resources for international collaboration is hampered by the lack of clarity about ethical and legal requirements for transfer of data and samples across international borders.


MAIN TEXT
Here, the International Clinical Trial Center Network (ICN) reports the legal and ethical requirements governing data and sample exchange (DSE) across four continents. The most recurring requirement is ethical approval, whereas only in specific conditions approval of national health authorities is required. Informed consent is not required in all sharing situations. However, waiver of informed consent is only allowed in certain countries/regions and under certain circumstances. The current legal and ethical landscape appears to be very complex and under constant evolution. Regulations differ between countries/regions and are often incomplete, leading to uncertainty.


CONCLUSION
With this work, ICN illuminates the unmet need for a single international collaborative framework to facilitate DSE. Harmonising requirements for global DSE will reduce inefficiency and waste in research. There are many challenges to realising this ambitious vision, including inconsistent terminology and definitions, and heterogeneous and dynamic legal constraints. Here, we identify areas of agreement and significant difference as a necessary first step towards facilitating international collaboration. We propose the establishment of a working group to continue the comparison across jurisdictions, create a standardised glossary and define a set of basic principles and fundamental requirements for DSE.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5237</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s12910-020-0448-9</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31964390</dc:relation>
          <dc:source>BMC medical ethics. - 2020</dc:source>
          <dc:subject xml:lang="en">Big data</dc:subject>
          <dc:subject xml:lang="en">Biobanking</dc:subject>
          <dc:subject xml:lang="en">Data sharing</dc:subject>
          <dc:subject xml:lang="en">International exchange</dc:subject>
          <dc:subject xml:lang="en">Research policies</dc:subject>
          <dc:subject xml:lang="en">Electronic Health Records</dc:subject>
          <dc:subject xml:lang="en">Global Health</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Information Dissemination</dc:subject>
          <dc:subject xml:lang="en">International Cooperation</dc:subject>
          <dc:subject xml:lang="en">Internationality</dc:subject>
          <dc:subject xml:lang="en">Ownership</dc:subject>
          <dc:subject xml:lang="en">Tissue Banks</dc:subject>
          <dc:title xml:lang="en">Legal and ethical framework for global health information and biospecimen exchange - an international perspective.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:5238</identifier>
        <datestamp>2025-10-24T20:15:28Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Savarino E</dc:creator>
          <dc:creator>di Pietro M</dc:creator>
          <dc:creator>Bredenoord AJ</dc:creator>
          <dc:creator>Carlson DA</dc:creator>
          <dc:creator>Clarke JO</dc:creator>
          <dc:creator>Khan A</dc:creator>
          <dc:creator>Vela MF</dc:creator>
          <dc:creator>Yadlapati R</dc:creator>
          <dc:creator>Pohl D</dc:creator>
          <dc:creator>Pandolfino JE</dc:creator>
          <dc:creator>Roman S</dc:creator>
          <dc:creator>Gyawali CP</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">The functional lumen imaging probe (FLIP) measures luminal dimensions using impedance planimetry, performed most often during sedated upper endoscopy. Mechanical properties of the esophageal wall and opening dynamics of the esophagogastric junction (EGJ) can be objectively evaluated in esophageal motor disorders, eosinophilic esophagitis, esophageal strictures, during esophageal surgery and in postsurgical symptomatic states. Distensibility index, the ratio of EGJ cross sectional area to intraballoon pressure, is the most useful FLIP metric. Secondary peristalsis from balloon distension can be displayed topographically as repetitive anterograde or retrograde contractile activity in the esophageal body, similar to high-resolution manometry. Real-time interpretation and postprocessing of FLIP metadata can complement the identification of esophageal outflow obstruction and achalasia, especially when findings are inconclusive from alternate esophageal tests in symptomatic patients. FLIP can complement the diagnosis of achalasia when manometry and barium studies are inconclusive or negative in patients with typical symptoms. FLIP can direct adequacy of disruption of the EGJ in achalasia when used during and immediately after myotomy and pneumatic dilation. Lumen diameter measured using FLIP in eosinophilic esophagitis and in complex strictures can potentially guide management. An abbreviated modification of the Grading of Recommendations Assessment, Development, and Evaluation was used to determine the quality of available evidence and recommendations regarding FLIP utilization. FLIP metrics that are diagnostic or suggestive of an abnormal motor pattern and metrics that define normal esophageal physiology were developed by consensus and are described in this review.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/5238</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.14309/ajg.0000000000000773</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/33156096</dc:relation>
          <dc:source>The American journal of gastroenterology. - 2020</dc:source>
          <dc:subject xml:lang="en">Hepatology</dc:subject>
          <dc:subject xml:lang="en">Gastroenterology</dc:subject>
          <dc:title xml:lang="en">Use of the Functional Lumen Imaging Probe in Clinical Esophagology.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12314</identifier>
        <datestamp>2025-10-24T20:47:18Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Galli A</dc:creator>
          <dc:creator>Robay D</dc:creator>
          <dc:creator>Osterwalder M</dc:creator>
          <dc:creator>Bao X</dc:creator>
          <dc:creator>Bénazet JD</dc:creator>
          <dc:creator>Tariq M</dc:creator>
          <dc:creator>Paro R</dc:creator>
          <dc:creator>Mackem S</dc:creator>
          <dc:creator>Zeller R</dc:creator>
          <dc:date>2010</dc:date>
          <dc:description xml:lang="en">The polarization of nascent embryonic fields and the endowment of cells with organizer properties are key to initiation of vertebrate organogenesis. One such event is antero-posterior (AP) polarization of early limb buds and activation of morphogenetic Sonic Hedgehog (SHH) signaling in the posterior mesenchyme, which in turn promotes outgrowth and specifies the pentadactylous autopod. Inactivation of the Hand2 transcriptional regulator from the onset of mouse forelimb bud development disrupts establishment of posterior identity and Shh expression, which results in a skeletal phenotype identical to Shh deficient limb buds. In wild-type limb buds, Hand2 is part of the protein complexes containing Hoxd13, another essential regulator of Shh activation in limb buds. Chromatin immunoprecipitation shows that Hand2-containing chromatin complexes are bound to the far upstream cis-regulatory region (ZRS), which is specifically required for Shh expression in the limb bud. Cell-biochemical studies indicate that Hand2 and Hoxd13 can efficiently transactivate gene expression via the ZRS, while the Gli3 repressor isoform interferes with this positive transcriptional regulation. Indeed, analysis of mouse forelimb buds lacking both Hand2 and Gli3 reveals the complete absence of antero-posterior (AP) polarity along the entire proximo-distal axis and extreme digit polydactyly without AP identities. Our study uncovers essential components of the transcriptional machinery and key interactions that set-up limb bud asymmetry upstream of establishing the SHH signaling limb bud organizer.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12314</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pgen.1000901</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20386744</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>PLoS genetics. - 2010</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Basic Helix-Loop-Helix Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Body Patterning</dc:subject>
          <dc:subject xml:lang="en">Chromatin</dc:subject>
          <dc:subject xml:lang="en">Embryo, Mammalian</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation, Developmental</dc:subject>
          <dc:subject xml:lang="en">Hedgehog Proteins</dc:subject>
          <dc:subject xml:lang="en">Homeodomain Proteins</dc:subject>
          <dc:subject xml:lang="en">Limb Buds</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Transgenic</dc:subject>
          <dc:subject xml:lang="en">Mutation</dc:subject>
          <dc:subject xml:lang="en">Transcription Factors</dc:subject>
          <dc:title xml:lang="en">Distinct roles of Hand2 in initiating polarity and posterior Shh expression during the onset of mouse limb bud development.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12371</identifier>
        <datestamp>2025-10-24T20:47:23Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Eisenring M</dc:creator>
          <dc:creator>vom Berg J</dc:creator>
          <dc:creator>Kristiansen G</dc:creator>
          <dc:creator>Saller E</dc:creator>
          <dc:creator>Becher B</dc:creator>
          <dc:date>2010</dc:date>
          <dc:description xml:lang="en">The potent tumoricidal activity of interleukin 12 (IL-12) is thought to be mediated by the activation and polarization of natural killer (NK) cells and T helper type 1 (T(H)1) cells, respectively. By systematic analysis of the IL-12-induced immune response to subcutaneous melanoma (B16), we found that tumor suppression was mediated independently of T lymphocytes or NK cells. IL-12 initiated local antitumor immunity by stimulating a subset of NKp46(+) lymphoid tissue-inducer (LTi) cells dependent on the transcription factor RORγt. The presence of these NKp46(+) LTi cells induced upregulation of adhesion molecules in the tumor vasculature and resulted in more leukocyte invasion. Thus, this innate cell type is responsive to IL-12 and is a powerful mediator of tumor suppression.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12371</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/ni.1947</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20935648</dc:relation>
          <dc:source>Nature immunology. - 2010</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Cell Line, Tumor</dc:subject>
          <dc:subject xml:lang="en">Interleukin-12</dc:subject>
          <dc:subject xml:lang="en">Lymphoid Tissue</dc:subject>
          <dc:subject xml:lang="en">Melanoma</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">Mice, Knockout</dc:subject>
          <dc:subject xml:lang="en">Natural Cytotoxicity Triggering Receptor 1</dc:subject>
          <dc:subject xml:lang="en">Nuclear Receptor Subfamily 1, Group F, Member 3</dc:subject>
          <dc:subject xml:lang="en">Tumor Cells, Cultured</dc:subject>
          <dc:title xml:lang="en">IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12381</identifier>
        <datestamp>2025-10-24T20:47:26Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Scherrer D</dc:creator>
          <dc:creator>Schmid S</dc:creator>
          <dc:creator>Körner C</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Strong topographic variation interacting with low stature alpine vegetation creates a multitude of micro-habitats poorly represented by common 2 m above the ground meteorological measurements (weather station data). However, the extent to which the actual habitat temperatures in alpine landscapes deviate from meteorological data at different spatial scales has rarely been quantified. In this study, we assessed thermal surface and soil conditions across topographically rich alpine landscapes by thermal imagery and miniature data loggers from regional (2-km(2)) to plot (1-m(2)) scale. The data were used to quantify the effects of spatial sampling resolution on current micro-habitat distributions and habitat loss due to climate warming scenarios. Soil temperatures showed substantial variation among slopes (2-3 K) dependent on slope exposure, within slopes (3-4 K) due to micro-topography and within 1-m(2) plots (1 K) as a result of plant cover effects. A reduction of spatial sampling resolution from 1 × 1 m to 100 × 100 m leads to an underestimation of current habitat diversity by 25% and predicts a six-times higher habitat loss in a 2-K warming scenario. Our results demonstrate that weather station data are unable to reflect the complex thermal patterns of aerodynamically decoupled alpine vegetation at the investigated scales. Thus, the use of interpolated weather station data to describe alpine life conditions without considering the micro-topographically induced thermal mosaic might lead to misinterpretation and inaccurate prediction.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12381</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00484-010-0364-7</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20924613</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>International journal of biometeorology. - 2011</dc:source>
          <dc:subject xml:lang="en">Altitude</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Biodiversity</dc:subject>
          <dc:subject xml:lang="en">Ecosystem</dc:subject>
          <dc:subject xml:lang="en">Global Warming</dc:subject>
          <dc:subject xml:lang="en">Meteorological Concepts</dc:subject>
          <dc:subject xml:lang="en">Microclimate</dc:subject>
          <dc:subject xml:lang="en">Plant Development</dc:subject>
          <dc:subject xml:lang="en">Soil</dc:subject>
          <dc:subject xml:lang="en">Species Specificity</dc:subject>
          <dc:subject xml:lang="en">Temperature</dc:subject>
          <dc:title xml:lang="en">Elevational species shifts in a warmer climate are overestimated when based on weather station data.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12407</identifier>
        <datestamp>2025-10-24T20:47:28Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bentz D</dc:creator>
          <dc:creator>Steiner M</dc:creator>
          <dc:creator>Meinlschmidt G</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Premenstrual dysphoric disorder (PMDD) and severe premenstrual syndrome (PMS) are common, yet often remain unrecognized and not adequately treated. One reason for this is the lack of a valid German screening instrument. The aim of the present study was to create a German version of the English "Premenstrual Symptoms Screening Tool (PSST)" and to verify its applicability.


MATERIAL AND METHODS
The German version of the PSST was created as "Screening-Instrument für prämenstruelle Symptome (SIPS)" and its reliability and validity determined based on data from 47 women with and without PMDD/severe PMS using Internet-based daily symptom ratings.


RESULTS
The retest reliability of the SIPS was r=0.69, and Cronbach's alpha was 0.924. As an indicator of the convergent validity of the SIPS, there were significant differences between women with and without PMDD/severe PMS as identified by the SIPS with regard to prospectively assessed premenstrual symptomatology (F[2,44]=4.52, p&lt;0.001) and symptom change (F[2,44]=25.23, p&lt;0.001).


CONCLUSIONS
The SIPS is reliable and valid and may help to improve the identification of women who require treatment for their premenstrual symptoms.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12407</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00115-010-3210-6</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21221519</dc:relation>
          <dc:source>Der Nervenarzt. - 2012</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Germany</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Mass Screening</dc:subject>
          <dc:subject xml:lang="en">Premenstrual Syndrome</dc:subject>
          <dc:subject xml:lang="en">Psychiatric Status Rating Scales</dc:subject>
          <dc:subject xml:lang="en">Psychometrics</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Sensitivity and Specificity</dc:subject>
          <dc:subject xml:lang="en">Surveys and Questionnaires</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">[SIPS--screening instrument for premenstrual symptoms. The German version of Premenstrual Symptoms Screening Tool to assess clinically relevant disturbances].</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12416</identifier>
        <datestamp>2025-10-24T20:47:30Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Leventhal ME</dc:creator>
          <dc:creator>Denhaerynck K</dc:creator>
          <dc:creator>Brunner-La Rocca HP</dc:creator>
          <dc:creator>Burnand B</dc:creator>
          <dc:creator>Conca-Zeller A</dc:creator>
          <dc:creator>Bernasconi AT</dc:creator>
          <dc:creator>Mahrer-Imhof R</dc:creator>
          <dc:creator>Froelicher ES</dc:creator>
          <dc:creator>De Geest S</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">PRINCIPLES
International guidelines for heart failure (HF) care recommend the implementation of inter-professional disease management programmes. To date, no such programme has been tested in Switzerland. The aim of this randomised controlled trial (RCT) was to test the effect on hospitalisation, mortality and quality of life of an adult ambulatory disease management programme for patients with HF in Switzerland.


METHODS
Consecutive patients admitted to internal medicine in a Swiss university hospital were screened for decompensated HF. A total of 42 eligible patients were randomised to an intervention (n = 22) or usual care group (n = 20). Medical treatment was optimised and lifestyle recommendations were given to all patients. Intervention patients additionally received a home visit by a HF-nurse, followed by 17 telephone calls of decreasing frequency over 12 months, focusing on self-care. Calls from the HF nurse to primary care physicians communicated health concerns and identified goals of care. Data were collected at baseline, 3, 6, 9 and 12 months. Mixed regression analysis (quality of life) was used. Outcome assessment was conducted by researchers blinded to group assignment.


RESULTS
After 12 months, 22 (52%) patients had an all-cause re-admission or died. Only 3 patients were hospitalised with HF decompensation. No significant effect of the intervention was found on HF related to quality of life.


CONCLUSIONS
An inter-professional disease management programme is possible in the Swiss healthcare setting but effects on outcomes need to be confirmed in larger studies.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12416</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2011.13171</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21384285</dc:relation>
          <dc:source>Swiss medical weekly. - 2011</dc:source>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Ambulatory Care</dc:subject>
          <dc:subject xml:lang="en">Disease Management</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Heart Failure</dc:subject>
          <dc:subject xml:lang="en">Hospitalization</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Length of Stay</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Patient Care Team</dc:subject>
          <dc:subject xml:lang="en">Patient Education as Topic</dc:subject>
          <dc:subject xml:lang="en">Patient Readmission</dc:subject>
          <dc:subject xml:lang="en">Quality of Life</dc:subject>
          <dc:subject xml:lang="en">Regression Analysis</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Swiss Interdisciplinary Management Programme for Heart Failure (SWIM-HF): a randomised controlled trial study of an outpatient inter-professional management programme for heart failure patients in Switzerland.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12448</identifier>
        <datestamp>2025-10-24T20:47:33Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Berner D</dc:creator>
          <dc:creator>Kaeuffer R</dc:creator>
          <dc:creator>Grandchamp AC</dc:creator>
          <dc:creator>Raeymaekers JA</dc:creator>
          <dc:creator>Räsänen K</dc:creator>
          <dc:creator>Hendry AP</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Ecological selection against hybrids between populations occupying different habitats might be an important component of reproductive isolation during the initial stages of speciation. The strength and directionality of this barrier to gene flow depends on the genetic architecture underlying divergence in ecologically relevant phenotypes. We here present line cross analyses of inheritance for two key foraging-related morphological traits involved in adaptive divergence between stickleback ecotypes residing parapatrically in lake and stream habitats within the Misty Lake watershed (Vancouver Island, Canada). One main finding is the striking genetic dominance of the lake phenotype for body depth. Selection associated with this phenotype against first- and later-generation hybrids should therefore be asymmetric, hindering introgression from the lake to the stream population but not vice versa. Another main finding is that divergence in gill raker number is inherited additively and should therefore contribute symmetrically to reproductive isolation. Our study suggests that traits involved in adaptation might contribute to reproductive isolation qualitatively differently, depending on their mode of inheritance.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12448</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1420-9101.2011.02330.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21649765</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of evolutionary biology. - 2011</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">British Columbia</dc:subject>
          <dc:subject xml:lang="en">Ecotype</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Gills</dc:subject>
          <dc:subject xml:lang="en">Lakes</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Quantitative Trait, Heritable</dc:subject>
          <dc:subject xml:lang="en">Reproductive Isolation</dc:subject>
          <dc:subject xml:lang="en">Rivers</dc:subject>
          <dc:subject xml:lang="en">Smegmamorpha</dc:subject>
          <dc:title xml:lang="en">Quantitative genetic inheritance of morphological divergence in a lake-stream stickleback ecotype pair: implications for reproductive isolation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12449</identifier>
        <datestamp>2025-10-24T20:47:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Rudin D</dc:creator>
          <dc:creator>Grize L</dc:creator>
          <dc:creator>Schindler C</dc:creator>
          <dc:creator>Marsch S</dc:creator>
          <dc:creator>Rüegg S</dc:creator>
          <dc:creator>Sutter R</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Status epilepticus is one of the most important neurological emergencies and requires immediate therapy and admission to the intensive care unit. We hypothesized that nonconvulsive and subtle status epilepticus are more frequent than reported.


METHODS
This observational cohort study describes types, courses, duration, length of hospital stay, outcome and case fatality rate of status epilepticus in adults in relation to demographic and clinical variables. It was conducted in an intensive care unit of a tertiary care center over three years.


RESULTS
111 status epilepticus episodes had a median duration of 48h. Hospitalization length was 18±15.3 days. 81% of the status epilepticus episodes were nonconvulsive and subtle. Case fatality rate was 17%. Age over 70 years had independent positive influence on status epilepticus course (OR: 5.135; p=0.0029). Hospital stay increased by 1.13h with each additional hour of status epilepticus (p=0.02). Subtle status epilepticus was a risk factor for refractoriness (p=0.0065).


CONCLUSIONS
Prevalence of nonconvulsive and subtle status epilepticus was higher than reported, emphasising the importance of clinical awareness. Older age was associated with more favorable course. This unexpected and contradictory result has to be taken into account during therapeutic interventions in the elderly and should warn from early resignation regarding treatment.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12449</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.eplepsyres.2011.05.018</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21676592</dc:relation>
          <dc:source>Epilepsy research. - 2011</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Algorithms</dc:subject>
          <dc:subject xml:lang="en">Anticonvulsants</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Hospitalization</dc:subject>
          <dc:subject xml:lang="en">Hospitals</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intensive Care Units</dc:subject>
          <dc:subject xml:lang="en">Length of Stay</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Observation</dc:subject>
          <dc:subject xml:lang="en">Outcome Assessment, Health Care</dc:subject>
          <dc:subject xml:lang="en">Prevalence</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Statistics, Nonparametric</dc:subject>
          <dc:subject xml:lang="en">Status Epilepticus</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">High prevalence of nonconvulsive and subtle status epilepticus in an ICU of a tertiary care center: a three-year observational cohort study.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12383</identifier>
        <datestamp>2025-10-24T20:47:37Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Borbély AA</dc:creator>
          <dc:creator>Tobler I</dc:creator>
          <dc:date>2011</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/12383</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/B978-0-444-52006-7.00013-7</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21056188</dc:relation>
          <dc:source>Handbook of clinical neurology. - 2011</dc:source>
          <dc:subject xml:lang="en">Brain</dc:subject>
          <dc:subject xml:lang="en">Circadian Rhythm</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Homeostasis</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Models, Biological</dc:subject>
          <dc:subject xml:lang="en">Sleep</dc:subject>
          <dc:title xml:lang="en">Manifestations and functional implications of sleep homeostasis.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12384</identifier>
        <datestamp>2025-10-24T20:47:37Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ohlerth S</dc:creator>
          <dc:creator>Becker-Birck M</dc:creator>
          <dc:creator>Augsburger H</dc:creator>
          <dc:creator>Jud R</dc:creator>
          <dc:creator>Makara M</dc:creator>
          <dc:creator>Braun U</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">The present study was performed to provide computed tomographic (CT) reference values for structures in the thorax of 26 clinically normal Saanen goats. Animals were anesthetized, positioned in sternal recumbency and transverse images with a reconstructed 1.5mm slice thickness were obtained by use of a 40-slice CT scanner. Absolute and relative measurements of the trachea, heart, cranial vena cava, thoracic aorta, caudal vena cava, right and left principal bronchus, right and left caudal lobar bronchus and the concomitant branch of the right and left pulmonary artery and vein, large caudal mediastinal lymph node and lung density were performed with dedicated software. Minimal to moderate interstitial or bronchopneumonia was incidentally found on CT in 24 animals. In conclusion, CT images obtained in this study can be used as a reference for the evaluation of thoracic diseases in goats.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12384</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.rvsc.2010.10.019</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21071049</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Research in veterinary science. - 2012</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Goats</dc:subject>
          <dc:subject xml:lang="en">Multidetector Computed Tomography</dc:subject>
          <dc:subject xml:lang="en">Radiography, Thoracic</dc:subject>
          <dc:subject xml:lang="en">Reference Values</dc:subject>
          <dc:subject xml:lang="en">Thorax</dc:subject>
          <dc:title xml:lang="en">Computed tomography measurements of thoracic structures in 26 clinically normal goats.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12397</identifier>
        <datestamp>2025-10-24T20:47:39Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>von Teichman A</dc:creator>
          <dc:creator>Compérat E</dc:creator>
          <dc:creator>Behnke S</dc:creator>
          <dc:creator>Storz M</dc:creator>
          <dc:creator>Moch H</dc:creator>
          <dc:creator>Schraml P</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Multilocular cystic renal cell carcinoma is a rare renal cell carcinoma with an excellent prognosis. To clarify the relationship with typical clear cell renal cell carcinoma, we evaluated 15 cases of multilocular cystic renal cell carcinomas diagnosed according to the 2004 WHO classification. Von Hippel Lindau (VHL) gene mutations were determined by whole genome amplification and direct sequencing. Carbonic anhydrase 9 (CAIX), a hypoxia-inducible factor (HIF) target, paired box gene 2 (PAX2), cyclin-dependent kinase inhibitor p27 and glycogen synthase kinase 3-β (GSK3β) were immunohistochemically evaluated as members of the VHL protein (pVHL)- and phosphatase and tensin homolog (PTEN)-controlled pathways. VHL mutations were identified in 3 of 12 (25%) tumors. Inactivated GSK3β, decreased PTEN expression and PAX2 positivity were observed in the vast majority of the multilocular cystic renal cell carcinomas. Strong nuclear staining of p27 was seen in 14 of 15 cases. Compared with multilocular cystic renal cell carcinomas, expression frequencies of PAX2, p-GSK3β, PTEN and CAIX were similar in a set of low-grade, early-stage clear cell renal cell carcinomas, whereas only 30% had strong p27 positivity. These results are consistent with the hypothesis that multilocular cystic renal cell carcinomas are related at the molecular level with clear cell renal cell carcinomas. Maintenance of a strong subcellular p27 expression in all multilocular cystic renal cell carcinomas analyzed may in part explain the excellent prognosis of these tumor patients.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12397</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/modpathol.2010.222</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21151099</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. - 2011</dc:source>
          <dc:subject xml:lang="en">Antigens, Neoplasm</dc:subject>
          <dc:subject xml:lang="en">Carbonic Anhydrase IX</dc:subject>
          <dc:subject xml:lang="en">Carbonic Anhydrases</dc:subject>
          <dc:subject xml:lang="en">Carcinoma, Renal Cell</dc:subject>
          <dc:subject xml:lang="en">Chi-Square Distribution</dc:subject>
          <dc:subject xml:lang="en">Cyclin-Dependent Kinase Inhibitor p27</dc:subject>
          <dc:subject xml:lang="en">DNA Mutational Analysis</dc:subject>
          <dc:subject xml:lang="en">Glycogen Synthase Kinase 3</dc:subject>
          <dc:subject xml:lang="en">Glycogen Synthase Kinase 3 beta</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunohistochemistry</dc:subject>
          <dc:subject xml:lang="en">Kidney Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Mutation</dc:subject>
          <dc:subject xml:lang="en">Neoplasm Staging</dc:subject>
          <dc:subject xml:lang="en">Neoplasms, Cystic, Mucinous, and Serous</dc:subject>
          <dc:subject xml:lang="en">PAX2 Transcription Factor</dc:subject>
          <dc:subject xml:lang="en">PTEN Phosphohydrolase</dc:subject>
          <dc:subject xml:lang="en">Phosphorylation</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:subject xml:lang="en">Von Hippel-Lindau Tumor Suppressor Protein</dc:subject>
          <dc:title xml:lang="en">VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12458</identifier>
        <datestamp>2025-10-24T20:47:42Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Betschart C</dc:creator>
          <dc:creator>Scheiner D</dc:creator>
          <dc:creator>Hess E</dc:creator>
          <dc:creator>Seifert B</dc:creator>
          <dc:creator>Fink D</dc:creator>
          <dc:creator>Perucchini D</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">INTRODUCTION AND HYPOTHESIS
The aim of the Incontinence Outcome Questionnaire (IOQ) is to assess quality of life and patient-reported outcome after midurethral slings.


METHODS
In this retrospective study, 626 patients with a minimum follow-up period of 1 year were sent the IOQ. Four hundred twenty-two of 626 (67.4%) patient responses were evaluated.


RESULTS
The mean IOQ QoL extended score was 33.7 ± 17.5 and comparable for tension-free vaginal tape (TVT), outside-in transobturator tape (TOT), and inside-out transobturator vaginal tape (TVT-O). Evaluation of IOQ question about readmission revealed a total of 32 patients (18 TVT, 12 TOT, and 2 TVT-O) who underwent a subsequent operation due to sling-related complications. Freedom from reoperation for recurrent SUI at 1, 2, and 5 years was 100%, 99.7 ± 0.3%, and 99.7 ± 0.3% for TVT, 100% for TVT-O, and 94.2 ± 2.5%, 91.9 ± 2.9%, and 89.9 ± 3.5% for TOT, respectively (p &lt; 0.001).


CONCLUSIONS
Patient satisfaction, assessed using the IOQ, is high after retropubic and transobturator slings. In our collective, relapse incontinence is higher after TOT.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12458</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00192-011-1366-7</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21318441</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>International urogynecology journal. - 2011</dc:source>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Patient Readmission</dc:subject>
          <dc:subject xml:lang="en">Patient Satisfaction</dc:subject>
          <dc:subject xml:lang="en">Quality of Life</dc:subject>
          <dc:subject xml:lang="en">Reoperation</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Suburethral Slings</dc:subject>
          <dc:subject xml:lang="en">Surveys and Questionnaires</dc:subject>
          <dc:subject xml:lang="en">Urinary Incontinence</dc:subject>
          <dc:subject xml:lang="en">Urologic Surgical Procedures</dc:subject>
          <dc:title xml:lang="en">Patient satisfaction after retropubic and transobturator slings: first assessment using the Incontinence Outcome Questionnaire (IOQ).</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12479</identifier>
        <datestamp>2025-10-24T20:47:44Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bosshart H</dc:creator>
          <dc:creator>Heinzelmann M</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">In the continuous presence of bacterial lipopolysaccharide (LPS), the membrane-bound LPS receptor, CD14, exhibits a biphasic pattern of surface expression in monocytes ex vivo; an initial increase is followed by a later decrease. In the presence of LPS, ex vivo changes in monocytic CD14 cell surface expression have been consistently interpreted as the direct result of LPS exposure. There has been little consideration for the possibility of additional cell culture effects. Here, an experiment is presented to dissect the differences between LPS effects and cell culture effects on monocytic CD14 cell surface expression ex vivo. The results show that in monocytes from diluted whole blood cultures, CD14 surface expression is induced in LPS-treated samples but decreased in untreated samples. These observations suggest that the previously observed biphasic surface expression pattern of CD14 in long-term LPS-treated monocytes may be the result of a superposition of LPS-induced expression and spontaneous disappearance of CD14 from the plasma membrane. Further, these results illustrate the importance of taking cell culture conditions into account when analyzing monocyte expression of CD14.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12479</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jim.2011.03.006</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21453706</dc:relation>
          <dc:source>Journal of immunological methods. - 2011</dc:source>
          <dc:subject xml:lang="en">Cell Culture Techniques</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Flow Cytometry</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunophenotyping</dc:subject>
          <dc:subject xml:lang="en">Leukocytes, Mononuclear</dc:subject>
          <dc:subject xml:lang="en">Lipopolysaccharide Receptors</dc:subject>
          <dc:subject xml:lang="en">Lipopolysaccharides</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:title xml:lang="en">Spontaneous decrease of CD14 cell surface expression in human peripheral blood monocytes ex vivo.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12499</identifier>
        <datestamp>2025-10-24T20:47:45Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Wenger M</dc:creator>
          <dc:creator>Sattler U</dc:creator>
          <dc:creator>Goldschmidt-Clermont E</dc:creator>
          <dc:creator>Segner H</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Research on the endocrine role of estrogens has focused on the reproductive system, while other potential target systems have been less studied. Here, we investigated the possible immunomodulating role of 17β-estradiol (E2) using rainbow trout (Oncorhynchus mykiss) as a model. The aims of the study were to examine a) whether estrogens can modulate immune gene transcription levels, and b) whether this has functional implications for the resistance of trout towards pathogens. Trout were reared from fertilization until 6 months of age under (1) control conditions, (2) short-term E2-treatment (6-month-old juveniles were fed a diet containing 20 mg E2/kg for 2 weeks), or c) long-term E2-treatment (twice a 2-h-bath-exposure of trout embryos to 400 μg 17β-estradiol (E2)/L, followed by rearing on the E2-spiked diet from start-feeding until 6 months of age). Analysis of plasma estrogen levels indicated that the internal estrogen concentrations of E2-exposed fish were within the physiological range and analysis of hepatic vitellogenin mRNA levels indicated that the E2 administration was effective in activating the endogenous estrogen receptor pathway. However, expression levels of the hepatic complement components C3-1, C3-3, and Factor H were not affected by E2-treatment. In a next step, 6-month-old juveniles were challenged with pathogenic bacteria (Yersinia ruckeri). In control fish, this bacterial infection resulted in significant up-regulation of the mRNA levels of hepatic complement genes (C3-1, C3-3, Factor B, Factor H), while E2-treated fish showed no or significantly lower up-regulation of the complement gene transcription levels. Apparently, the E2-treated trout had a lower capacity to activate their immune system to defend against the bacterial infection. This interpretation is corroborated by the finding that survival of E2-treated fish under bacterial challenge was significantly lower than in the control group. In conclusion, the results from this study suggest that estrogens are able to modulate immune parameters of trout with functional consequences on their ability to cope with pathogens.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12499</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.fsi.2011.04.007</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21549195</dc:relation>
          <dc:source>Fish &amp; shellfish immunology. - 2011</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Complement System Proteins</dc:subject>
          <dc:subject xml:lang="en">Estradiol</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Fish Diseases</dc:subject>
          <dc:subject xml:lang="en">Fish Proteins</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Profiling</dc:subject>
          <dc:subject xml:lang="en">Immunity, Innate</dc:subject>
          <dc:subject xml:lang="en">Liver</dc:subject>
          <dc:subject xml:lang="en">Oncorhynchus mykiss</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Vitellogenins</dc:subject>
          <dc:subject xml:lang="en">Yersinia Infections</dc:subject>
          <dc:subject xml:lang="en">Yersinia ruckeri</dc:subject>
          <dc:title xml:lang="en">17Beta-estradiol affects the response of complement components and survival of rainbow trout (Oncorhynchus mykiss) challenged by bacterial infection.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12528</identifier>
        <datestamp>2025-10-24T20:47:47Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ster J</dc:creator>
          <dc:creator>Mateos JM</dc:creator>
          <dc:creator>Grewe BF</dc:creator>
          <dc:creator>Coiret G</dc:creator>
          <dc:creator>Corti C</dc:creator>
          <dc:creator>Corsi M</dc:creator>
          <dc:creator>Helmchen F</dc:creator>
          <dc:creator>Gerber U</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Impaired function or expression of group II metabotropic glutamate receptors (mGluRIIs) is observed in brain disorders such as schizophrenia. This class of receptor is thought to modulate activity of neuronal circuits primarily by inhibiting neurotransmitter release. Here, we characterize a postsynaptic excitatory response mediated by somato-dendritic mGluRIIs in hippocampal CA3 pyramidal cells and in stratum oriens interneurons. The specific mGluRII agonists DCG-IV or LCCG-1 induced an inward current blocked by the mGluRII antagonist LY341495. Experiments with transgenic mice revealed a significant reduction of the inward current in mGluR3(-/-) but not in mGluR2(-/-) mice. The excitatory response was associated with periods of synchronized activity at theta frequency. Furthermore, cholinergically induced network oscillations exhibited decreased frequency when mGluRIIs were blocked. Thus, our data indicate that hippocampal responses are modulated not only by presynaptic mGluRIIs that reduce glutamate release but also by postsynaptic mGluRIIs that depolarize neurons and enhance CA3 network activity.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12528</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1073/pnas.1100548108</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21628565</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Proceedings of the National Academy of Sciences of the United States of America. - 2011</dc:source>
          <dc:subject xml:lang="en">Action Potentials</dc:subject>
          <dc:subject xml:lang="en">Amino Acids</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">CA3 Region, Hippocampal</dc:subject>
          <dc:subject xml:lang="en">Cyclopropanes</dc:subject>
          <dc:subject xml:lang="en">Excitatory Amino Acid Agonists</dc:subject>
          <dc:subject xml:lang="en">Excitatory Amino Acid Antagonists</dc:subject>
          <dc:subject xml:lang="en">Excitatory Postsynaptic Potentials</dc:subject>
          <dc:subject xml:lang="en">Glycine</dc:subject>
          <dc:subject xml:lang="en">Interneurons</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Knockout</dc:subject>
          <dc:subject xml:lang="en">Microscopy, Electron</dc:subject>
          <dc:subject xml:lang="en">Nerve Net</dc:subject>
          <dc:subject xml:lang="en">Patch-Clamp Techniques</dc:subject>
          <dc:subject xml:lang="en">Pyramidal Cells</dc:subject>
          <dc:subject xml:lang="en">Rats</dc:subject>
          <dc:subject xml:lang="en">Rats, Wistar</dc:subject>
          <dc:subject xml:lang="en">Receptors, Metabotropic Glutamate</dc:subject>
          <dc:subject xml:lang="en">Theta Rhythm</dc:subject>
          <dc:subject xml:lang="en">Xanthenes</dc:subject>
          <dc:title xml:lang="en">Enhancement of CA3 hippocampal network activity by activation of group II metabotropic glutamate receptors.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12403</identifier>
        <datestamp>2025-10-24T20:47:49Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Tzankov A</dc:creator>
          <dc:creator>Sotlar K</dc:creator>
          <dc:creator>Muhlematter D</dc:creator>
          <dc:creator>Theocharides A</dc:creator>
          <dc:creator>Went P</dc:creator>
          <dc:creator>Jotterand M</dc:creator>
          <dc:creator>Horny HP</dc:creator>
          <dc:creator>Dirnhofer S</dc:creator>
          <dc:date>2008</dc:date>
          <dc:description xml:lang="en">Systemic mastocytoses represent neoplastic proliferations of mast cells. In about 20% of cases systemic mastocytoses are accompanied by clonal haematopoietic non-mast cell-lineage disorders, most commonly myeloid neoplasms. A case of systemic mastocytosis carrying the characteristic mutation at codon 816 (D816V) in the KIT gene of mast cells, with two concurrent accompanying clonal haematopoietic non-mast cell-lineage disorders, chronic myeloproliferative disease, unclassifiable and precursor B lymphoblastic leukaemia is documented. Both accompanying clonal haematopoietic non-mast cell-lineage disorders carried the wild-type KIT gene, but had a novel t(13;13)(q12;q22) involving the FLT3 locus at 13q12. The chronic myeloproliferative disease, unclassifiable and the precursor B lymphoblastic leukaemia were cured by syngenous stem cell transplantation, but the systemic mastocytosis persisted for more than 10 years. The additional impact of molecular techniques on the correct diagnosis in haematological malignancies is highlighted, and evidence is provided that, apart from internal tandem duplications and mutations, FLT3 can be activated by translocations.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12403</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1136/jcp.2008.058073</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/18663058</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of clinical pathology. - 2008</dc:source>
          <dc:subject xml:lang="en">Chromosomes, Human, Pair 13</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">In Situ Hybridization, Fluorescence</dc:subject>
          <dc:subject xml:lang="en">Karyotyping</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Mastocytosis, Systemic</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Myeloproliferative Disorders</dc:subject>
          <dc:subject xml:lang="en">Peripheral Blood Stem Cell Transplantation</dc:subject>
          <dc:subject xml:lang="en">Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</dc:subject>
          <dc:subject xml:lang="en">Translocation, Genetic</dc:subject>
          <dc:subject xml:lang="en">fms-Like Tyrosine Kinase 3</dc:subject>
          <dc:title xml:lang="en">Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12425</identifier>
        <datestamp>2025-10-24T20:47:51Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Blum JA</dc:creator>
          <dc:creator>Zellweger MJ</dc:creator>
          <dc:creator>Burri C</dc:creator>
          <dc:creator>Hatz C</dc:creator>
          <dc:date>2008</dc:date>
          <dc:description xml:lang="en">American trypanosomiasis (Chagas disease) and human African trypanosomiasis (HAT; sleeping sickness) are both caused by single-celled flagellates that are transmitted by arthropods. Cardiac problems are the main cause of morbidity in chronic Chagas disease, but neurological problems dominate in HAT. Physicians need to be aware of Chagas disease and HAT in patients living in or returning from endemic regions, even if they left those regions long ago. Chagas heart disease has to be taken into account in the differential diagnosis of cardiomyopathy, primarily in patients with pathological electrocardiographic (ECG) findings, such as right bundle branch block or left anterior hemiblock, with segmental wall motion abnormalities or aneurysms on echocardiography, and in young patients with stroke in the absence of arterial hypertension. In HAT patients, cardiac involvement as seen by ECG alterations, such as repolarisation changes and low voltage, is frequent. HAT cardiopathy in general is benign and does not cause relevant congestive heart failure and subsides with treatment. We review the differences between the American and African trypanosomiasis with the main focus on the heart.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12425</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/S1473-3099(08)70230-5</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/18922485</dc:relation>
          <dc:source>The Lancet. Infectious diseases. - 2008</dc:source>
          <dc:subject xml:lang="en">Chagas Disease</dc:subject>
          <dc:subject xml:lang="en">Heart Diseases</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Trypanosomiasis, African</dc:subject>
          <dc:title xml:lang="en">Cardiac involvement in African and American trypanosomiasis.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12460</identifier>
        <datestamp>2025-10-24T20:47:55Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Hunziker S</dc:creator>
          <dc:creator>Tschan F</dc:creator>
          <dc:creator>Semmer NK</dc:creator>
          <dc:creator>Zobrist R</dc:creator>
          <dc:creator>Spychiger M</dc:creator>
          <dc:creator>Breuer M</dc:creator>
          <dc:creator>Hunziker PR</dc:creator>
          <dc:creator>Marsch SC</dc:creator>
          <dc:date>2009</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Cardiac arrests are handled by teams rather than by individual health-care workers. Recent investigations demonstrate that adherence to CPR guidelines can be less than optimal, that deviations from treatment algorithms are associated with lower survival rates, and that deficits in performance are associated with shortcomings in the process of team-building. The aim of this study was to explore and quantify the effects of ad-hoc team-building on the adherence to the algorithms of CPR among two types of physicians that play an important role as first responders during CPR: general practitioners and hospital physicians.


METHODS
To unmask team-building this prospective randomised study compared the performance of preformed teams, i.e. teams that had undergone their process of team-building prior to the onset of a cardiac arrest, with that of teams that had to form ad-hoc during the cardiac arrest. 50 teams consisting of three general practitioners each and 50 teams consisting of three hospital physicians each, were randomised to two different versions of a simulated witnessed cardiac arrest: the arrest occurred either in the presence of only one physician while the remaining two physicians were summoned to help ("ad-hoc"), or it occurred in the presence of all three physicians ("preformed"). All scenarios were videotaped and performance was analysed post-hoc by two independent observers.


RESULTS
Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 +/- 37 vs. 124 +/- 33 sec, P &lt; 0.0001), delayed their first defibrillation (67 +/- 42 vs. 107 +/- 46 sec, P &lt; 0.0001), and made less leadership statements (15 +/- 5 vs. 21 +/- 6, P &lt; 0.0001).


CONCLUSION
Hands-on time and time to defibrillation, two performance markers of CPR with a proven relevance for medical outcome, are negatively affected by shortcomings in the process of ad-hoc team-building and particularly deficits in leadership. Team-building has thus to be regarded as an additional task imposed on teams forming ad-hoc during CPR. All physicians should be aware that early structuring of the own team is a prerequisite for timely and effective execution of CPR.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12460</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-227X-9-3</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/19216796</dc:relation>
          <dc:source>BMC emergency medicine. - 2009</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Algorithms</dc:subject>
          <dc:subject xml:lang="en">Cardiopulmonary Resuscitation</dc:subject>
          <dc:subject xml:lang="en">Communication</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Guideline Adherence</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Patient Care Team</dc:subject>
          <dc:subject xml:lang="en">Patient Simulation</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Surveys and Questionnaires</dc:subject>
          <dc:subject xml:lang="en">Time Factors</dc:subject>
          <dc:subject xml:lang="en">Videotape Recording</dc:subject>
          <dc:title xml:lang="en">Hands-on time during cardiopulmonary resuscitation is affected by the process of teambuilding: a prospective randomised simulator-based trial.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12476</identifier>
        <datestamp>2025-10-24T20:47:57Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Rickenbacher I</dc:creator>
          <dc:creator>Gugleta K</dc:creator>
          <dc:creator>Zawinka C</dc:creator>
          <dc:creator>Schötzau A</dc:creator>
          <dc:creator>Katamay R</dc:creator>
          <dc:creator>Flammer J</dc:creator>
          <dc:creator>Orgül S</dc:creator>
          <dc:date>2009</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Vascular dysregulation is considered to be a risk factor in several ophthalmic diseases. The purpose of this study was to evaluate the reaction of retinal vessels to flicker light in otherwise healthy subjects with a vasospastic propensity.


PATIENTS AND METHODS
Thirty healthy Caucasians, aged between 18-35 years were recruited for this study and grouped into vasospastics, based on a history of frequent cold hands, even in summer, with concordant findings in nailfold capillary microscopy, or as controls, if such a history was absent. The reaction of the retinal vascular diameter to flicker light was observed in a distance of two to three discs diameters away from the optic nerve head with the retinal vessel analyser. Three phases of flicker light of twenty seconds followed by baseline light phases of eighty seconds were recorded. The maximal vasodilatory amplitude of each flicker phase was determined and the results averaged.


RESULTS
The maximal average dilatory amplitude at the arterial side reached (mean +/- SD) 2.9 +/- 1.7 % and 4.8 +/- 2.6 % of the baseline amplitude respectively in vasospastic subjects and in healthy controls (t = 2.34; p = 0.025). The reaction at the venous side was statistically comparable in both groups.


CONCLUSIONS
Otherwise healthy, vasospastic subject disclosed an altered reaction of the retinal vasculature to flicker light in this study.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12476</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1055/s-0028-1109271</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/19384788</dc:relation>
          <dc:source>Klinische Monatsblatter fur Augenheilkunde. - 2009</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Photic Stimulation</dc:subject>
          <dc:subject xml:lang="en">Retinal Vessels</dc:subject>
          <dc:subject xml:lang="en">Vasospasm, Intracranial</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">[Response of retinal vessel diameter to flicker-light in vasospastics compared to healthy controls].</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12484</identifier>
        <datestamp>2025-10-24T20:47:58Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Dongus S</dc:creator>
          <dc:creator>Nyika D</dc:creator>
          <dc:creator>Kannady K</dc:creator>
          <dc:creator>Mtasiwa D</dc:creator>
          <dc:creator>Mshinda H</dc:creator>
          <dc:creator>Gosoniu L</dc:creator>
          <dc:creator>Drescher AW</dc:creator>
          <dc:creator>Fillinger U</dc:creator>
          <dc:creator>Tanner M</dc:creator>
          <dc:creator>Killeen GF</dc:creator>
          <dc:creator>Castro MC</dc:creator>
          <dc:date>2009</dc:date>
          <dc:description xml:lang="en">A cross-sectional survey of agricultural areas, combined with routinely monitored mosquito larval information, was conducted in urban Dar es Salaam, Tanzania, to investigate how agricultural and geographical features may influence the presence of Anopheles larvae. Data were integrated into a geographical information systems framework, and predictors of the presence of Anopheles larvae in farming areas were assessed using multivariate logistic regression with independent random effects. It was found that more than 5% of the study area (total size 16.8 km2) was used for farming in backyard gardens and larger open spaces. The proportion of habitats containing Anopheles larvae was 1.7 times higher in agricultural areas compared to other areas (95% confidence interval = 1.56-1.92). Significant geographic predictors of the presence of Anopheles larvae in gardens included location in lowland areas, proximity to river, and relatively impermeable soils. Agriculture-related predictors comprised specific seedbed types, mid-sized gardens, irrigation by wells, as well as cultivation of sugar cane or leafy vegetables. Negative predictors included small garden size, irrigation by tap water, rainfed production and cultivation of leguminous crops or fruit trees. Although there was an increased chance of finding Anopheles larvae in agricultural sites, it was found that breeding sites originated by urban agriculture account for less than a fifth of all breeding sites of malaria vectors in Dar es Salaam. It is suggested that strategies comprising an integrated malaria control effort in malaria-endemic African cities include participatory involvement of farmers by planting shade trees near larval habitats.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12484</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4081/gh.2009.220</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/19440962</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Geospatial health. - 2009</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Anopheles</dc:subject>
          <dc:subject xml:lang="en">Cross-Sectional Studies</dc:subject>
          <dc:subject xml:lang="en">Ecosystem</dc:subject>
          <dc:subject xml:lang="en">Gardening</dc:subject>
          <dc:subject xml:lang="en">Larva</dc:subject>
          <dc:subject xml:lang="en">Logistic Models</dc:subject>
          <dc:subject xml:lang="en">Parasite Egg Count</dc:subject>
          <dc:subject xml:lang="en">Tanzania</dc:subject>
          <dc:subject xml:lang="en">Urban Population</dc:subject>
          <dc:title xml:lang="en">Urban agriculture and Anopheles habitats in Dar es Salaam, Tanzania.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12500</identifier>
        <datestamp>2025-10-24T20:47:59Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bozic-Weber B</dc:creator>
          <dc:creator>Constable EC</dc:creator>
          <dc:creator>Housecroft CE</dc:creator>
          <dc:creator>Kopecky P</dc:creator>
          <dc:creator>Neuburger M</dc:creator>
          <dc:creator>Zampese JA</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">6-(1-Methylpyrrol-2-yl)-2,2'-bipyridine, 3, and 6-(selenophene-2-yl)-2,2'-bipyridine, 4, have been prepared and characterized in solution and by structural determinations. Copper(I) complexes [CuL(2)][PF(6)] in which L is 2,2'-bipyridine substituted in the 6-position by furyl, thienyl, N-methylpyrrolyl, selenopheneyl, methyl or phenyl, (L = 1-6) have been synthesized. The complexes have been characterized by electrospray mass spectrometry, and solution NMR and UV-VIS spectroscopies. The single crystal structures of [Cu(1)(2)][PF(6)], [Cu(2)(2)][PF(6)], [Cu(3)(2)][PF(6)], [Cu(5)(2)][PF(6)] and [Cu(6)(2)][PF(6)] have been determined. In those compounds containing an aromatic substituent attached to the bpy unit, the substituent is twisted with respect to the latter. In [Cu(3)(2)][PF(6)] and [Cu(5)(2)][PF(6)], this results in intra-cation π-stacking between ligands which is very efficient in [Cu(3)(2)](+) despite the steric requirements of the N-methyl substituents. Face-to-face stacking between the ligands in the [Cu(2)(2)](+) ion is achieved by complementary substituent twisting and elongation of one Cu-N bond, but there is no analogous intra-cation π-stacking in [Cu(1)(2)](+). Ligand exchange reactions between [CuL(2)][PF(6)] (L = 1-6) and TiO(2)-anchored ligands 7-10 (L' = 2,2'-bipyridine-based ligands with CO(2)H or PO(OH)(2) anchoring groups) have been applied to produce 24 surface-anchored heteroleptic copper(i) complexes, the formation of which has been evidenced by using MALDI-TOF mass spectrometry and thin layer solid state diffuse reflectance electronic absorption spectroscopy. The efficiencies of the complexes as dyes in DSCs have been measured, and the best efficiencies are observed for [CuLL'] with L' = 10 which contains phosphonate anchoring groups.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12500</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1039/c1dt11052g</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21993898</dc:relation>
          <dc:source>Dalton transactions (Cambridge, England : 2003). - 2011</dc:source>
          <dc:title xml:lang="en">The intramolecular aryl embrace: from light emission to light absorption.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12509</identifier>
        <datestamp>2025-10-24T20:48:01Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Rovó A</dc:creator>
          <dc:creator>Tichelli A</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">Cardiovascular diseases (CVD) are emerging late effects after allogeneic hematopoietic stem cell transplantation (allo-HSCT), leading to considerable morbidity and mortality. These late CVD are in most cases related to enhanced atherosclerosis, promoted by the early appearance after transplantation of cardiovascular risk factors. According to the data obtained from the general population it is very likely that early intervention on these cardiovascular risk factors might defer the appearance of late CVD. This review focuses on the published data of cardiovascular diseases after transplantation, the potential associated risk factors, and the postulated pathophysiological mechanisms. A suggested approach for early identification of patients at risk, optimal surveillance, and screening of the modifiable cardiovascular risk factors and the possible early interventions are also discussed here. Long-term survivors should be assessed lifelong after HSCT; all healthcare providers involved in the follow-up of these patients should be aware of premature health threatening of cardiovascular diseases after transplantation.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12509</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1053/j.seminhematol.2011.10.001</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22221782</dc:relation>
          <dc:source>Seminars in hematology. - 2012</dc:source>
          <dc:subject xml:lang="en">Cardiovascular Diseases</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Hematopoietic Stem Cell Transplantation</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:subject xml:lang="en">Survivors</dc:subject>
          <dc:subject xml:lang="en">Time Factors</dc:subject>
          <dc:subject xml:lang="en">Transplantation, Homologous</dc:subject>
          <dc:title xml:lang="en">Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12517</identifier>
        <datestamp>2025-10-24T20:48:03Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Güven S</dc:creator>
          <dc:creator>Karagianni M</dc:creator>
          <dc:creator>Schwalbe M</dc:creator>
          <dc:creator>Schreiner S</dc:creator>
          <dc:creator>Farhadi J</dc:creator>
          <dc:creator>Bula S</dc:creator>
          <dc:creator>Bieback K</dc:creator>
          <dc:creator>Martin I</dc:creator>
          <dc:creator>Scherberich A</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">The stromal vascular fraction of adipose tissue has gained popularity as a source of autologous progenitor cells for tissue engineering and regenerative medicine applications. The aim of this study was to validate a newly developed, automated procedure to isolate adipose-derived mesenchymal stem/stromal cells (ASCs) from adult human lipoaspirates in a closed and clinical-grade device, based on the Sepax(®) technology. Using a total of 11 donors, this procedure was compared with the standard operator-based manual separation in terms of isolation yield, clonogenic fraction, phenotype, and differentiation potential of ASCs. As compared with the manual process, automation resulted in a 62% higher isolation yield, with 2.6±1.2×10(5) nucleated cells per mL of liposuction, and a 24% higher frequency of clonogenic progenitors. The variability in the isolation yield and clonogenicity across different preparations was reduced by 18% and 50%, respectively. The cytofluorimetric profile and in vitro differentiation capacity into mesenchymal lineages were comparable in the cells isolated using the two procedures. The new Sepax-based process thus allows an efficient isolation of ASCs with higher and more reproducible yields than the standard manual procedure, along with minimal operator intervention. These results are expected to facilitate the use of ASCs for clinical purposes, either within an intraoperative setting or in combination with further in vitro cell expansion/cultivation.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12517</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1089/ten.TEC.2011.0617</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22372873</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Tissue engineering. Part C, Methods. - 2012</dc:source>
          <dc:subject xml:lang="en">Adipose Tissue</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Automation</dc:subject>
          <dc:subject xml:lang="en">Cell Culture Techniques</dc:subject>
          <dc:subject xml:lang="en">Cell Differentiation</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Chondrocytes</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Flow Cytometry</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lipectomy</dc:subject>
          <dc:subject xml:lang="en">Mesoderm</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Osteoblasts</dc:subject>
          <dc:subject xml:lang="en">Phenotype</dc:subject>
          <dc:subject xml:lang="en">Stem Cells</dc:subject>
          <dc:subject xml:lang="en">Tissue Culture Techniques</dc:subject>
          <dc:title xml:lang="en">Validation of an automated procedure to isolate human adipose tissue-derived cells by using the Sepax® technology.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12550</identifier>
        <datestamp>2025-10-24T20:48:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ochoa-Espinosa A</dc:creator>
          <dc:creator>Baer MM</dc:creator>
          <dc:creator>Affolter M</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">New work shows the instructive role of Src42A kinase in tube size regulation. By inducing polarized cell-shape changes, Src42A promotes tube elongation in the Drosophila tracheal system.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12550</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cub.2012.04.033</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22677286</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Current biology : CB. - 2012</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Drosophila</dc:subject>
          <dc:subject xml:lang="en">Drosophila Proteins</dc:subject>
          <dc:subject xml:lang="en">Malpighian Tubules</dc:subject>
          <dc:subject xml:lang="en">Proto-Oncogene Proteins pp60(c-src)</dc:subject>
          <dc:title xml:lang="en">Tubulogenesis: Src42A goes to great lengths in tube elongation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12553</identifier>
        <datestamp>2025-10-24T20:48:13Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Duong FH</dc:creator>
          <dc:creator>Christen V</dc:creator>
          <dc:creator>Lin S</dc:creator>
          <dc:creator>Heim MH</dc:creator>
          <dc:date>2010</dc:date>
          <dc:description xml:lang="en">UNLABELLED
The molecular mechanisms underlying hepatocarcinogenesis in chronic viral hepatitis are poorly understood. A potential tumorigenic pathway could involve protein phosphatase 2A (PP2A) and protein arginine methyltransferase 1 (PRMT1), because both enzymes are dysregulated in chronic hepatitis C, and both enzymes have been involved in chromatin remodeling and DNA damage repair. We used cell lines that allow the inducible expression of hepatitis C virus proteins (UHCV57.3) and of the catalytic subunit of PP2A (UPP2A-C8) as well as Huh7.5 cells infected with recombinant cell culture-derived hepatitis C virus (HCVcc) to study epigenetic histone modifications and DNA damage repair. The induction of viral proteins, the overexpression of PP2Ac, or the infection of Huh7.5 cells with HCVcc resulted in an inhibition of histone H4 methylation/acetylation and histone H2AX phosphorylation, in a significantly changed expression of genes important for hepatocarcinogenesis, and inhibited DNA damage repair. Overexpression of PP2Ac in NIH-3T3 cells increased anchorage-independent growth. These changes were partially reversed by the treatment of cells with the methyl-group donor S-adenosyl-L-methionine (SAMe).


CONCLUSION
Hepatitis C virus-induced overexpression of PP2Ac contributes to hepatocarcinogenesis through dysregulation of epigenetic histone modifications. The correction of defective histone modifications by S-adenosyl-L-methionine makes this drug a candidate for chemopreventive therapies in patients with chronic hepatitis C who are at risk for developing hepatocellular carcinoma.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12553</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/hep.23388</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20043320</dc:relation>
          <dc:source>Hepatology (Baltimore, Md.). - 2010</dc:source>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">DNA Repair</dc:subject>
          <dc:subject xml:lang="en">Hepacivirus</dc:subject>
          <dc:subject xml:lang="en">Histones</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Liver Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Protein Phosphatase 2</dc:subject>
          <dc:subject xml:lang="en">Up-Regulation</dc:subject>
          <dc:title xml:lang="en">Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12570</identifier>
        <datestamp>2025-10-24T20:48:15Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Steffel J</dc:creator>
          <dc:creator>Rempel H</dc:creator>
          <dc:creator>Breitenstein A</dc:creator>
          <dc:creator>Schmidt S</dc:creator>
          <dc:creator>Namdar M</dc:creator>
          <dc:creator>Krasniqi N</dc:creator>
          <dc:creator>Holzmeister J</dc:creator>
          <dc:creator>Lüscher TF</dc:creator>
          <dc:creator>Ruschitzka F</dc:creator>
          <dc:creator>Hürlimann D</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients suffering from chronic heart failure (CHF). Optimal device programming is crucial for maximum patient benefit. The goal of the present study was to assess device settings from CHF patients undergoing CRT optimization in a "real world" setting, and to delineate parameters most frequently requiring adjustment.


METHODS
All patients who underwent CRT device implantation in the Cardiology Clinicat the University Hospital Zurich between January 2011 and September 2012 and in whom follow-up was available were included in this analysis.


RESULTS
A total of 170 CHF patients were included in this analysis. True biventricular pacing was present in 44% of all patients, while QRS fusion was detected in 49.9%. The majority of the patients presented with suboptimal atrioventricular (AV) delays requiring adjustment. AV delays were therefore shortened due to the presence of QRS fusion in 53.3% and 38.1% of patients (sAV and pAV, respectively) or prolonged because of truncation of the A wave in the left ventricular inflow pulse wave Doppler measurement (17.5% and 28.4% for sAV and pAV, respectively). In contrast, interventricular delay (VV delay) was rarely changed (11.9%).


CONCLUSIONS
In our "real world" cohort, a substantial proportion of patients presented to their first post-operative consultation with suboptimal device settings. Our data indicate that the opportunity to optimize device settings is frequently wasted in the "real world", underlining the necessity for expert device follow-up to deliver optimal care to this challenging group of heart failure patients.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12570</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.5603/CJ.a2013.0123</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/23990194</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Cardiology journal. - 2014</dc:source>
          <dc:subject xml:lang="en">Cardiac Resynchronization Therapy</dc:subject>
          <dc:subject xml:lang="en">Echocardiography, Doppler</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Heart Failure</dc:subject>
          <dc:subject xml:lang="en">Heart Rate</dc:subject>
          <dc:subject xml:lang="en">Heart Ventricles</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Comprehensive cardiac resynchronization therapy optimization in the real world.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12577</identifier>
        <datestamp>2025-10-24T20:48:17Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Auer JA</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">The first meeting leading to the formation of the European College of Veterinary Surgeons (ECVS) was held August 30/31, 1990 in Lenzburg, Switzerland. Specialists in small animal and large animal surgery from practice and academicians from many European countries were invited. The constitution was developed based on that of the American College of Veterinary Surgeons (ACVS). ECVS was founded during the ACVS European Surgical Forum in Nice in 1991. The provisional Board elected at this meeting stayed active during the initial 4 years to provide stability. For the 146 Charter Members to become a Diplomate, they had to pass an examination. Therefore, the ECVS is the only Specialty College that does not have a "Grand Father Clause." In 2000 ECVS, was the first College to acquire full recognition-status by the European Board of Specialization (EBVS), which underlines the leading role the surgeons play in the development of the European veterinary specialty colleges. Like its American Sister College, ECVS maintains high standards for surgical training programs for Residents and administers rigorous certifying examinations. It is appropriate to recall the facts that lead to foundation of ECVS on its 20-year anniversary.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12577</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1532-950X.2011.00865.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21815897</dc:relation>
          <dc:source>Veterinary surgery : VS. - 2011</dc:source>
          <dc:subject xml:lang="en">Certification</dc:subject>
          <dc:subject xml:lang="en">Education, Graduate</dc:subject>
          <dc:subject xml:lang="en">Education, Veterinary</dc:subject>
          <dc:subject xml:lang="en">Europe</dc:subject>
          <dc:subject xml:lang="en">History, 20th Century</dc:subject>
          <dc:subject xml:lang="en">History, 21st Century</dc:subject>
          <dc:subject xml:lang="en">Societies, Scientific</dc:subject>
          <dc:subject xml:lang="en">Surgery, Veterinary</dc:subject>
          <dc:title xml:lang="en">The European College of Veterinary Surgeons 1991-2011: a 20-year success story.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12585</identifier>
        <datestamp>2025-10-24T20:48:19Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Khaiseb S</dc:creator>
          <dc:creator>Sydler T</dc:creator>
          <dc:creator>Zimmermann D</dc:creator>
          <dc:creator>Pospischil A</dc:creator>
          <dc:creator>Sidler X</dc:creator>
          <dc:creator>Brugnera E</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">A member of the family Circoviridae, porcine circovirus type 2 (PCV2), is associated with postweaning multisystemic wasting syndrome (PMWS), a recent emerging disease worldwide. PCV2 is also found in clinically asymptomatic animals. This paradoxical finding makes the syndrome etiology challenging. We developed new assays to study PCV2 with links to syndrome etiology. For analysis, we used PCV2-infected tissues from subclinically infected and diseased piglets. We compared antigen- and PCV2 DNA-derived signals for tissue localization and intensity. Oligonucleotides were designed to the signature motif of the PCV2 capsid open reading frame to discriminate experimentally between PCV2 genotype groups by PCR, in situ hybridization (ISH), and fluorescence in situ hybridization (FISH). Unexpectedly, all PCV2-infected animals carried both PCV2a and PCV2b genotype group members. Using confocal microscopy, genotype single-cell infections and cell superinfections were visible. Additionally, we discriminated replicative DNA from total PCV2 DNA isoforms with FISH. This aided in our inquiry into cellular genotype-specific replication. Importantly, single-genotype-group replication was not observed. In infected cells with replicating virus, both genotype groups were equally present. These findings suggest PCV2 genotype group members relaxed replication regulation requirements and may even point to PCV2 replication cooperativity in vivo. These observations explain the readily seen PCV2 DNA recombinations and the high overall PCV2 genome plasticity. Hence, we suggest a novel mechanism of syndrome etiology that consists of a continuously changing PCV2 genome pool in hosts and pig herds, posing a constant challenge to the individual maturing immune system.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12585</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1128/JVI.05156-11</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21865380</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of virology. - 2011</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Capsid Proteins</dc:subject>
          <dc:subject xml:lang="en">Circovirus</dc:subject>
          <dc:subject xml:lang="en">DNA, Viral</dc:subject>
          <dc:subject xml:lang="en">Evolution, Molecular</dc:subject>
          <dc:subject xml:lang="en">Genotype</dc:subject>
          <dc:subject xml:lang="en">In Situ Hybridization</dc:subject>
          <dc:subject xml:lang="en">Microscopy, Confocal</dc:subject>
          <dc:subject xml:lang="en">Polymerase Chain Reaction</dc:subject>
          <dc:subject xml:lang="en">Porcine Postweaning Multisystemic Wasting Syndrome</dc:subject>
          <dc:subject xml:lang="en">Swine</dc:subject>
          <dc:subject xml:lang="en">Virus Replication</dc:subject>
          <dc:title xml:lang="en">Coreplication of the major genotype group members of porcine circovirus type 2 as a prerequisite to coevolution may explain the variable disease manifestations.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12598</identifier>
        <datestamp>2025-10-24T20:48:23Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bielicki JA</dc:creator>
          <dc:creator>Achermann R</dc:creator>
          <dc:creator>Berger C</dc:creator>
          <dc:date>2013</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
Incomplete and delayed vaccination is a barrier to individual and population protection from vaccine-preventable diseases. We aimed to assess visit frequency and pattern in relation to vaccination status in a Swiss cohort of 2-year-old children in order to review opportunities for completion of scheduled immunizations.


METHOD
A retrospective dynamic cohort study design involving children insured with a single health insurer in Switzerland was chosen. Time-to-event analysis was used to evaluate timing of defined immunizations of interest from submitted invoices. Diphtheria, tetanus, acellular pertussis (DTaP) and measles, mumps and rubella (MMR) immunizations administered to children registered with this health insurer were assessed. The specified vaccines are recommended at 2, 4, 6 and 15-24 months, and 12 and 15-24 months of age, respectively.


RESULTS
21,588 children born between January 1st, 2006 and June 30th, 2008 and registered with the health insurer from no later than 4 weeks of age were included. Only 40.9% of the cohort was up-to-date for both vaccines (DTaP and MMR) at 2 years of age. The average number of visits made during up to 2 years of age was 14.7 (95% CI: 15.9-16.3). Less than 5% of children made fewer than 5 visits, the minimum number required to complete all recommended immunizations by 2 years of age. Although number of visits varied by final vaccination status, more than 90% of the cohort made sufficient visits to complete the specified courses, even when contraindications were assumed to be present at up to half the visits.


CONCLUSION
Swiss children who are not fully immunized at 2 years of age make fewer visits to ambulatory health care up to that age, but they have more than sufficient opportunities to complete immunizations as scheduled. Ambulatory healthcare providers in Switzerland have ample opportunity to promote and administer vaccinations in a timely manner.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12598</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.vaccine.2013.09.025</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24075922</dc:relation>
          <dc:source>Vaccine. - 2013</dc:source>
          <dc:subject xml:lang="en">Immunization programme</dc:subject>
          <dc:subject xml:lang="en">Organizational Case Study</dc:subject>
          <dc:subject xml:lang="en">Physician's Practice Patterns</dc:subject>
          <dc:subject xml:lang="en">Preventive Health Services</dc:subject>
          <dc:subject xml:lang="en">Ambulatory Care</dc:subject>
          <dc:subject xml:lang="en">Child, Preschool</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunization Schedule</dc:subject>
          <dc:subject xml:lang="en">Infant</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Medication Adherence</dc:subject>
          <dc:subject xml:lang="en">Office Visits</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:subject xml:lang="en">Vaccination</dc:subject>
          <dc:title xml:lang="en">In touch but not up-to-date: ambulatory visits and vaccination status in a cohort of young Swiss children.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12599</identifier>
        <datestamp>2025-10-24T20:48:23Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Lachat M</dc:creator>
          <dc:creator>Veith FJ</dc:creator>
          <dc:creator>Pfammatter T</dc:creator>
          <dc:creator>Glenck M</dc:creator>
          <dc:creator>Bettex D</dc:creator>
          <dc:creator>Mayer D</dc:creator>
          <dc:creator>Rancic Z</dc:creator>
          <dc:creator>Gloekler S</dc:creator>
          <dc:creator>Pecoraro F</dc:creator>
          <dc:date>2013</dc:date>
          <dc:description xml:lang="en">PURPOSE
To evaluate the performance of periscope and/or chimney grafts (CPGs) in the endovascular treatment of pararenal or thoracoabdominal aneurysms using off-the-shelf devices.


METHODS
Between February 2002 and August 2012, 77 consecutive patients (62 men; mean age 73±9 years) suffering from pararenal aortic (n=55), thoracoabdominal (n=16), or arch to visceral artery aneurysms (n=6) were treated with aortic stent-graft implantation requiring chimney and/or periscope grafts to maintain side branch perfusion. CPGs were planned in advance and were not used as bailout. A standardized follow-up protocol including computed tomographic angiography, laboratory testing, and clinical examination was performed at 6 weeks; 3, 6, and 12 months; and annually thereafter.


RESULTS
Technical success was achieved in 76 (99%) patients; 1 branch stent-graft became dislocated from a renal artery, which could not be re-accessed. Overall, 169 target vessels (121 renal arteries, 30 superior mesenteric arteries, 17 celiac trunks, and 1 inferior mesenteric artery) were addressed with the chimney graft configuration in 111 and the periscope graft configuration in 58. In total, 228 devices were used for the CPGs: 213 Viabahn stent-grafts and 15 bare metal stents. Over a mean 25±16 months (range 1-121), 9 patients died of unrelated causes. Nearly all (95%) of the patients demonstrated a decreased or stable aneurysm size on imaging; there was a mean 13% shrinkage in aneurysm diameter. Twenty patients had primary type I/III endoleaks at discharge; in follow-up, only 3 of these were still present (no secondary or recurrent endoleaks were noted). Additional endovascular maneuvers were required for CPG-related complications in 13 patients from intervention throughout follow-up. Overall, 4 CPGs occluded (98% target vessel patency); no stent-graft migration was observed. Renal function remained stable in all patients.


CONCLUSION
In this series, the use of CPGs has proven to be a feasible, safe, and effective way to treat thoracoabdominal and pararenal aneurysms with maintenance of blood flow to the renovisceral arteries. Nearly all of the aneurysms showed no increase in diameter over a &gt;2-year mean follow-up, which supports the midterm adequacy of the CPG technique as a method to effectively revascularize branch vessels with few endoleaks or branch occlusions.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12599</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1583/13-4372.1</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24093310</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. - 2013</dc:source>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Aortic Aneurysm, Abdominal</dc:subject>
          <dc:subject xml:lang="en">Aortic Aneurysm, Thoracic</dc:subject>
          <dc:subject xml:lang="en">Aortography</dc:subject>
          <dc:subject xml:lang="en">Blood Vessel Prosthesis</dc:subject>
          <dc:subject xml:lang="en">Blood Vessel Prosthesis Implantation</dc:subject>
          <dc:subject xml:lang="en">Endoleak</dc:subject>
          <dc:subject xml:lang="en">Endovascular Procedures</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Kaplan-Meier Estimate</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Prosthesis Design</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Stents</dc:subject>
          <dc:subject xml:lang="en">Time Factors</dc:subject>
          <dc:subject xml:lang="en">Tomography, X-Ray Computed</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">Vascular Patency</dc:subject>
          <dc:title xml:lang="en">Chimney and periscope grafts observed over 2 years after their use to revascularize 169 renovisceral branches in 77 patients with complex aortic aneurysms.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12603</identifier>
        <datestamp>2025-10-24T20:48:24Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Leeners B</dc:creator>
          <dc:creator>Hengartner MP</dc:creator>
          <dc:creator>Rössler W</dc:creator>
          <dc:creator>Ajdacic-Gross V</dc:creator>
          <dc:creator>Angst J</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">INTRODUCTION
There are little published data on the prevalence of orgasmic difficulties in representative samples and no longitudinal data on the subject. In addition, our knowledge of the factors, which increase or protect against the risk of orgasmic difficulties, is still rudimentary.


AIM
The aim of this study was to evaluate the cumulative incidence rate and longitudinal course of orgasmic difficulties from age 30 to age 50, and the role of psychopathological and personality covariates in a representative population cohort of women.


METHODS
Semi-structured interviews with single-item questions on sexual problems in general as well as on orgasmic difficulties were conducted. Psychopathological covariates were from the Symptom Checklist 90 Revised and personality characteristics from the Freiburg Personality Inventory. Coping resources were measured by the scales of mastery and self-esteem.


MAIN OUTCOME MEASURES
One-year prevalences of orgasmic difficulties, associations with psychopathological and personality covariates as well as coping resources were the main outcome measures.


RESULTS
Orgasmic difficulties were reported annually by 7.4% to 13.5% of the women with a mean of 10.0% and a cumulative risk of 27.3% from age 30 to 50. No relation between age and the prevalence of orgasmic difficulties could be demonstrated. Psychopathological covariates such as depression, psychoticism, interpersonal sensitivity, obsessive-compulsive symptoms, and somatization were moderately associated with orgasmic difficulties. Also, personality traits, i.e., nervousness, aggressiveness, depressiveness, irritability, sociability, and openness, were related to orgasmic difficulties.


CONCLUSIONS
With a cumulative risk of 27.3%, orgasmic difficulties represent a frequent sexual problem. Annual prevalence rates are particularly high in women with psychopathological characteristics and modestly related to various personality traits. Our findings support the relevance of psychosocial factors in the regulation of female orgasm. More basic research is needed to better understand underlying pathophysiological mechanisms and to improve diagnostic as well as therapeutic tools for women suffering from orgasmic difficulties.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12603</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/jsm.12709</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25358802</dc:relation>
          <dc:source>The journal of sexual medicine. - 2014</dc:source>
          <dc:subject xml:lang="en">Age</dc:subject>
          <dc:subject xml:lang="en">Coping Resources</dc:subject>
          <dc:subject xml:lang="en">Female Sexual Dysfunction</dc:subject>
          <dc:subject xml:lang="en">Longitudinal Course</dc:subject>
          <dc:subject xml:lang="en">Orgasmic Difficulties</dc:subject>
          <dc:subject xml:lang="en">Personality Traits</dc:subject>
          <dc:subject xml:lang="en">Psychopathology</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Anxiety</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Depression</dc:subject>
          <dc:subject xml:lang="en">Emotions</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Longitudinal Studies</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Orgasm</dc:subject>
          <dc:subject xml:lang="en">Personality</dc:subject>
          <dc:subject xml:lang="en">Personality Disorders</dc:subject>
          <dc:subject xml:lang="en">Prevalence</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Self Concept</dc:subject>
          <dc:subject xml:lang="en">Sexual Dysfunctions, Psychological</dc:subject>
          <dc:subject xml:lang="en">Women's Health</dc:subject>
          <dc:title xml:lang="en">The role of psychopathological and personality covariates in orgasmic difficulties: a prospective longitudinal evaluation in a cohort of women from age 30 to 50.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12606</identifier>
        <datestamp>2025-10-24T20:48:25Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Merki-Feld GS</dc:creator>
          <dc:creator>Skouby S</dc:creator>
          <dc:creator>Serfaty D</dc:creator>
          <dc:creator>Lech M</dc:creator>
          <dc:creator>Bitzer J</dc:creator>
          <dc:creator>Crosignani PG</dc:creator>
          <dc:creator>Cagnacci A</dc:creator>
          <dc:creator>Sitruk-Ware R</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">The obesity 'epidemic' continues to increase, mostly but not only in developed countries. As overweight and obese women are at an increased risk for venous thromboembolism (VTE) at baseline and at a much higher risk during pregnancy, it is essential to help these women to plan pregnancies carefully and to use contraceptives with a positive ratio of benefits versus risks. The Expert Group on hormonal and molecular contraception of the European Society of Contraception convened to review the existing evidence and propose recommendations to the prescribers in line with most recent studies and with the Medical Eligibility Criteria of the World Health Organisation.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12606</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3109/13625187.2014.960561</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25380138</dc:relation>
          <dc:source>The European journal of contraception &amp; reproductive health care : the official journal of the European Society of Contraception. - 2015</dc:source>
          <dc:subject xml:lang="en">Contraceptive failure</dc:subject>
          <dc:subject xml:lang="en">Depo-medroxyprogesterone</dc:subject>
          <dc:subject xml:lang="en">Efficacy</dc:subject>
          <dc:subject xml:lang="en">Hormonal contraception</dc:subject>
          <dc:subject xml:lang="en">Obesity</dc:subject>
          <dc:subject xml:lang="en">Progestin-only contraception</dc:subject>
          <dc:subject xml:lang="en">Thromboembolic risk</dc:subject>
          <dc:subject xml:lang="en">Weight</dc:subject>
          <dc:subject xml:lang="en">Contraception</dc:subject>
          <dc:subject xml:lang="en">Contraception, Postcoital</dc:subject>
          <dc:subject xml:lang="en">Contraceptive Agents, Female</dc:subject>
          <dc:subject xml:lang="en">Developed Countries</dc:subject>
          <dc:subject xml:lang="en">Europe</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intrauterine Devices, Medicated</dc:subject>
          <dc:subject xml:lang="en">Obesity</dc:subject>
          <dc:subject xml:lang="en">Overweight</dc:subject>
          <dc:subject xml:lang="en">Pregnancy</dc:subject>
          <dc:subject xml:lang="en">Societies, Medical</dc:subject>
          <dc:subject xml:lang="en">Venous Thromboembolism</dc:subject>
          <dc:title xml:lang="en">European society of contraception statement on contraception in obese women.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12617</identifier>
        <datestamp>2025-10-24T20:48:26Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Sturm V</dc:creator>
          <dc:creator>Hejcmanova M</dc:creator>
          <dc:creator>Landau K</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Monocular infantile blindness may be associated with bilateral horizontal nystagmus, a subtype of fusion maldevelopment nystagmus syndrome (FMNS). Patients often adopt a significant anomalous head posture (AHP) towards the fixing eye in order to dampen the nystagmus. This clinical entity has also been reported as unilateral Ciancia syndrome. The aim of the study was to ascertain the clinical features and surgical outcome of patients with FMNS with infantile unilateral visual loss.


METHODS
In this retrospective case series, nine consecutive patients with FMNS with infantile unilateral visual loss underwent strabismus surgery to correct an AHP and/or improve ocular alignment. Outcome measures included amount of AHP and deviation at last follow-up.


RESULTS
Eye muscle surgery according to the principles of Kestenbaum resulted in a marked reduction or elimination of the AHP. On average, a reduction of AHP of 1.3°/mm was achieved by predominantly performing combined horizontal recess-resect surgery in the intact eye. In cases of existing esotropia (ET) this procedure also markedly reduced the angle of deviation. A dosage calculation of 3 prism diopters/mm was established.


CONCLUSIONS
We advocate a tailored surgical approach in FMNS with infantile unilateral visual loss. In typical patients who adopt a significant AHP accompanied by a large ET, we suggest an initial combined recess-resect surgery in the intact eye. This procedure regularly led to a marked reduction of the head turn and ET. In patients without significant strabismus, a full Kestenbaum procedure was successful, while ET in a patient with a minor AHP was corrected by performing a bimedial recession.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12617</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2415-14-137</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25413480</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>BMC ophthalmology. - 2014</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Blindness</dc:subject>
          <dc:subject xml:lang="en">Child</dc:subject>
          <dc:subject xml:lang="en">Child, Preschool</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Nystagmus, Pathologic</dc:subject>
          <dc:subject xml:lang="en">Oculomotor Muscles</dc:subject>
          <dc:subject xml:lang="en">Ophthalmologic Surgical Procedures</dc:subject>
          <dc:subject xml:lang="en">Posture</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Strabismus</dc:subject>
          <dc:subject xml:lang="en">Vision, Monocular</dc:subject>
          <dc:subject xml:lang="en">Visual Acuity</dc:subject>
          <dc:title xml:lang="en">Effects of extraocular muscle surgery in children with monocular blindness and bilateral nystagmus.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12687</identifier>
        <datestamp>2025-10-24T20:48:29Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Abdelhady W</dc:creator>
          <dc:creator>Chen L</dc:creator>
          <dc:creator>Bayer AS</dc:creator>
          <dc:creator>Seidl K</dc:creator>
          <dc:creator>Yeaman MR</dc:creator>
          <dc:creator>Kreiswirth BN</dc:creator>
          <dc:creator>Xiong YQ</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
Persistent MRSA infections are especially relevant to endovascular infections and correlate with suboptimal outcomes. However, the virulence signatures of Staphylococcus aureus that drive such persistence outcomes are not well defined. In the current study, we investigated correlations between accessory gene regulator (agr) activation and the outcome of vancomycin treatment in an experimental model of infective endocarditis (IE) due to MRSA strains with different agr and clonal complex (CC) types.


METHODS
Twelve isolates with the four most common MRSA CC and agr types (CC5-agr II, CC8-agr I, CC30-agr III and CC45-agr I) were evaluated for heterogeneous vancomycin-intermediate S. aureus (hVISA), agr function, agrA and RNAIII transcription, agr locus sequences, virulence and response to vancomycin in the IE model.


RESULTS
Early agr RNAIII activation (beginning at 2 h of growth) in parallel with strong δ-haemolysin production correlated with persistent outcomes in the IE model following vancomycin therapy. Importantly, such treatment failures occurred across the range of CC/agr types studied. In addition, these MRSA strains: (i) were vancomycin susceptible in vitro; (ii) were not hVISA or vancomycin tolerant; and (iii) did not evolve hVISA phenotypes or perturbed δ-haemolysin activity in vivo following vancomycin therapy. Moreover, agr locus sequence analyses revealed no common point mutations that correlated with either temporal RNAIII transcription or vancomycin treatment outcomes, encompassing different CC and agr types.


CONCLUSIONS
These data suggest that temporal agr RNAIII activation and agr functional profiles may be useful biomarkers to predict the in vivo persistence of endovascular MRSA infections despite vancomycin therapy.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12687</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dku547</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25564565</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The Journal of antimicrobial chemotherapy. - 2015</dc:source>
          <dc:subject xml:lang="en">antibiotics</dc:subject>
          <dc:subject xml:lang="en">bacteria</dc:subject>
          <dc:subject xml:lang="en">resistance</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Anti-Bacterial Agents</dc:subject>
          <dc:subject xml:lang="en">Bacterial Proteins</dc:subject>
          <dc:subject xml:lang="en">Disease Models, Animal</dc:subject>
          <dc:subject xml:lang="en">Endocarditis</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Profiling</dc:subject>
          <dc:subject xml:lang="en">Methicillin-Resistant Staphylococcus aureus</dc:subject>
          <dc:subject xml:lang="en">Rabbits</dc:subject>
          <dc:subject xml:lang="en">Sequence Analysis, DNA</dc:subject>
          <dc:subject xml:lang="en">Staphylococcal Infections</dc:subject>
          <dc:subject xml:lang="en">Trans-Activators</dc:subject>
          <dc:subject xml:lang="en">Transcriptional Activation</dc:subject>
          <dc:subject xml:lang="en">Treatment Failure</dc:subject>
          <dc:subject xml:lang="en">Virulence</dc:subject>
          <dc:title xml:lang="en">Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12693</identifier>
        <datestamp>2025-10-24T20:48:29Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Mallano T</dc:creator>
          <dc:creator>Palumbo-Zerr K</dc:creator>
          <dc:creator>Zerr P</dc:creator>
          <dc:creator>Ramming A</dc:creator>
          <dc:creator>Zeller B</dc:creator>
          <dc:creator>Beyer C</dc:creator>
          <dc:creator>Dees C</dc:creator>
          <dc:creator>Huang J</dc:creator>
          <dc:creator>Hai T</dc:creator>
          <dc:creator>Distler O</dc:creator>
          <dc:creator>Schett G</dc:creator>
          <dc:creator>Distler JH</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Activating transcription factor 3 (ATF3), a member of the ATF/cAMP-responsive element binding (CREB) family of transcription factors, regulates cellular response to stress including oxidative stress. The aim of this study was to analyse the role of ATF3 in fibroblast activation in systemic sclerosis (SSc).


METHODS
ATF3 was analysed by reverse transcription quantitative PCR, western blot and immunohistochemistry. ATF3 knockout fibroblasts and mice were used to study the functional role of ATF3. Knockdown experiments, reporter assays and coimmunoprecipitation were performed to study the effects of ATF3 on Smad and activation protein 1 (AP-1) signalling. The role of c-Jun was analysed by costaining, specific inactivation and coimmunoprecipitation.


RESULTS
Transforming growth factor-β (TGFβ) upregulates the expression of ATF3 in SSc fibroblasts. ATF3-deficient fibroblasts were less sensitive to TGFβ, whereas ectopic expression of ATF3 enhanced the profibrotic effects of TGFβ. Mechanistically, ATF3 interacts with Smad3 directly on stimulation with TGFβ and regulates Smad activity in a c-Jun-dependent manner. Knockout of ATF3 protected mice from bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active TGFβ receptor I. Reporter assays and analyses of the expression of Smad target genes demonstrated that binding of ATF3 regulates the transcriptional activity of Smad3.


CONCLUSIONS
We demonstrate for the first time a key role for ATF3 in fibrosis. Knockout of the ATF3 gene reduced the stimulatory effect of TGFβ on fibroblasts by interfering with canonical Smad signalling and protected the mice from experimental fibrosis in two different models. ATF3 might thus be a candidate for molecular targeted therapies for SSc.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12693</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1136/annrheumdis-2014-206214</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25589515</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Annals of the rheumatic diseases. - 2016</dc:source>
          <dc:subject xml:lang="en">Fibroblasts</dc:subject>
          <dc:subject xml:lang="en">Systemic Sclerosis</dc:subject>
          <dc:subject xml:lang="en">Treatment</dc:subject>
          <dc:subject xml:lang="en">Activating Transcription Factor 3</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Blotting, Western</dc:subject>
          <dc:subject xml:lang="en">Case-Control Studies</dc:subject>
          <dc:subject xml:lang="en">Dermis</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Fibroblasts</dc:subject>
          <dc:subject xml:lang="en">Fibrosis</dc:subject>
          <dc:subject xml:lang="en">Fluorescent Antibody Technique</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Profiling</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunohistochemistry</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Knockout</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Protein-Serine-Threonine Kinases</dc:subject>
          <dc:subject xml:lang="en">Proto-Oncogene Proteins c-jun</dc:subject>
          <dc:subject xml:lang="en">Receptor, Transforming Growth Factor-beta Type I</dc:subject>
          <dc:subject xml:lang="en">Receptors, Transforming Growth Factor beta</dc:subject>
          <dc:subject xml:lang="en">Reverse Transcriptase Polymerase Chain Reaction</dc:subject>
          <dc:subject xml:lang="en">Scleroderma, Systemic</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:subject xml:lang="en">Smad3 Protein</dc:subject>
          <dc:subject xml:lang="en">Transcription Factor AP-1</dc:subject>
          <dc:subject xml:lang="en">Transforming Growth Factor beta</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12755</identifier>
        <datestamp>2025-10-24T20:48:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Felber M</dc:creator>
          <dc:creator>Bauwens M</dc:creator>
          <dc:creator>Mateos JM</dc:creator>
          <dc:creator>Imstepf S</dc:creator>
          <dc:creator>Mottaghy FM</dc:creator>
          <dc:creator>Alberto R</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">Radiolabeling allows noninvasive imaging by single photon emission computed tomography (SPECT) or positron emission tomography (PET) for assessing the biodistribution of nanostructures. Herein, the synthesis of a new coating ligand for gold nanoparticles (AuNPs) and quantum dots (QDs) is reported. This ligand is multifunctional; it combines the metal chelate with conjugating functions to biological vectors. The concept allows the coupling of any targeting function to the chelator; an example for the prostate specific membrane antigen is given. Derivatized NPs can directly be labeled in one step with [(99m) Tc(OH2 )3 (CO)3 ](+) . AuNPs in particular are highly stable, a prerequisite for in vivo studies excluding misinterpretation of the biodistribution data. AuNPs with differing sizes (7 and 14 nm core diameter) were administered intravenously into nude NMRI mice bearing LNCaP xenografts. MicroSPECT images show for both probes rapid clearance from the blood pool through the hepatobiliary pathway. The 7 nm AuNPs revealed a significantly higher bone uptake than the 14 nm AuNPs. The high affinity towards bone mineral is further confirmed in vitro with hydroxyapatite.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12755</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/chem.201405704</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25765900</dc:relation>
          <dc:source>Chemistry (Weinheim an der Bergstrasse, Germany). - 2015</dc:source>
          <dc:subject xml:lang="en">gold</dc:subject>
          <dc:subject xml:lang="en">nanoparticles</dc:subject>
          <dc:subject xml:lang="en">radiochemistry</dc:subject>
          <dc:subject xml:lang="en">radiolabeling</dc:subject>
          <dc:subject xml:lang="en">technetium</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">COS Cells</dc:subject>
          <dc:subject xml:lang="en">Cell Line</dc:subject>
          <dc:subject xml:lang="en">Chlorocebus aethiops</dc:subject>
          <dc:subject xml:lang="en">Gold</dc:subject>
          <dc:subject xml:lang="en">Ligands</dc:subject>
          <dc:subject xml:lang="en">Metal Nanoparticles</dc:subject>
          <dc:subject xml:lang="en">Mice, Nude</dc:subject>
          <dc:subject xml:lang="en">Models, Molecular</dc:subject>
          <dc:subject xml:lang="en">Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Organotechnetium Compounds</dc:subject>
          <dc:subject xml:lang="en">Quantum Dots</dc:subject>
          <dc:subject xml:lang="en">Tissue Distribution</dc:subject>
          <dc:subject xml:lang="en">Tomography, Emission-Computed, Single-Photon</dc:subject>
          <dc:title xml:lang="en">(99m) Tc radiolabeling and biological evaluation of nanoparticles functionalized with a versatile coating ligand.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12786</identifier>
        <datestamp>2025-10-24T20:48:36Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Szövényi P</dc:creator>
          <dc:creator>Frangedakis E</dc:creator>
          <dc:creator>Ricca M</dc:creator>
          <dc:creator>Quandt D</dc:creator>
          <dc:creator>Wicke S</dc:creator>
          <dc:creator>Langdale JA</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Plants colonized terrestrial environments approximately 480 million years ago and have contributed significantly to the diversification of life on Earth. Phylogenetic analyses position a subset of charophyte algae as the sister group to land plants, and distinguish two land plant groups that diverged around 450 million years ago - the bryophytes and the vascular plants. Relationships between liverworts, mosses hornworts and vascular plants have proven difficult to resolve, and as such it is not clear which bryophyte lineage is the sister group to all other land plants and which is the sister to vascular plants. The lack of comparative molecular studies in representatives of all three lineages exacerbates this uncertainty. Such comparisons can be made between mosses and liverworts because representative model organisms are well established in these two bryophyte lineages. To date, however, a model hornwort species has not been available.


RESULTS
Here we report the establishment of Anthoceros agrestis as a model hornwort species for laboratory experiments. Axenic culture conditions for maintenance and vegetative propagation have been determined, and treatments for the induction of sexual reproduction and sporophyte development have been established. In addition, protocols have been developed for the extraction of DNA and RNA that is of a quality suitable for molecular analyses. Analysis of haploid-derived genome sequence data of two A. agrestis isolates revealed single nucleotide polymorphisms at multiple loci, and thus these two strains are suitable starting material for classical genetic and mapping experiments.


CONCLUSIONS
Methods and resources have been developed to enable A. agrestis to be used as a model species for developmental, molecular, genomic, and genetic studies. This advance provides an unprecedented opportunity to investigate the biology of hornworts.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12786</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s12870-015-0481-x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25886741</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>BMC plant biology. - 2015</dc:source>
          <dc:subject xml:lang="en">Anthocerotophyta</dc:subject>
          <dc:subject xml:lang="en">Axenic Culture</dc:subject>
          <dc:subject xml:lang="en">Molecular Sequence Data</dc:subject>
          <dc:subject xml:lang="en">Sequence Analysis, DNA</dc:subject>
          <dc:title xml:lang="en">Establishment of Anthoceros agrestis as a model species for studying the biology of hornworts.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12620</identifier>
        <datestamp>2025-10-24T20:48:37Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gerber PA</dc:creator>
          <dc:creator>Berneis K</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">PURPOSE OF REVIEW
This article aims at reviewing the recent findings that have been made concerning the crosstalk of carbohydrate metabolism with the generation of small, dense low-density lipoprotein (LDL) particles, which are known to be associated with an adverse cardiovascular risk profile.


RECENT FINDINGS
Studies conducted during the past few years have quite unanimously shown that the quantity of carbohydrates ingested is associated with a decrease of LDL particle size and an increase in its density. Conversely, diets that aim at a reduction of carbohydrate intake are able to improve LDL quality. Furthermore, a reduction of the glycaemic index without changing the amount of carbohydrates ingested has similar effects. Diseases with altered carbohydrate metabolism, for example, type 2 diabetes, are associated with small, dense LDL particles. Finally, even the kind of monosaccharide the carbohydrate intake consists of is important concerning LDL particle size: fructose has been shown to alter the LDL particle subclass profile more adversely than glucose in many recent studies.


SUMMARY
LDL particle quality, rather than its quantity, is affected by carbohydrate metabolism, which is of clinical importance, in particular, in the light of increased carbohydrate consumption in today's world.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12620</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/MCO.0b013e3283545a6d</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22617560</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Current opinion in clinical nutrition and metabolic care. - 2012</dc:source>
          <dc:subject xml:lang="en">Blood Glucose</dc:subject>
          <dc:subject xml:lang="en">Cardiovascular Diseases</dc:subject>
          <dc:subject xml:lang="en">Diet</dc:subject>
          <dc:subject xml:lang="en">Diet, Carbohydrate-Restricted</dc:subject>
          <dc:subject xml:lang="en">Dietary Carbohydrates</dc:subject>
          <dc:subject xml:lang="en">Energy Intake</dc:subject>
          <dc:subject xml:lang="en">Glycemic Index</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lipoproteins, LDL</dc:subject>
          <dc:subject xml:lang="en">Metabolic Diseases</dc:subject>
          <dc:subject xml:lang="en">Monosaccharides</dc:subject>
          <dc:subject xml:lang="en">Particle Size</dc:subject>
          <dc:title xml:lang="en">Regulation of low-density lipoprotein subfractions by carbohydrates.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12707</identifier>
        <datestamp>2025-10-24T20:48:42Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Eichholzer M</dc:creator>
          <dc:creator>Steinbrecher A</dc:creator>
          <dc:creator>Kaaks R</dc:creator>
          <dc:creator>Teucher B</dc:creator>
          <dc:creator>Linseisen J</dc:creator>
          <dc:creator>Rohrmann S</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">UNLABELLED
Study Type--Prognosis (case control) Level of Evidence 2. What's known on the subject? and What does the study add? Geographical and ethnic differences in the distribution of BPH and the results of migrant studies indicate that not only age, androgens and genetics, but also modifiable factors may play a role in the aetiology of BPH. Oxidative stress induced by chronic inflammation could be a cause and antioxidants, including selenoproteins, may reduce the risk. The published data related to this topic are scarce and are mainly based on cross-sectional and case-control studies. In a nested case-control study, we observed a significant inverse association between serum selenium concentrations and the risk of BPH. These results need to be confirmed in larger, prospective epidemiological studies. Prostate enlargement is an increasing health problem as a result of an ageing population in many countries. Modifiable factors may also play a role. In the present study, before this antioxidant can be recommended as a preventive measure.


OBJECTIVE
• To determine whether geographical differences in the distribution of benign prostatic hyperplasia (BPH) and migrant studies indicate that modifiable factors play a role in the aetiology of BPH. Oxidative stress produced by chronic inflammation could represent one of the causes, and antioxidants, including selenoproteins, may reduce the risk.


SUBJECTS AND METHODS
• Conditional logistic regression was used to examine the associations of serum selenium and selenoprotein P concentrations and glutathione peroxidase activity with respect to the risk of BPH in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition-Heidelberg cohort, including 111 cases and 214 matched controls. • In addition, dietary glucosinolate intake and the serum glutathione S-transferase α concentration was investigated.


RESULTS
• The risk of BPH significantly decreased with an increasing serum selenium concentration; the risk estimate was 0.83 (35% CI 0.69-0.99) per 10 µg/L increase in serum selenium concentration. • However, no significant association was present for serum selenoprotein P concentration or glutathione peroxidase activity. Risk estimates for BPH decreased with a higher intake of glucosinolates, although the results were not statistically significant.


CONCLUSION
• A low serum selenium concentration may increase the risk of BPH, although the findings reported in the present study need to be confirmed in larger, well-designed epidemiological studies.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12707</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1464-410X.2012.11383.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22882569</dc:relation>
          <dc:source>BJU international. - 2012</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Biomarkers</dc:subject>
          <dc:subject xml:lang="en">Dietary Supplements</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Germany</dc:subject>
          <dc:subject xml:lang="en">Glucosinolates</dc:subject>
          <dc:subject xml:lang="en">Glutathione Transferase</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Incidence</dc:subject>
          <dc:subject xml:lang="en">Isoenzymes</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Prostatic Hyperplasia</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:subject xml:lang="en">Selenium</dc:subject>
          <dc:title xml:lang="en">Effects of selenium status, dietary glucosinolate intake and serum glutathione S-transferase α activity on the risk of benign prostatic hyperplasia.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12729</identifier>
        <datestamp>2025-10-24T20:48:46Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Wulf MA</dc:creator>
          <dc:creator>Bode B</dc:creator>
          <dc:creator>Zimmermann D</dc:creator>
          <dc:creator>Rufibach K</dc:creator>
          <dc:creator>Weder W</dc:creator>
          <dc:creator>Moch H</dc:creator>
          <dc:creator>Soltermann A</dc:creator>
          <dc:creator>Tischler V</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">Epidermal growth factor receptor (EGFR) gene mutation and high gene copy number (CN) predict response to EGFR tyrosine kinase inhibitor therapy in the adenocarcinoma subtype of non-small cell lung cancer (NSCLC). The aims of this study were first to compare automated enzyme metallographic silver-enhanced in situ hybridization (SISH) with conventionally used fluorescence in situ hybridization (FISH) in the determination of EGFR CN in NSCLC tissue sections, and second to assess the association of EGFR CN with EGFR mutations and clinicopathological parameters. FISH and SISH were performed on tissue microarrays and large sections. Samples from 56 consecutively surgically resected NSCLC patients (cohort 1) and from 60 selected lung adenocarcinoma patients (cohort 2) were analyzed. EGFR CN was classified applying the Colorado criteria, and agreement between both methods was evaluated using κ values. EGFR CN was compared with EGFR protein expression and EGFR gene mutations. The results of SISH and FISH were identical in 114 of the 116 cases examined using the 2 techniques. One case was FISH+, SISH-, and 1 case was FISH- and SISH+. The agreement between the 2 methods was good in cohort 1 (κ=0.642 [0.428, 0.823]) and excellent in cohort 2 (κ=0.963 [0.870, 1.000]). EGFR positivity by FISH and SISH was associated with high EGFR protein expression (P&lt;0.001) and EGFR mutation (P&lt;0.001). These results validate the use of SISH for assessing EGFR CN alterations in NSCLC. The advantage of a permanent result and the possibility of bright-field microscopy make SISH an attractive alternative to FISH.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12729</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/PAS.0b013e31826ff153</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/23154768</dc:relation>
          <dc:source>The American journal of surgical pathology. - 2012</dc:source>
          <dc:subject xml:lang="en">Acetates</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Automation, Laboratory</dc:subject>
          <dc:subject xml:lang="en">Biomarkers, Tumor</dc:subject>
          <dc:subject xml:lang="en">Carcinoma, Non-Small-Cell Lung</dc:subject>
          <dc:subject xml:lang="en">DNA Copy Number Variations</dc:subject>
          <dc:subject xml:lang="en">DNA Mutational Analysis</dc:subject>
          <dc:subject xml:lang="en">ErbB Receptors</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Gene Dosage</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunohistochemistry</dc:subject>
          <dc:subject xml:lang="en">In Situ Hybridization</dc:subject>
          <dc:subject xml:lang="en">In Situ Hybridization, Fluorescence</dc:subject>
          <dc:subject xml:lang="en">Lung Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Mutation</dc:subject>
          <dc:subject xml:lang="en">Predictive Value of Tests</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Silver Compounds</dc:subject>
          <dc:subject xml:lang="en">Tissue Array Analysis</dc:subject>
          <dc:title xml:lang="en">Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12752</identifier>
        <datestamp>2025-10-24T20:48:47Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Jäncke L</dc:creator>
          <dc:creator>Rogenmoser L</dc:creator>
          <dc:creator>Meyer M</dc:creator>
          <dc:creator>Elmer S</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Coloured-hearing (CH) synesthesia is a perceptual phenomenon in which an acoustic stimulus (the inducer) initiates a concurrent colour perception (the concurrent). Individuals with CH synesthesia "see" colours when hearing tones, words, or music; this specific phenomenon suggesting a close relationship between auditory and visual representations. To date, it is still unknown whether the perception of colours is associated with a modulation of brain functions in the inducing brain area, namely in the auditory-related cortex and associated brain areas. In addition, there is an on-going debate as to whether attention to the inducer is necessarily required for eliciting a visual concurrent, or whether the latter can emerge in a pre-attentive fashion.


RESULTS
By using the EEG technique in the context of a pre-attentive mismatch negativity (MMN) paradigm, we show that the binding of tones and colours in CH synesthetes is associated with increased MMN amplitudes in response to deviant tones supposed to induce novel concurrent colour perceptions. Most notably, the increased MMN amplitudes we revealed in the CH synesthetes were associated with stronger intracerebral current densities originating from the auditory cortex, parietal cortex, and ventral visual areas.


CONCLUSIONS
The automatic binding of tones and colours in CH synesthetes is accompanied by an early pre-attentive process recruiting the auditory cortex, inferior and superior parietal lobules, as well as ventral occipital areas.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12752</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2202-13-151</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/23241212</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>BMC neuroscience. - 2012</dc:source>
          <dc:subject xml:lang="en">Acoustic Stimulation</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Attention</dc:subject>
          <dc:subject xml:lang="en">Auditory Cortex</dc:subject>
          <dc:subject xml:lang="en">Auditory Perception</dc:subject>
          <dc:subject xml:lang="en">Brain Waves</dc:subject>
          <dc:subject xml:lang="en">Case-Control Studies</dc:subject>
          <dc:subject xml:lang="en">Color Perception</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Parietal Lobe</dc:subject>
          <dc:subject xml:lang="en">Perceptual Disorders</dc:subject>
          <dc:subject xml:lang="en">Synesthesia</dc:subject>
          <dc:subject xml:lang="en">Visual Cortex</dc:subject>
          <dc:title xml:lang="en">Pre-attentive modulation of brain responses to tones in coloured-hearing synesthetes.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12616</identifier>
        <datestamp>2025-10-24T20:48:49Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Burkhardt JK</dc:creator>
          <dc:creator>Burkhardt WF</dc:creator>
          <dc:creator>Zinn PO</dc:creator>
          <dc:creator>Bozinov O</dc:creator>
          <dc:creator>Bertalanffy H</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">All medical subspecialties and, in particular, high-tech field neurosurgery are subject to continuous change in therapeutic concepts due to novel treatment options emerging through research and evolution in the field. Hence, the question arises if the patient's informed consent needs to be adjusted in the face of multiple therapeutic options with different configurations of risk/benefit relationships. In this paper we discuss different therapeutic scenarios with regard to ruptured intracerebral aneurysms (RIA) and unruptured intracerebral aneurysms (UIA), and we advise the medical doctor involved in the process. Indeed, experienced neurosurgeons and endovascular interventionalists are very familiar with the management of these scenarios; likewise, interns, residents, and otherwise affiliated physicians may be faced with these situations. In general, asymptomatic and mentally capacitated patients as well as legal guardians of minor patients and of mentally incapacitated patients with incidental aneurysms and more than one therapeutic option need to be accurately informed about the advantages and disadvantages of the treatment options available to them. In case of emergency or when treating a mentally disabled patient who is incapable of making a sound judgment and has no legal guardian, the attending doctor will have to choose the best possible treatment option.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12616</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.zefq.2010.07.040</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21958620</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. - 2011</dc:source>
          <dc:subject xml:lang="en">Aneurysm, Ruptured</dc:subject>
          <dc:subject xml:lang="en">Germany</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Informed Consent</dc:subject>
          <dc:subject xml:lang="en">Intracranial Aneurysm</dc:subject>
          <dc:subject xml:lang="en">Legal Guardians</dc:subject>
          <dc:subject xml:lang="en">Malpractice</dc:subject>
          <dc:subject xml:lang="en">Mental Competency</dc:subject>
          <dc:subject xml:lang="en">National Health Programs</dc:subject>
          <dc:subject xml:lang="en">Outcome and Process Assessment, Health Care</dc:subject>
          <dc:subject xml:lang="en">Patient Education as Topic</dc:subject>
          <dc:subject xml:lang="en">Prognosis</dc:subject>
          <dc:subject xml:lang="en">Risk Assessment</dc:subject>
          <dc:title xml:lang="en">[Intracerebral aneurysm--treatment options, informed consent, and legal aspects].</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12621</identifier>
        <datestamp>2025-10-24T20:48:49Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Staubli S</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">This paper studies the effect of a large-scale policy change in the Austrian disability insurance program, which tightened eligibility criteria for men above a certain age. Using administrative data on the universe of Austrian private-sector employees, the results of difference-in-difference regressions suggest a substantial and statistically significant decline in disability enrollment of 6 to 7.4 percentage points and an increase in employment of 1.6 to 3.4 percentage points. The policy change had important spillover effects into the unemployment and sickness insurance program. Specifically, the share of individuals receiving unemployment benefits increased by 3.5 to 3.9 percentage points, and the share receiving sickness insurance benefits, by roughly 0.7 percentage points.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12621</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jpubeco.2011.05.008</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21969737</dc:relation>
          <dc:source>Journal of public economics. - 2011</dc:source>
          <dc:title xml:lang="en">The impact of stricter criteria for disability insurance on labor force participation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12623</identifier>
        <datestamp>2025-10-24T20:48:49Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Münz C</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">Macroautophagy is a catabolic pathway in eukaryotic cells that has recently been shown to facilitate pathogen detection, pathogen restriction and pathogen-derived antigen presentation to CD4(+) T cells. Due to these protective functions during immune responses, several pathogens, including RNA and DNA viruses, have developed strategies to inhibit autophagosome generation or maturation. Interestingly, most of the respective viral proteins exert these functions via binding to Beclin-1, an essential macroautophagy protein that constitutes part of the phosphatidylinositol-3 kinase complexes that mark membranes for autophagosome generation and facilitate autophagosome fusion with lyososomes. The viruses that inhibit macroautophagy by this pathway include herpesviruses, HIV and influenza A virus. Inhibition either before or after autophagosome formation seems to benefit their viral replication by different mechanisms, which are discussed here.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12623</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/v3071166</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/21994775</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Viruses. - 2011</dc:source>
          <dc:subject xml:lang="en">HIV</dc:subject>
          <dc:subject xml:lang="en">HSV</dc:subject>
          <dc:subject xml:lang="en">KSHV</dc:subject>
          <dc:subject xml:lang="en">autophagy</dc:subject>
          <dc:subject xml:lang="en">immune evasion</dc:subject>
          <dc:subject xml:lang="en">immunity</dc:subject>
          <dc:subject xml:lang="en">influenza virus</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Apoptosis Regulatory Proteins</dc:subject>
          <dc:subject xml:lang="en">Autophagy</dc:subject>
          <dc:subject xml:lang="en">Beclin-1</dc:subject>
          <dc:subject xml:lang="en">DNA Viruses</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immune Evasion</dc:subject>
          <dc:subject xml:lang="en">Membrane Proteins</dc:subject>
          <dc:subject xml:lang="en">RNA Viruses</dc:subject>
          <dc:subject xml:lang="en">Virus Diseases</dc:subject>
          <dc:title xml:lang="en">Beclin-1 targeting for viral immune escape.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12632</identifier>
        <datestamp>2025-10-24T20:48:51Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Schweiger A</dc:creator>
          <dc:creator>Grimm F</dc:creator>
          <dc:creator>Tanner I</dc:creator>
          <dc:creator>Müllhaupt B</dc:creator>
          <dc:creator>Bertogg K</dc:creator>
          <dc:creator>Müller N</dc:creator>
          <dc:creator>Deplazes P</dc:creator>
          <dc:date>2012</dc:date>
          <dc:description xml:lang="en">PURPOSE
Human alveolar (AE) and cystic echinococcosis (CE) caused by the metacestode stages of Echinococcus multilocularis and E. granulosus, respectively, lack pathognomonic clinical signs. Diagnosis therefore relies on the results of imaging and serological studies. The primary goal of this study was to evaluate the efficacy of several easy-to-produce crude or partially purified E. granulosus and E. multilocularis metacestode-derived antigens as tools for the serological diagnosis and differential diagnosis of patients suspicious for AE or CE.


METHODS
The sera of 51 treatment-naïve AE and 32 CE patients, 98 Swiss blood donors and 38 patients who were initially suspicious for echinococcosis but suffering from various other liver diseases (e.g., liver neoplasia, etc.) were analysed.


RESULTS
According to the results of enzyme-linked immunosorbent assays (ELISA), metacestode-derived antigens of E. granulosus had sensitivities varying from 81 to 97% and &gt;99.9% for the diagnosis of CE and AE, respectively. Antigens derived from E. multilocularis metacestodes had sensitivities ranging from 84 to 91% and &gt;99.9% for the diagnosis of CE and AE, respectively. Specificities ranged from 92 to &gt;99.9%. Post-test probabilities for the differential diagnosis of AE from liver neoplasias, CE from cystic liver lesions, and screening for AE in Switzerland were around 95, 86 and 2.2%, respectively. Cross-reactions with antibodies in sera of patients with other parasitic affections (fasciolosis, schistosomosis, amebosis, cysticercosis, and filarioses) did occur at variable frequencies, but could be eliminated through the use of confirmatory testing.


CONCLUSIONS
Different metacestode-derived antigens of E. granulosus and E. multilocularis are valuable, widely accessible, and cost-efficient tools for the serological diagnosis of echinococcosis. However, confirmatory testing is necessary, due to the lack of species specificity and the occurrence of cross-reactions to other helminthic diseases.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12632</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s15010-011-0205-6</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22076692</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Infection. - 2012</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Antibodies, Helminth</dc:subject>
          <dc:subject xml:lang="en">Antigens, Helminth</dc:subject>
          <dc:subject xml:lang="en">Cross Reactions</dc:subject>
          <dc:subject xml:lang="en">Diagnosis, Differential</dc:subject>
          <dc:subject xml:lang="en">Echinococcosis</dc:subject>
          <dc:subject xml:lang="en">Echinococcosis, Hepatic</dc:subject>
          <dc:subject xml:lang="en">Echinococcus granulosus</dc:subject>
          <dc:subject xml:lang="en">Echinococcus multilocularis</dc:subject>
          <dc:subject xml:lang="en">Enzyme-Linked Immunosorbent Assay</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:title xml:lang="en">Serological diagnosis of echinococcosis: the diagnostic potential of native antigens.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12652</identifier>
        <datestamp>2025-10-24T20:48:53Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kampa BM</dc:creator>
          <dc:creator>Roth MM</dc:creator>
          <dc:creator>Göbel W</dc:creator>
          <dc:creator>Helmchen F</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">How are visual scenes encoded in local neural networks of visual cortex? In rodents, visual cortex lacks a columnar organization so that processing of diverse features from a spot in visual space could be performed locally by populations of neighboring neurons. To examine how complex visual scenes are represented by local microcircuits in mouse visual cortex we measured visually evoked responses of layer 2/3 neuronal populations using 3D two-photon calcium imaging. Both natural and artificial movie scenes (10 seconds duration) evoked distributed and sparsely organized responses in local populations of 70-150 neurons within the sampled volumes. About 50% of neurons showed calcium transients during visual scene presentation, of which about half displayed reliable temporal activation patterns. The majority of the reliably responding neurons were activated primarily by one of the four visual scenes applied. Consequently, single-neurons performed poorly in decoding, which visual scene had been presented. In contrast, high levels of decoding performance (&gt;80%) were reached when considering population responses, requiring about 80 randomly picked cells or 20 reliable responders. Furthermore, reliable responding neurons tended to have neighbors sharing the same stimulus preference. Because of this local redundancy, it was beneficial for efficient scene decoding to read out activity from spatially distributed rather than locally clustered neurons. Our results suggest a population code in layer 2/3 of visual cortex, where the visual environment is dynamically represented in the activation of distinct functional sub-networks.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12652</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3389/fncir.2011.00018</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22180739</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Frontiers in neural circuits. - 2011</dc:source>
          <dc:subject xml:lang="en">3D imaging</dc:subject>
          <dc:subject xml:lang="en">calcium imaging</dc:subject>
          <dc:subject xml:lang="en">natural movies</dc:subject>
          <dc:subject xml:lang="en">neocortex</dc:subject>
          <dc:subject xml:lang="en">two-photon microscopy</dc:subject>
          <dc:title xml:lang="en">Representation of visual scenes by local neuronal populations in layer 2/3 of mouse visual cortex.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12660</identifier>
        <datestamp>2025-10-24T20:48:58Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Scharl M</dc:creator>
          <dc:creator>Frei P</dc:creator>
          <dc:creator>Frei SM</dc:creator>
          <dc:creator>Biedermann L</dc:creator>
          <dc:creator>Weber A</dc:creator>
          <dc:creator>Rogler G</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Anal adenocarcinomas arising from perianal fistulae represent a rare complication in Crohn's disease (CD) patients. We have previously demonstrated the involvement of an epithelial-to-mesenchymal transition (EMT) in the pathogenesis of CD-associated fistulae. Although EMT has also been implicated in the development of colorectal and anal carcinoma, the molecular link from fistula to carcinoma is unclear. We present a case of a 48-year-old White woman who developed a mucinous anal adenocarcinoma originating from a perianal, CD-associated fistula 24 years after being diagnosed with CD. To characterize the expression of EMT-associated molecules in fistula and carcinoma tissue, immunohistochemical analysis for Snail1, Slug, β-catenin and E-cadherin was performed. A mucinous anal adenocarcinoma developed on a perianal fistula in a patient with long-standing CD. After neoadjuvant radiochemotherapy, the fistula-associated tumour was resected and the patient is presently in remission. Using immunohistochemical analysis, we detected a remarkable staining of the Slug transcription factor in transitional cells lining the fistula tract. This observation is unique to this 'carcinoma'-fistula: we had previously shown Slug expression in cells surrounding the fistula tract but not in transitional cells. Expression of Snail1, β-catenin and E-cadherin in this case was comparable with our previous findings. We describe a rare case of a CD fistula-associated adenocarcinoma within an area of squamous epithelium of the perianal area and an unusual expression pattern of EMT markers in this fistula. This case seems to underline the relevance of our previous findings demonstrating that EMT plays an important role for fistula pathogenesis and likely carcinogenesis in CD patients.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12660</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/MEG.0b013e32836371a2</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24284372</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>European journal of gastroenterology &amp; hepatology. - 2014</dc:source>
          <dc:subject xml:lang="en">Adenocarcinoma, Mucinous</dc:subject>
          <dc:subject xml:lang="en">Antigens, CD</dc:subject>
          <dc:subject xml:lang="en">Anus Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Biomarkers, Tumor</dc:subject>
          <dc:subject xml:lang="en">Cadherins</dc:subject>
          <dc:subject xml:lang="en">Chemoradiotherapy, Adjuvant</dc:subject>
          <dc:subject xml:lang="en">Colonoscopy</dc:subject>
          <dc:subject xml:lang="en">Crohn Disease</dc:subject>
          <dc:subject xml:lang="en">Endosonography</dc:subject>
          <dc:subject xml:lang="en">Epithelial-Mesenchymal Transition</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Magnetic Resonance Imaging</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Neoadjuvant Therapy</dc:subject>
          <dc:subject xml:lang="en">Rectal Fistula</dc:subject>
          <dc:subject xml:lang="en">Snail Family Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">beta Catenin</dc:subject>
          <dc:title xml:lang="en">Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12686</identifier>
        <datestamp>2025-10-24T20:49:02Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Roesslein M</dc:creator>
          <dc:creator>Froehlich C</dc:creator>
          <dc:creator>Jans F</dc:creator>
          <dc:creator>Piegeler T</dc:creator>
          <dc:creator>Goebel U</dc:creator>
          <dc:creator>Loop T</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">AIMS
Dobutamine is cytoprotective when applied before a subsequent stress. However, the underlying molecular mechanism is unknown. Dobutamine also inhibits nuclear factor (NF)-κB in human T lymphocytes. Other inhibitors of NF-κB induce a so-called heat shock response. We hypothesized that dobutamine mediates protection from apoptotic cell death by the induction of a heat shock response.


MAIN METHODS
Jurkat T lymphoma cells were preincubated with dobutamine (0.1, 0.5 mM) before the induction of apoptosis (staurosporine, 2 μM). DNA-binding of heat shock factor (HSF)-1 was analyzed by electrophoretic mobility shift assay, mRNA-expression of heat shock protein (hsp)70 and hsp90 by Northern Blot, activity of caspase-3 by fluorogenic caspase activity assay and cleavage of pro-caspase-3 by Western Blot. Apoptosis was assessed by flow cytometry after annexin V-fluorescein isothiocyanate staining. Hsp70 and hsp90 were inhibited using N-formyl-3,4-methylenedioxy-benzylidene-gamma-butyrolaetam and 17-allylamino-17-demethoxygeldana-mycin, respectively. All data are given as median and 25/75% percentile.


KEY FINDINGS
Pre-incubation with dobutamine inhibited staurosporine-induced annexin V-fluorescence (28 [20-32] % vs. 12 [9-15] % for dobutamine 0.1 mM and 7 [5-12] % for dobutamine 0.5 mM, p&lt;0.001), cleavage of pro-caspase-3 as well as caspase-3-like activity (0.46 [0.40-0.48] vs. 0.32 [0.27-0.39] for Dobutamine 0.1 mM and 0.20 [0.19-0.23] for Dobutamine 0.5 mM, p&lt;0.01). Dobutamine induced DNA-binding of HSF-1 and mRNA-expression of hsp70 and hsp90. While inhibition of Hsp90 had no effect, inhibition of Hsp70 increased the number of annexin V-positive cells (33 [32-36] % vs. 18 [16-24] %) and caspase-3-like activity (0.21 [0.19-0.23] vs. 0.16 [0.13-0.17], p&lt;0.05).


SIGNIFICANCE
Dobutamine protects from apoptotic cell death via the induction of Hsp70.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12686</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lfs.2014.01.005</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24447628</dc:relation>
          <dc:source>Life sciences. - 2014</dc:source>
          <dc:subject xml:lang="en">Apoptosis</dc:subject>
          <dc:subject xml:lang="en">Dobutamine</dc:subject>
          <dc:subject xml:lang="en">Dobutamine hydrochloride (PubChem CID: 65324)</dc:subject>
          <dc:subject xml:lang="en">Heat shock protein 70</dc:subject>
          <dc:subject xml:lang="en">Heat shock response</dc:subject>
          <dc:subject xml:lang="en">Protection</dc:subject>
          <dc:subject xml:lang="en">Adrenergic beta-1 Receptor Agonists</dc:subject>
          <dc:subject xml:lang="en">Apoptosis</dc:subject>
          <dc:subject xml:lang="en">Blotting, Northern</dc:subject>
          <dc:subject xml:lang="en">Cell Line, Tumor</dc:subject>
          <dc:subject xml:lang="en">Cytoprotection</dc:subject>
          <dc:subject xml:lang="en">Dobutamine</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Polyacrylamide Gel</dc:subject>
          <dc:subject xml:lang="en">Flow Cytometry</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation</dc:subject>
          <dc:subject xml:lang="en">HSP70 Heat-Shock Proteins</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Protein-Serine-Threonine Kinases</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Real-Time Polymerase Chain Reaction</dc:subject>
          <dc:title xml:lang="en">Dobutamine mediates cytoprotection by induction of heat shock protein 70 in vitro.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12732</identifier>
        <datestamp>2025-10-24T20:49:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Beyer C</dc:creator>
          <dc:creator>Huang J</dc:creator>
          <dc:creator>Beer J</dc:creator>
          <dc:creator>Zhang Y</dc:creator>
          <dc:creator>Palumbo-Zerr K</dc:creator>
          <dc:creator>Zerr P</dc:creator>
          <dc:creator>Distler A</dc:creator>
          <dc:creator>Dees C</dc:creator>
          <dc:creator>Maier C</dc:creator>
          <dc:creator>Munoz L</dc:creator>
          <dc:creator>Krönke G</dc:creator>
          <dc:creator>Uderhardt S</dc:creator>
          <dc:creator>Distler O</dc:creator>
          <dc:creator>Jones S</dc:creator>
          <dc:creator>Rose-John S</dc:creator>
          <dc:creator>Oravecz T</dc:creator>
          <dc:creator>Schett G</dc:creator>
          <dc:creator>Distler JH</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
To investigate the role of liver X receptors (LXRs) in experimental skin fibrosis and evaluate their potential as novel antifibrotic targets.


METHODS
We studied the role of LXRs in bleomycin-induced skin fibrosis, in the model of sclerodermatous graft-versus-host disease (sclGvHD) and in tight skin-1 (Tsk-1) mice, reflecting different subtypes of fibrotic disease. We examined both LXR isoforms using LXRα-, LXRβ- and LXR-α/β-double-knockout mice. Finally, we investigated the effects of LXRs on fibroblasts and macrophages to establish the antifibrotic mode of action of LXRs.


RESULTS
LXR activation by the agonist T0901317 had antifibrotic effects in bleomycin-induced skin fibrosis, in the sclGvHD model and in Tsk-1 mice. The antifibrotic activity of LXRs was particularly prominent in the inflammation-driven bleomycin and sclGvHD models. LXRα-, LXRβ- and LXRα/β-double-knockout mice showed a similar response to bleomycin as wildtype animals. Low levels of the LXR target gene ABCA-1 in the skin of bleomycin-challenged and control mice suggested a low baseline activation of the antifibrotic LXR signalling, which, however, could be specifically activated by T0901317. Fibroblasts were not the direct target cells of LXRs agonists, but LXR activation inhibited fibrosis by interfering with infiltration of macrophages and their release of the pro-fibrotic interleukin-6.


CONCLUSIONS
We identified LXRs as novel targets for antifibrotic therapies, a yet unknown aspect of these nuclear receptors. Our data suggest that LXR activation might be particularly effective in patients with inflammatory disease subtypes. Activation of LXRs interfered with the release of interleukin-6 from macrophages and, thus, inhibited fibroblast activation and collagen release.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12732</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1136/annrheumdis-2013-204401</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24618263</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Annals of the rheumatic diseases. - 2015</dc:source>
          <dc:subject xml:lang="en">Fibroblasts</dc:subject>
          <dc:subject xml:lang="en">Systemic Sclerosis</dc:subject>
          <dc:subject xml:lang="en">Treatment</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Antibiotics, Antineoplastic</dc:subject>
          <dc:subject xml:lang="en">Bleomycin</dc:subject>
          <dc:subject xml:lang="en">Disease Models, Animal</dc:subject>
          <dc:subject xml:lang="en">Fibroblasts</dc:subject>
          <dc:subject xml:lang="en">Fibrosis</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hydrocarbons, Fluorinated</dc:subject>
          <dc:subject xml:lang="en">Interleukin-6</dc:subject>
          <dc:subject xml:lang="en">Liver X Receptors</dc:subject>
          <dc:subject xml:lang="en">Macrophages</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Knockout</dc:subject>
          <dc:subject xml:lang="en">Orphan Nuclear Receptors</dc:subject>
          <dc:subject xml:lang="en">Scleroderma, Diffuse</dc:subject>
          <dc:subject xml:lang="en">Skin</dc:subject>
          <dc:subject xml:lang="en">Skin Diseases</dc:subject>
          <dc:subject xml:lang="en">Sulfonamides</dc:subject>
          <dc:title xml:lang="en">Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12741</identifier>
        <datestamp>2025-10-24T20:49:07Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Maier PJ</dc:creator>
          <dc:creator>Zemoura K</dc:creator>
          <dc:creator>Acuña MA</dc:creator>
          <dc:creator>Yévenes GE</dc:creator>
          <dc:creator>Zeilhofer HU</dc:creator>
          <dc:creator>Benke D</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Cerebral ischemia frequently leads to long-term disability and death. Excitotoxicity is believed to be the main cause for ischemia-induced neuronal death. Although a role of glutamate receptors in this process has been firmly established, the contribution of metabotropic GABAB receptors, which control excitatory neurotransmission, is less clear. A prominent characteristic of ischemic insults is endoplasmic reticulum (ER) stress associated with the up-regulation of the transcription factor CCAAT/enhancer-binding protein-homologous protein (CHOP). After inducing ER stress in cultured cortical neurons by sustained Ca(2+) release from intracellular stores or by a brief episode of oxygen and glucose deprivation (in vitro model of cerebral ischemia), we observed an increased expression of CHOP accompanied by a strong reduction of cell surface GABAB receptors. Our results indicate that down-regulation of cell surface GABAB receptors is caused by the interaction of the receptors with CHOP in the ER. Binding of CHOP prevented heterodimerization of the receptor subunits GABAB1 and GABAB2 and subsequent forward trafficking of the receptors to the cell surface. The reduced level of cell surface receptors diminished GABAB receptor signaling and, thus, neuronal inhibition. These findings indicate that ischemia-mediated up-regulation of CHOP down-regulates cell surface GABAB receptors by preventing their trafficking from the ER to the plasma membrane. This mechanism leads to diminished neuronal inhibition and may contribute to excitotoxicity in cerebral ischemia.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12741</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1074/jbc.M114.550517</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24668805</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The Journal of biological chemistry. - 2014</dc:source>
          <dc:subject xml:lang="en">CHOP</dc:subject>
          <dc:subject xml:lang="en">Cell Surface</dc:subject>
          <dc:subject xml:lang="en">Cerebral Ischemia</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum (ER)</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum Stress</dc:subject>
          <dc:subject xml:lang="en">G Protein-coupled Receptors (GPCR)</dc:subject>
          <dc:subject xml:lang="en">GABA Receptors</dc:subject>
          <dc:subject xml:lang="en">Neurons</dc:subject>
          <dc:subject xml:lang="en">Trafficking</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Brain Ischemia</dc:subject>
          <dc:subject xml:lang="en">Cell Membrane</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Down-Regulation</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum Stress</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Gene Expression</dc:subject>
          <dc:subject xml:lang="en">Glucose</dc:subject>
          <dc:subject xml:lang="en">HEK293 Cells</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Microscopy, Confocal</dc:subject>
          <dc:subject xml:lang="en">Neurons</dc:subject>
          <dc:subject xml:lang="en">Oxygen</dc:subject>
          <dc:subject xml:lang="en">Protein Binding</dc:subject>
          <dc:subject xml:lang="en">Rats</dc:subject>
          <dc:subject xml:lang="en">Rats, Wistar</dc:subject>
          <dc:subject xml:lang="en">Receptors, GABA-B</dc:subject>
          <dc:subject xml:lang="en">Reverse Transcriptase Polymerase Chain Reaction</dc:subject>
          <dc:subject xml:lang="en">Transcription Factor CHOP</dc:subject>
          <dc:title xml:lang="en">Ischemia-like oxygen and glucose deprivation mediates down-regulation of cell surface γ-aminobutyric acidB receptors via the endoplasmic reticulum (ER) stress-induced transcription factor CCAAT/enhancer-binding protein (C/EBP)-homologous protein (CHOP).</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12777</identifier>
        <datestamp>2025-10-24T20:49:10Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Csomor PA</dc:creator>
          <dc:creator>Preller KH</dc:creator>
          <dc:creator>Geyer MA</dc:creator>
          <dc:creator>Studerus E</dc:creator>
          <dc:creator>Huber T</dc:creator>
          <dc:creator>Vollenweider FX</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12777</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/npp.2014.102</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24801767</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. - 2014</dc:source>
          <dc:subject xml:lang="en">Acoustic Stimulation</dc:subject>
          <dc:subject xml:lang="en">Amisulpride</dc:subject>
          <dc:subject xml:lang="en">Antipsychotic Agents</dc:subject>
          <dc:subject xml:lang="en">Aripiprazole</dc:subject>
          <dc:subject xml:lang="en">Auditory Perception</dc:subject>
          <dc:subject xml:lang="en">Benzhydryl Compounds</dc:subject>
          <dc:subject xml:lang="en">Brain</dc:subject>
          <dc:subject xml:lang="en">Double-Blind Method</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Electromyography</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lorazepam</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Modafinil</dc:subject>
          <dc:subject xml:lang="en">Piperazines</dc:subject>
          <dc:subject xml:lang="en">Prepulse Inhibition</dc:subject>
          <dc:subject xml:lang="en">Psychometrics</dc:subject>
          <dc:subject xml:lang="en">Psychotropic Drugs</dc:subject>
          <dc:subject xml:lang="en">Quinolones</dc:subject>
          <dc:subject xml:lang="en">Risperidone</dc:subject>
          <dc:subject xml:lang="en">Sensory Gating</dc:subject>
          <dc:subject xml:lang="en">Sulpiride</dc:subject>
          <dc:subject xml:lang="en">Valproic Acid</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12814</identifier>
        <datestamp>2025-10-24T20:49:11Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Noll G</dc:creator>
          <dc:creator>Noll S</dc:creator>
          <dc:creator>Hürlimann D</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Atrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF. Warfarin is successfully used to reduce thromboembolic events. More recently, direct thrombin (dabigatran) and factor Xa (apixaban, edoxaban, rivaroxaban) inhibitors have been compared to warfarin in large randomized trials. All new substances have been shown to be non-inferior to warfarin concerning thromboembolic events. Severe bleeding, such as fatal and intracranial bleeding, was less frequent with direct oral anticoagulants. Results of the studies and subgroup analyses are discussed. Further trials using direct oral anticoagulants in special populations such as very old and patients with kidney disease are needed.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12814</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1053/j.seminhematol.2014.04.001</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24861798</dc:relation>
          <dc:source>Seminars in hematology. - 2014</dc:source>
          <dc:subject xml:lang="en">Administration, Oral</dc:subject>
          <dc:subject xml:lang="en">Anticoagulants</dc:subject>
          <dc:subject xml:lang="en">Atrial Fibrillation</dc:subject>
          <dc:subject xml:lang="en">Benzimidazoles</dc:subject>
          <dc:subject xml:lang="en">Dabigatran</dc:subject>
          <dc:subject xml:lang="en">Embolism</dc:subject>
          <dc:subject xml:lang="en">Hemorrhage</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Morpholines</dc:subject>
          <dc:subject xml:lang="en">Pyrazoles</dc:subject>
          <dc:subject xml:lang="en">Pyridines</dc:subject>
          <dc:subject xml:lang="en">Pyridones</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:subject xml:lang="en">Rivaroxaban</dc:subject>
          <dc:subject xml:lang="en">Stroke</dc:subject>
          <dc:subject xml:lang="en">Thiazoles</dc:subject>
          <dc:subject xml:lang="en">Thiophenes</dc:subject>
          <dc:subject xml:lang="en">Warfarin</dc:subject>
          <dc:subject xml:lang="en">beta-Alanine</dc:subject>
          <dc:title xml:lang="en">Direct oral anticoagulants in atrial fibrillation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12835</identifier>
        <datestamp>2025-10-24T20:49:13Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Fuge P</dc:creator>
          <dc:creator>Aust S</dc:creator>
          <dc:creator>Fan Y</dc:creator>
          <dc:creator>Weigand A</dc:creator>
          <dc:creator>Gärtner M</dc:creator>
          <dc:creator>Feeser M</dc:creator>
          <dc:creator>Bajbouj M</dc:creator>
          <dc:creator>Grimm S</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Early life stress (ELS) experience is associated with persisting working memory (WM) deficits; changes to the corticotropin-releasing hormone (CRH) system; and structural, functional, and epigenetic changes in the hippocampus. Single nucleotide polymorphisms in the CRH receptor 1 (CRHR1) gene interact with ELS experience to predict depression as well as neuroendocrine and neuronal reactivity. Although these findings indicate that vulnerable genotypes might also show impaired WM performance after ELS experience, no previous study investigated whether there is an interaction effect of CRHR1 polymorphisms and ELS experience on WM performance.


METHODS
Subjects (N = 451) were genotyped for rs110402 and rs242924 within the CRHR1 gene. We used an n-back task to investigate the hypothesis that WM performance in healthy subjects may be subtly influenced by functional differences in CRHR1 and represents an early marker of increased vulnerability after exposure to ELS.


RESULTS
Exposure to ELS had a particularly strong impact on WM performance in subjects with the common homozygous GG GG genotype, whereas only severe exposure to ELS interfered with WM accuracy in AT carriers.


CONCLUSIONS
Our data indicate that specific CRHR1 polymorphisms moderate the effect of ELS experience on WM performance. Exposure to ELS in combination with a vulnerable genotype results in subtle memory deficits in adulthood, which might develop before psychopathological symptoms.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12835</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.biopsych.2014.04.016</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24931706</dc:relation>
          <dc:source>Biological psychiatry. - 2014</dc:source>
          <dc:subject xml:lang="en">Corticotropin-releasing hormone receptor 1</dc:subject>
          <dc:subject xml:lang="en">early life stress</dc:subject>
          <dc:subject xml:lang="en">hippocampus</dc:subject>
          <dc:subject xml:lang="en">rs110402</dc:subject>
          <dc:subject xml:lang="en">rs242924</dc:subject>
          <dc:subject xml:lang="en">working memory</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Age Factors</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Genotype</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Memory, Short-Term</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Polymorphism, Single Nucleotide</dc:subject>
          <dc:subject xml:lang="en">Receptors, Corticotropin-Releasing Hormone</dc:subject>
          <dc:subject xml:lang="en">Stress, Psychological</dc:subject>
          <dc:title xml:lang="en">Interaction of early life stress and corticotropin-releasing hormone receptor gene: effects on working memory.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12837</identifier>
        <datestamp>2025-10-24T20:49:13Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Haas F</dc:creator>
          <dc:creator>Yamauchi K</dc:creator>
          <dc:creator>Murat M</dc:creator>
          <dc:creator>Bernasconi M</dc:creator>
          <dc:creator>Yamanaka N</dc:creator>
          <dc:creator>Speck RF</dc:creator>
          <dc:creator>Nadal D</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">UNLABELLED
In order to understand and possibly treat B-cell malignancies associated with latent gammaherpesvirus infection, it is vital to understand the factors that control the balance between the two transcriptional states of gammaherpesviruses: latency and lytic replication. We used murine gammaherpesvirus 68 (MHV 68) as a model system to investigate how engagement of endosomal Toll-like receptors (TLRs) impacts reactivation from latency in vitro and establishment of latent infection in vivo. We found that treatment with TLR7 ligand R848 or TLR9 ligand CpG oligodeoxynucleotide (ODN) suppresses reactivation of MHV 68 in vitro. These suppressive effects correlated with the ability to activate cellular transcription factor NF-κB. Downregulation of TLR9 by RNA interference in vitro led to a reduction of nuclear levels of NF-κB p65 and consequently to an increase of spontaneous reactivation in cells latently infected with MHV 68, indicating that the TLR9 pathway suppresses spontaneous reactivation events. In vivo, sustained stimulation of TLR7 by repeated R848 treatment led to an increased frequency of infected splenocytes compared to mock-treated control results. Frequencies of infected splenic B cells in tlr7-/- or tlr9-/- mice after establishment of latency did not differ from those seen with their wild-type counterparts. Nevertheless, MHV 68-infected B cells from tlr9-/- mice showed a higher frequency of reactivation than B cells from wild-type or tlr7-/- mice in ex vivo reactivation assays. Thus, we show a suppressive effect of TLR7 or TLR9 triggering on MHV 68 reactivation that correlates with NF-κB activation and that the mere presence of a functional TLR9 signaling pathway contributes to dampen lytic gammaherpesvirus reactivation in infected cells.


IMPORTANCE
A hallmark of gammaherpesviruses is their establishment of latency in B cells that is reversible through lytic reactivation. Latency can result in B-cell malignancies. Activation of the innate immune system is thought to contribute to controlling the switch between the transcriptional states of latency and reactivation. Nevertheless, the mechanisms involved are not clear. Here, we show that engagement of Toll-like receptor 7 (TLR7) and TLR9 suppresses reactivation of murine gammaherpesvirus MHV 68 in vitro and that stimulation of TLR7 in vivo increases the frequency of infected cells. TLR7 and TLR9 are innate immunity sensors of nucleic acids localized in endosomes. Additionally, we demonstrate that impairment of TLR9 signaling in latently infected B cells leads to increased reactivation. Thus, activated endosomal TLR7 and TLR9 pathways play an important role in promoting establishment of latent gammaherpesvirus infection. Counteracting signaling of these pathways allows reactivation and could represent treatment targets in gammaherpesvirus-associated malignancies.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12837</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1128/JVI.01486-14</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24942583</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of virology. - 2014</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Herpesviridae Infections</dc:subject>
          <dc:subject xml:lang="en">Membrane Glycoproteins</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">NF-kappa B</dc:subject>
          <dc:subject xml:lang="en">Rhadinovirus</dc:subject>
          <dc:subject xml:lang="en">Toll-Like Receptor 7</dc:subject>
          <dc:subject xml:lang="en">Toll-Like Receptor 9</dc:subject>
          <dc:subject xml:lang="en">Tumor Virus Infections</dc:subject>
          <dc:subject xml:lang="en">Virus Activation</dc:subject>
          <dc:subject xml:lang="en">Virus Latency</dc:subject>
          <dc:title xml:lang="en">Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12891</identifier>
        <datestamp>2025-10-24T20:49:17Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Knüpfer SC</dc:creator>
          <dc:creator>Liechti MD</dc:creator>
          <dc:creator>Mordasini L</dc:creator>
          <dc:creator>Abt D</dc:creator>
          <dc:creator>Engeler DS</dc:creator>
          <dc:creator>Wöllner J</dc:creator>
          <dc:creator>Pannek J</dc:creator>
          <dc:creator>Kiss B</dc:creator>
          <dc:creator>Burkhard FC</dc:creator>
          <dc:creator>Schneider MP</dc:creator>
          <dc:creator>Miramontes E</dc:creator>
          <dc:creator>Kessels AG</dc:creator>
          <dc:creator>Bachmann LM</dc:creator>
          <dc:creator>Kessler TM</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Sacral neuromodulation has become a well-established and widely accepted treatment for refractory non-neurogenic lower urinary tract dysfunction, but its value in patients with a neurological cause is unclear. Although there is evidence indicating that sacral neuromodulation may be effective and safe for treating neurogenic lower urinary tract dysfunction, the number of investigated patients is low and there is a lack of randomized controlled trials.


METHODS AND DESIGN
This study is a prospective, randomized, placebo-controlled, double-blind multicenter trial including 4 sacral neuromodulation referral centers in Switzerland. Patients with refractory neurogenic lower urinary tract dysfunction are enrolled. After minimally invasive bilateral tined lead placement into the sacral foramina S3 and/or S4, patients undergo prolonged sacral neuromodulation testing for 3-6 weeks. In case of successful (defined as improvement of at least 50% in key bladder diary variables (i.e. number of voids and/or number of leakages, post void residual) compared to baseline values) prolonged sacral neuromodulation testing, the neuromodulator is implanted in the upper buttock. After a 2 months post-implantation phase when the neuromodulator is turned ON to optimize the effectiveness of neuromodulation using sub-sensory threshold stimulation, the patients are randomized in a 1:1 allocation in sacral neuromodulation ON or OFF. At the end of the 2 months double-blind sacral neuromodulation phase, the patients have a neuro-urological re-evaluation, unblinding takes place, and the neuromodulator is turned ON in all patients. The primary outcome measure is success of sacral neuromodulation, secondary outcome measures are adverse events, urodynamic parameters, questionnaires, and costs of sacral neuromodulation.


DISCUSSION
It is of utmost importance to know whether the minimally invasive and completely reversible sacral neuromodulation would be a valuable treatment option for patients with refractory neurogenic lower urinary tract dysfunction. If this type of treatment is effective in the neurological population, it would revolutionize the management of neurogenic lower urinary tract dysfunction.


TRIAL REGISTRATION



TRIAL REGISTRATION NUMBER
http://www.clinicaltrials.gov; Identifier: NCT02165774.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12891</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2490-14-65</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25123172</dc:relation>
          <dc:source>BMC urology. - 2014</dc:source>
          <dc:subject xml:lang="en">Analysis of Variance</dc:subject>
          <dc:subject xml:lang="en">Double-Blind Method</dc:subject>
          <dc:subject xml:lang="en">Electric Stimulation Therapy</dc:subject>
          <dc:subject xml:lang="en">Electrodes, Implanted</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Patient Selection</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Research Design</dc:subject>
          <dc:subject xml:lang="en">Sacrococcygeal Region</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">Urinary Bladder, Neurogenic</dc:subject>
          <dc:title xml:lang="en">Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12913</identifier>
        <datestamp>2025-10-24T20:49:18Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Cantù C</dc:creator>
          <dc:creator>Zimmerli D</dc:creator>
          <dc:creator>Hausmann G</dc:creator>
          <dc:creator>Valenta T</dc:creator>
          <dc:creator>Moor A</dc:creator>
          <dc:creator>Aguet M</dc:creator>
          <dc:creator>Basler K</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Bcl9 and Bcl9l (Bcl9/9l) encode Wnt signaling components that mediate the interaction between β-catenin and Pygopus (Pygo) via two evolutionarily conserved domains, HD1 and HD2, respectively. We generated mouse strains lacking these domains to probe the β-catenin-dependent and β-catenin-independent roles of Bcl9/9l and Pygo during mouse development. While lens development is critically dependent on the presence of the HD1 domain, it is not affected by the lack of the HD2 domain, indicating that Bcl9/9l act in this context in a β-catenin-independent manner. Furthermore, we uncover a new regulatory circuit in which Pax6, the master regulator of eye development, directly activates Bcl9/9l transcription.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12913</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1101/gad.246140.114</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25184676</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Genes &amp; development. - 2014</dc:source>
          <dc:subject xml:lang="en">Bcl9</dc:subject>
          <dc:subject xml:lang="en">Pax6</dc:subject>
          <dc:subject xml:lang="en">Pygopus</dc:subject>
          <dc:subject xml:lang="en">Wnt</dc:subject>
          <dc:subject xml:lang="en">lens induction</dc:subject>
          <dc:subject xml:lang="en">mouse</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Eye Proteins</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation, Developmental</dc:subject>
          <dc:subject xml:lang="en">Gene Knock-In Techniques</dc:subject>
          <dc:subject xml:lang="en">Homeodomain Proteins</dc:subject>
          <dc:subject xml:lang="en">Intracellular Signaling Peptides and Proteins</dc:subject>
          <dc:subject xml:lang="en">Lens, Crystalline</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">Neoplasm Proteins</dc:subject>
          <dc:subject xml:lang="en">PAX6 Transcription Factor</dc:subject>
          <dc:subject xml:lang="en">Paired Box Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Protein Structure, Tertiary</dc:subject>
          <dc:subject xml:lang="en">Repressor Proteins</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:subject xml:lang="en">Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Wnt Proteins</dc:subject>
          <dc:subject xml:lang="en">beta Catenin</dc:subject>
          <dc:title xml:lang="en">Pax6-dependent, but β-catenin-independent, function of Bcl9 proteins in mouse lens development.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12763</identifier>
        <datestamp>2025-10-24T20:49:20Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Langer N</dc:creator>
          <dc:creator>Pedroni A</dc:creator>
          <dc:creator>Jäncke L</dc:creator>
          <dc:date>2013</dc:date>
          <dc:description xml:lang="en">Graph theory deterministically models networks as sets of vertices, which are linked by connections. Such mathematical representation of networks, called graphs are increasingly used in neuroscience to model functional brain networks. It was shown that many forms of structural and functional brain networks have small-world characteristics, thus, constitute networks of dense local and highly effective distal information processing. Motivated by a previous small-world connectivity analysis of resting EEG-data we explored implications of a commonly used analysis approach. This common course of analysis is to compare small-world characteristics between two groups using classical inferential statistics. This however, becomes problematic when using measures of inter-subject correlations, as it is the case in commonly used brain imaging methods such as structural and diffusion tensor imaging with the exception of fibre tracking. Since for each voxel, or region there is only one data point, a measure of connectivity can only be computed for a group. To empirically determine an adequate small-world network threshold and to generate the necessary distribution of measures for classical inferential statistics, samples are generated by thresholding the networks on the group level over a range of thresholds. We believe that there are mainly two problems with this approach. First, the number of thresholded networks is arbitrary. Second, the obtained thresholded networks are not independent samples. Both issues become problematic when using commonly applied parametric statistical tests. Here, we demonstrate potential consequences of the number of thresholds and non-independency of samples in two examples (using artificial data and EEG data). Consequently alternative approaches are presented, which overcome these methodological issues.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12763</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0053199</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/23301043</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>PloS one. - 2013</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Algorithms</dc:subject>
          <dc:subject xml:lang="en">Brain</dc:subject>
          <dc:subject xml:lang="en">Brain Mapping</dc:subject>
          <dc:subject xml:lang="en">Data Interpretation, Statistical</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intelligence Tests</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Models, Neurological</dc:subject>
          <dc:subject xml:lang="en">Nerve Net</dc:subject>
          <dc:subject xml:lang="en">Neural Pathways</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">The problem of thresholding in small-world network analysis.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12787</identifier>
        <datestamp>2025-10-24T20:49:32Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>van Eijk RP</dc:creator>
          <dc:creator>van der Zwan A</dc:creator>
          <dc:creator>Bleys RL</dc:creator>
          <dc:creator>Regli L</dc:creator>
          <dc:creator>Esposito G</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
Postmortem CT angiography is a common procedure used to visualize the entire human vasculature. For visualization of a specific organ's vascular anatomy, casting is the preferred method. Because of the permanent and damaging nature of casting, the organ cannot be further used as an experimental model after angiography. Therefore, there is a need for a minimally traumatic method to visualize organ-specific vascular anatomy. The purpose of this study was to develop and evaluate a contrast enhancement technique that is capable of visualizing the intracranial vascular anatomy while preserving the anatomic integrity in cadaver heads.


MATERIALS AND METHODS
Seven human heads were used in this study. Heads were prepared by cannulating the vertebral and internal carotid arteries. Contrast agent was injected as a mixture of tap water, polyethylene glycol 600, and an iodinated contrast agent. Postmortem imaging was executed on a 64-MDCT scanner. Primary image review and 3D reconstruction were performed on a CT workstation.


RESULTS
Clear visualization of the major cerebral arteries and smaller intracranial branches was achieved. Adequate visualization was obtained for both the anterior and posterior intracranial circulation. The minimally traumatic angiography method preserved the vascular integrity of the cadaver heads.


CONCLUSION
A novel application of postmortem CT angiography is presented here. The technique can be used for radiologic evaluation of the intracranial circulation in cadaver heads. After CT angiography, the specimen can be used for further experimental or laboratory testing and teaching purposes.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12787</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.2214/AJR.15.14500</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26587934</dc:relation>
          <dc:source>AJR. American journal of roentgenology. - 2015</dc:source>
          <dc:subject xml:lang="en">CT angiography</dc:subject>
          <dc:subject xml:lang="en">intracranial circulation</dc:subject>
          <dc:subject xml:lang="en">postmortem</dc:subject>
          <dc:subject xml:lang="en">Cadaver</dc:subject>
          <dc:subject xml:lang="en">Cerebral Angiography</dc:subject>
          <dc:subject xml:lang="en">Cerebrovascular Circulation</dc:subject>
          <dc:subject xml:lang="en">Contrast Media</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Imaging, Three-Dimensional</dc:subject>
          <dc:subject xml:lang="en">Iohexol</dc:subject>
          <dc:subject xml:lang="en">Radiographic Image Interpretation, Computer-Assisted</dc:subject>
          <dc:subject xml:lang="en">Tomography, X-Ray Computed</dc:subject>
          <dc:title xml:lang="en">Novel Application of Postmortem CT Angiography for Evaluation of the Intracranial Vascular Anatomy in Cadaver Heads.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12793</identifier>
        <datestamp>2025-10-24T20:49:33Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ozdemir C</dc:creator>
          <dc:creator>Kucuksezer UC</dc:creator>
          <dc:creator>Akdis M</dc:creator>
          <dc:creator>Akdis CA</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">Allergen immunotherapy (AIT) is an effective way to treat allergic disorders, targeting the underlying mechanisms and altering the disease course by inducing a long-lasting clinical and immune tolerance to allergens. Although sublingual and subcutaneous routes are used in daily practice, many novel ways to decrease side effects and duration and increase efficacy have been pursued. Further studies are needed to develop biomarkers for the identification of AIT responder patients and also to use the developed knowledge in allergy prevention studies. Future directions in AIT include treatments for autoimmune diseases, chronic infections, organ transplantation, and breaking immune tolerance to cancer cells.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12793</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.iac.2015.08.003</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26617228</dc:relation>
          <dc:source>Immunology and allergy clinics of North America. - 2016</dc:source>
          <dc:subject xml:lang="en">Allergens</dc:subject>
          <dc:subject xml:lang="en">Allergy</dc:subject>
          <dc:subject xml:lang="en">Immunotherapy</dc:subject>
          <dc:subject xml:lang="en">T regulatory cells</dc:subject>
          <dc:subject xml:lang="en">Tolerance</dc:subject>
          <dc:subject xml:lang="en">Administration, Sublingual</dc:subject>
          <dc:subject xml:lang="en">Air Pollutants</dc:subject>
          <dc:subject xml:lang="en">Allergens</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Desensitization, Immunologic</dc:subject>
          <dc:subject xml:lang="en">Environmental Exposure</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypersensitivity</dc:subject>
          <dc:subject xml:lang="en">Immune Tolerance</dc:subject>
          <dc:subject xml:lang="en">Injections, Subcutaneous</dc:subject>
          <dc:subject xml:lang="en">T-Lymphocytes, Regulatory</dc:subject>
          <dc:title xml:lang="en">Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12808</identifier>
        <datestamp>2025-10-24T20:49:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bernasconi L</dc:creator>
          <dc:creator>Ramenzoni LL</dc:creator>
          <dc:creator>Al-Majid A</dc:creator>
          <dc:creator>Tini GM</dc:creator>
          <dc:creator>Graber SM</dc:creator>
          <dc:creator>Schmidlin PR</dc:creator>
          <dc:creator>Irani S</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
To determine whether bronchial colonisations/infections with periodontopathogenic bacteria are associated with elevated inflammatory markers such as MMPs, interleukins and Tumor necrosis factor alpha in the bronchial fluid.


METHODS
Periodontal status was assessed in consecutive outpatients planned for elective bronchoscopies, and PCR for periodontopathogenic bacteria was performed from a protected specimen brush sample taken from the bronchial mucosa. Additionally, MMPs, interleukins and Tumor necrosis factor alpha were measured in the bronchial fluid.


RESULTS
Out of the four species assessed, one species was found in 13 of 91 (14%) patients, and two in 12 (13%), three in 13 (14%) and all four in 1 (1%) patient, respectively. In multiple linear regression models the presence of Treponema denticola showed a consistent pattern of positive effects in bronchial fluid (Bonferroni adjusted p-values) on the levels of MMP9 (p adj.: 0.028) and MMP12 (p adj.: 0.029). Active smoking was independently associated with increased levels of aMMP8 (p adj.: 0.005) and MMP9 (p adj.: 0.009). Levels of IL-1 ß, IL-8 and Tumor necrosis factor alpha measured in the bronchial fluid were not affected by the presence of periodontopathogenic bacteria.


CONCLUSIONS
Bronchial colonisation/infection with Treponema denticola and smoking are independently associated with elevated MMPs (MMP9/MMP12 and MMP8/MMP9, respectively) in the bronchial fluid.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12808</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0144461</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26656474</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>PloS one. - 2015</dc:source>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Bronchi</dc:subject>
          <dc:subject xml:lang="en">Bronchoalveolar Lavage Fluid</dc:subject>
          <dc:subject xml:lang="en">Bronchoscopy</dc:subject>
          <dc:subject xml:lang="en">Cross-Sectional Studies</dc:subject>
          <dc:subject xml:lang="en">Cytokines</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Matrix Metalloproteinase 12</dc:subject>
          <dc:subject xml:lang="en">Matrix Metalloproteinase 8</dc:subject>
          <dc:subject xml:lang="en">Matrix Metalloproteinase 9</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Periodontal Pocket</dc:subject>
          <dc:subject xml:lang="en">Periodontitis</dc:subject>
          <dc:subject xml:lang="en">Respiratory Mucosa</dc:subject>
          <dc:subject xml:lang="en">Smoking</dc:subject>
          <dc:subject xml:lang="en">Treponema denticola</dc:subject>
          <dc:title xml:lang="en">Elevated Matrix Metalloproteinase Levels in Bronchi Infected with Periodontopathogenic Bacteria.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12828</identifier>
        <datestamp>2025-10-24T20:49:36Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Beyer T</dc:creator>
          <dc:creator>Lassen ML</dc:creator>
          <dc:creator>Boellaard R</dc:creator>
          <dc:creator>Delso G</dc:creator>
          <dc:creator>Yaqub M</dc:creator>
          <dc:creator>Sattler B</dc:creator>
          <dc:creator>Quick HH</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
We assess inter- and intra-subject variability of magnetic resonance (MR)-based attenuation maps (MRμMaps) of human subjects for state-of-the-art positron emission tomography (PET)/MR imaging systems.


MATERIALS AND METHODS
Four healthy male subjects underwent repeated MR imaging with a Siemens Biograph mMR, Philips Ingenuity TF and GE SIGNA PET/MR system using product-specific MR sequences and image processing algorithms for generating MRμMaps. Total lung volumes and mean attenuation values in nine thoracic reference regions were calculated. Linear regression was used for comparing lung volumes on MRμMaps. Intra- and inter-system variability was investigated using a mixed effects model.


RESULTS
Intra-system variability was seen for the lung volume of some subjects, (p = 0.29). Mean attenuation values across subjects were significantly different (p &lt; 0.001) due to different segmentations of the trachea. Differences in the attenuation values caused noticeable intra-individual and inter-system differences that translated into a subsequent bias of the corrected PET activity values, as verified by independent simulations.


CONCLUSION
Significant differences of MRμMaps generated for the same subjects but different PET/MR systems resulted in differences in attenuation correction factors, particularly in the thorax. These differences currently limit the quantitative use of PET/MR in multi-center imaging studies.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12828</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s10334-015-0505-4</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26739263</dc:relation>
          <dc:source>Magma (New York, N.Y.). - 2016</dc:source>
          <dc:subject xml:lang="en">Accuracy</dc:subject>
          <dc:subject xml:lang="en">Combined PET/MR</dc:subject>
          <dc:subject xml:lang="en">MR-based attenuation correction</dc:subject>
          <dc:subject xml:lang="en">Reproducibility</dc:subject>
          <dc:subject xml:lang="en">Whole-body hybrid imaging</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Algorithms</dc:subject>
          <dc:subject xml:lang="en">Computer Simulation</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Image Processing, Computer-Assisted</dc:subject>
          <dc:subject xml:lang="en">Lung</dc:subject>
          <dc:subject xml:lang="en">Magnetic Resonance Imaging</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Multimodal Imaging</dc:subject>
          <dc:subject xml:lang="en">Positron-Emission Tomography</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Whole Body Imaging</dc:subject>
          <dc:title xml:lang="en">Investigating the state-of-the-art in whole-body MR-based attenuation correction: an intra-individual, inter-system, inventory study on three clinical PET/MR systems.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12836</identifier>
        <datestamp>2025-10-24T20:49:36Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Wettstein MS</dc:creator>
          <dc:creator>Poyet C</dc:creator>
          <dc:creator>Grossmann NC</dc:creator>
          <dc:creator>Fankhauser CD</dc:creator>
          <dc:creator>Keller EX</dc:creator>
          <dc:creator>Kozomara M</dc:creator>
          <dc:creator>Meyer S</dc:creator>
          <dc:creator>Sulser T</dc:creator>
          <dc:creator>Müller A</dc:creator>
          <dc:creator>Hermanns T</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">PURPOSE
To assess whether and to what extent irrigation fluid absorption occurs during laser vaporization (LV) of the prostate using the 180 W XPS™ GreenLight laser.


METHODS
This prospective investigation was performed in a tertiary care center with a consecutive series of patients undergoing 180 W LV of the prostate. Intraoperative irrigation was performed with isotonic saline containing 1 % ethanol. The volume of irrigation fluid absorption was calculated from periodically performed breath ethanol measurements during LV. Additionally, intraoperative changes in biochemical and hematological blood parameters were assessed.


RESULTS
Positive breath ethanol tests were detectable in 22 of 54 patients. The median absorption volume in these patients was 950 ml (range 208-4579 ml). Ten patients absorbed more than 2000 ml. Absorbers had smaller prostates, more capsular perforations and injuries to venous sinuses, and more total energy was applied with higher output power. Five patients had transient symptoms potentially related to fluid absorption. A significant drop in hemoglobin, hematocrit, venous pH and bicarbonate and an increase in chloride were detectable in the absorber group. These changes were significantly different in the non-absorber group.


CONCLUSIONS
Absorption of irrigation fluid did occur in a relevant proportion of patients undergoing XPS™ GreenLight LV. High-volume absorption (≥2000 ml), which might be clinically relevant, was detectable in almost 20 % of all procedures. Absorption of saline irrigation fluid does not result in a classical TUR syndrome, but fluid and chloride overload can lead to serious complications, particularly in cardiovascular high-risk patients. Thus, patients with symptoms potentially related to fluid absorption should be monitored carefully.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12836</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00345-016-1766-x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26780733</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>World journal of urology. - 2016</dc:source>
          <dc:subject xml:lang="en">Ethanol</dc:subject>
          <dc:subject xml:lang="en">Intraoperative complications</dc:subject>
          <dc:subject xml:lang="en">Laser therapy</dc:subject>
          <dc:subject xml:lang="en">Prostate</dc:subject>
          <dc:subject xml:lang="en">Therapeutic irrigation</dc:subject>
          <dc:subject xml:lang="en">Absorption, Physiological</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Breath Tests</dc:subject>
          <dc:subject xml:lang="en">Ethanol</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intraoperative Complications</dc:subject>
          <dc:subject xml:lang="en">Laser Therapy</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Prostatectomy</dc:subject>
          <dc:subject xml:lang="en">Sodium Chloride</dc:subject>
          <dc:subject xml:lang="en">Therapeutic Irrigation</dc:subject>
          <dc:title xml:lang="en">Absorption of irrigation fluid during XPS™ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12882</identifier>
        <datestamp>2025-10-24T20:49:40Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Meo M</dc:creator>
          <dc:creator>Meste O</dc:creator>
          <dc:creator>Signore S</dc:creator>
          <dc:creator>Sorrentino A</dc:creator>
          <dc:creator>Cannata A</dc:creator>
          <dc:creator>Zhou Y</dc:creator>
          <dc:creator>Matsuda A</dc:creator>
          <dc:creator>Luciani M</dc:creator>
          <dc:creator>Kannappan R</dc:creator>
          <dc:creator>Goichberg P</dc:creator>
          <dc:creator>Leri A</dc:creator>
          <dc:creator>Anversa P</dc:creator>
          <dc:creator>Rota M</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Diabetes is associated with prolongation of the QT interval of the electrocardiogram and enhanced dispersion of ventricular repolarization, factors that, together with atherosclerosis and myocardial ischemia, may promote the occurrence of electrical disorders. Thus, we tested the possibility that alterations in transmembrane ionic currents reduce the repolarization reserve of myocytes, leading to action potential (AP) prolongation and enhanced beat-to-beat variability of repolarization.


METHODS AND RESULTS
Diabetes was induced in mice with streptozotocin (STZ), and effects of hyperglycemia on electrical properties of whole heart and myocytes were studied with respect to an untreated control group (Ctrl) using electrocardiographic recordings in vivo, ex vivo perfused hearts, and single-cell patch-clamp analysis. Additionally, a newly developed algorithm was introduced to obtain detailed information of the impact of high glucose on AP profile. Compared to Ctrl, hyperglycemia in STZ-treated animals was coupled with prolongation of the QT interval, enhanced temporal dispersion of electrical recovery, and susceptibility to ventricular arrhythmias, defects observed, in part, in the Akita mutant mouse model of type I diabetes. AP was prolonged and beat-to-beat variability of repolarization was enhanced in diabetic myocytes, with respect to Ctrl cells. Density of Kv K(+) and L-type Ca(2+) currents were decreased in STZ myocytes, in comparison to cells from normoglycemic mice. Pharmacological reduction of Kv currents in Ctrl cells lengthened AP duration and increased temporal dispersion of repolarization, reiterating features identified in diabetic myocytes.


CONCLUSIONS
Reductions in the repolarizing K(+) currents may contribute to electrical disturbances of the diabetic heart.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12882</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1161/JAHA.115.003078</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26896476</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of the American Heart Association. - 2016</dc:source>
          <dc:subject xml:lang="en">diabetes</dc:subject>
          <dc:subject xml:lang="en">electrophysiology</dc:subject>
          <dc:subject xml:lang="en">repolarization</dc:subject>
          <dc:subject xml:lang="en">variability</dc:subject>
          <dc:subject xml:lang="en">Action Potentials</dc:subject>
          <dc:subject xml:lang="en">Algorithms</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Arrhythmias, Cardiac</dc:subject>
          <dc:subject xml:lang="en">Blood Glucose</dc:subject>
          <dc:subject xml:lang="en">Diabetes Mellitus, Experimental</dc:subject>
          <dc:subject xml:lang="en">Diabetic Cardiomyopathies</dc:subject>
          <dc:subject xml:lang="en">Electrocardiography</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Heart Rate</dc:subject>
          <dc:subject xml:lang="en">Kinetics</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">Myocytes, Cardiac</dc:subject>
          <dc:subject xml:lang="en">Patch-Clamp Techniques</dc:subject>
          <dc:subject xml:lang="en">Potassium</dc:subject>
          <dc:subject xml:lang="en">Potassium Channels</dc:subject>
          <dc:subject xml:lang="en">Signal Processing, Computer-Assisted</dc:subject>
          <dc:title xml:lang="en">Reduction in Kv Current Enhances the Temporal Dispersion of the Action Potential in Diabetic Myocytes: Insights From a Novel Repolarization Algorithm.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12914</identifier>
        <datestamp>2025-10-24T20:49:42Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ziv C</dc:creator>
          <dc:creator>Malitsky S</dc:creator>
          <dc:creator>Othman A</dc:creator>
          <dc:creator>Ben-Dor S</dc:creator>
          <dc:creator>Wei Y</dc:creator>
          <dc:creator>Zheng S</dc:creator>
          <dc:creator>Aharoni A</dc:creator>
          <dc:creator>Hornemann T</dc:creator>
          <dc:creator>Vardi A</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">Marine viruses are the most abundant biological entities in the oceans shaping community structure and nutrient cycling. The interaction between the bloom-forming alga Emiliania huxleyi and its specific large dsDNA virus (EhV) is a major factor determining the fate of carbon in the ocean, thus serving as a key host-pathogen model system. The EhV genome encodes for a set of genes involved in the de novo sphingolipid biosynthesis, not reported in any viral genome to date. We combined detailed lipidomic and biochemical analyses to characterize the functional role of this virus-encoded pathway during lytic viral infection. We identified a major metabolic shift, mediated by differential substrate specificity of virus-encoded serine palmitoyltransferase, a key enzyme of sphingolipid biosynthesis. Consequently, unique viral glycosphingolipids, composed of unusual hydroxylated C17 sphingoid bases (t17:0) were highly enriched in the infected cells, and their synthesis was found to be essential for viral assembly. These findings uncover the biochemical bases of the virus-induced metabolic rewiring of the host sphingolipid biosynthesis during the chemical "arms race" in the ocean.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12914</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1073/pnas.1523168113</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26984500</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Proceedings of the National Academy of Sciences of the United States of America. - 2016</dc:source>
          <dc:subject xml:lang="en">Emiliania huxelyi</dc:subject>
          <dc:subject xml:lang="en">algal blooms</dc:subject>
          <dc:subject xml:lang="en">marine viruses</dc:subject>
          <dc:subject xml:lang="en">serine palmitoyltransferase</dc:subject>
          <dc:subject xml:lang="en">sphingolipids</dc:subject>
          <dc:subject xml:lang="en">DNA Viruses</dc:subject>
          <dc:subject xml:lang="en">Eutrophication</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation, Viral</dc:subject>
          <dc:subject xml:lang="en">Glycosphingolipids</dc:subject>
          <dc:subject xml:lang="en">Haptophyta</dc:subject>
          <dc:subject xml:lang="en">Host-Pathogen Interactions</dc:subject>
          <dc:subject xml:lang="en">Hydroxylation</dc:subject>
          <dc:subject xml:lang="en">Plant Diseases</dc:subject>
          <dc:subject xml:lang="en">Serine C-Palmitoyltransferase</dc:subject>
          <dc:subject xml:lang="en">Sphingolipids</dc:subject>
          <dc:subject xml:lang="en">Viral Proteins</dc:subject>
          <dc:title xml:lang="en">Viral serine palmitoyltransferase induces metabolic switch in sphingolipid biosynthesis and is required for infection of a marine alga.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12919</identifier>
        <datestamp>2025-10-24T20:49:42Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Jentzsch T</dc:creator>
          <dc:creator>Rahm S</dc:creator>
          <dc:creator>Seifert B</dc:creator>
          <dc:creator>Farei-Campagna J</dc:creator>
          <dc:creator>Werner CM</dc:creator>
          <dc:creator>Bouaicha S</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">PURPOSE
To investigate the association between arthroscopy simulator performance and video game skills.


METHODS
This study compared the performances of 30 volunteers without experience performing arthroscopies in 3 different tasks of a validated virtual reality knee arthroscopy simulator with the video game experience using a questionnaire and actual performances in 5 different 2- and 3-dimensional (D) video games of varying genres on 2 different platforms.


RESULTS
Positive correlations between knee arthroscopy simulator and video game performances (ρ = 0.63, P &lt; .001) as well as experiences (ρ = 0.50, P = .005) were found. The strongest correlations were found for the task of catching (hooking) 6 foreign bodies (virtual rings; "triangulation") and the dribbling performance in a sports game and a first-person shooter game, as well as the meniscus resection and a tile-matching puzzle game (all ρ ≥ 0.60, P &lt; .001). No correlations were found for any of the knee arthroscopy simulator tasks and a strategy game.


CONCLUSIONS
Although knee arthroscopy performances do not correlate with 2-D strategy video game skills, they show a correlation with 2-D tile-matching puzzle games only for easier tasks with a rather limited focus, and highly correlate with 3-D sports and first-person shooter video games. These findings show that experienced and good 3-D gamers are better arthroscopists than nonexperienced and poor 3-D gamers.


LEVEL OF EVIDENCE
Level II, observational cross-sectional study.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12919</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.arthro.2015.12.047</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27006104</dc:relation>
          <dc:source>Arthroscopy : the journal of arthroscopic &amp; related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. - 2016</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Arthroscopy</dc:subject>
          <dc:subject xml:lang="en">Computer Simulation</dc:subject>
          <dc:subject xml:lang="en">Cross-Sectional Studies</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Knee Joint</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Simulation Training</dc:subject>
          <dc:subject xml:lang="en">Video Games</dc:subject>
          <dc:title xml:lang="en">Correlation Between Arthroscopy Simulator and Video Game Performance: A Cross-Sectional Study of 30 Volunteers Comparing 2- and 3-Dimensional Video Games.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12803</identifier>
        <datestamp>2025-10-24T20:49:43Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>O'Neill F</dc:creator>
          <dc:creator>Riwanto M</dc:creator>
          <dc:creator>Charakida M</dc:creator>
          <dc:creator>Colin S</dc:creator>
          <dc:creator>Manz J</dc:creator>
          <dc:creator>McLoughlin E</dc:creator>
          <dc:creator>Khan T</dc:creator>
          <dc:creator>Klein N</dc:creator>
          <dc:creator>Kay CW</dc:creator>
          <dc:creator>Patel K</dc:creator>
          <dc:creator>Chinetti G</dc:creator>
          <dc:creator>Staels B</dc:creator>
          <dc:creator>D'Aiuto F</dc:creator>
          <dc:creator>Landmesser U</dc:creator>
          <dc:creator>Deanfield J</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
HDL functionality has been shown to be impaired in inflammatory conditions, including coronary artery disease. The present study aims to determine the impact of low grade and acute inflammation on HDL function and structure.


APPROACH AND RESULTS
i) The endothelial protective effects of HDL were compared between 26 periodontal patients and 26 age and sex matched controls by measuring paraoxonase activity in serum and nitric oxide bioavailability and superoxide production in endothelial cells. Paraoxonase activity and nitric oxide bioavailability were reduced, while superoxide production was increased (p&lt;0.01) in periodontal patients compared to controls. ii) HDL function, including cholesterol efflux and vascular cell adhesion molecule-1 expression, was subsequently measured in the periodontal patients following an inflammatory stimulus. There was an acute deterioration in HDL's endothelial protective function, without change in cholesterol efflux, after 24h (p&lt;0.01 for all). These functional changes tracked increases of inflammatory markers and altered HDL composition. Finally, HDL function returned to baseline levels after resolution of inflammation.


CONCLUSION
This study demonstrates that even minor alterations in systemic inflammation can impair the endothelial protective effects of HDL. These functional changes were independent of cholesterol efflux and were associated with remodeling of the HDL proteome. All measures of HDL's endothelial protective functions recovered with resolution of inflammation. These findings suggest that HDL dysfunction may represent a novel mechanism linking inflammation with progression of atheroma.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12803</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijcard.2015.03.058</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25919891</dc:relation>
          <dc:source>International journal of cardiology. - 2015</dc:source>
          <dc:subject xml:lang="en">Atherosclerosis</dc:subject>
          <dc:subject xml:lang="en">High-density lipoprotein</dc:subject>
          <dc:subject xml:lang="en">Inflammation</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aryldialkylphosphatase</dc:subject>
          <dc:subject xml:lang="en">Case-Control Studies</dc:subject>
          <dc:subject xml:lang="en">Chronic Disease</dc:subject>
          <dc:subject xml:lang="en">Endothelial Cells</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Inflammation</dc:subject>
          <dc:subject xml:lang="en">Inflammation Mediators</dc:subject>
          <dc:subject xml:lang="en">Lipoproteins, HDL</dc:subject>
          <dc:subject xml:lang="en">Longitudinal Studies</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Nitric Oxide</dc:subject>
          <dc:subject xml:lang="en">Periodontitis</dc:subject>
          <dc:subject xml:lang="en">Severity of Illness Index</dc:subject>
          <dc:subject xml:lang="en">Time Factors</dc:subject>
          <dc:subject xml:lang="en">Vascular Cell Adhesion Molecule-1</dc:subject>
          <dc:title xml:lang="en">Structural and functional changes in HDL with low grade and chronic inflammation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12817</identifier>
        <datestamp>2025-10-24T20:49:45Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Starck CT</dc:creator>
          <dc:creator>Steffel J</dc:creator>
          <dc:creator>Caliskan E</dc:creator>
          <dc:creator>Holubec T</dc:creator>
          <dc:creator>Schoenrath F</dc:creator>
          <dc:creator>Maisano F</dc:creator>
          <dc:creator>Falk V</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">AIMS
We investigated the safety and efficacy of a new bidirectional rotational mechanical extraction sheath (Evolution RL, Cook Medical, USA).


METHODS AND RESULTS
From April 2013 until September 2014, we performed lead extraction procedures in 71 patients with 112 leads scheduled for extraction. During this time period, we used the new Evolution RL rotational sheath in 40 patients on 52 leads (24 pacemaker leads and 28 implantable cardioverter-defibrillator leads) scheduled for extraction. The mean lead implant duration in these patients was 100.2 (22-271) months. Forty leads were right ventricular leads, 10 right atrial leads, and 2 coronary sinus leads. Clinical success among the leads approached with the Evolution RL device was 98.1%. Operative mortality was zero. Major complications did not occur. Four minor complications were encountered (all pocket haematomas). No device-related complications were noted. In cases with multiple leads in situ, no wrapping of companion leads was seen. The average number of extraction tools used per lead was 2.4 (2-4) in the Evolution RL cohort.


CONCLUSION
Based on the presented results of our initial experience with the new bidirectional rotational mechanical extraction device, its use is safe and efficient with high success rates in long implanted leads.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12817</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/europace/euv126</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25995394</dc:relation>
          <dc:source>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. - 2016</dc:source>
          <dc:subject xml:lang="en">ICD</dc:subject>
          <dc:subject xml:lang="en">Lead extraction</dc:subject>
          <dc:subject xml:lang="en">Pacemaker</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Cardiac Catheterization</dc:subject>
          <dc:subject xml:lang="en">Cardiac Catheters</dc:subject>
          <dc:subject xml:lang="en">Defibrillators, Implantable</dc:subject>
          <dc:subject xml:lang="en">Device Removal</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Pacemaker, Artificial</dc:subject>
          <dc:subject xml:lang="en">Prosthesis Design</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Clinical performance of a new bidirectional rotational mechanical lead extraction sheath.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12820</identifier>
        <datestamp>2025-10-24T20:49:45Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Schörg A</dc:creator>
          <dc:creator>Santambrogio S</dc:creator>
          <dc:creator>Platt JL</dc:creator>
          <dc:creator>Schödel J</dc:creator>
          <dc:creator>Lindenmeyer MT</dc:creator>
          <dc:creator>Cohen CD</dc:creator>
          <dc:creator>Schrödter K</dc:creator>
          <dc:creator>Mole DR</dc:creator>
          <dc:creator>Wenger RH</dc:creator>
          <dc:creator>Hoogewijs D</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">A crucial step in the cellular adaptation to oxygen deficiency is the binding of hypoxia-inducible factors (HIFs) to hypoxia response elements (HREs) of oxygen-regulated genes. Genome-wide HIF-1α/2α/β DNA-binding studies revealed that the majority of HREs reside distant to the promoter regions, but the function of these distal HREs has only been marginally studied in the genomic context. We used chromatin immunoprecipitation (ChIP), gene editing (TALEN) and chromosome conformation capture (3C) to localize and functionally characterize a 82 kb upstream HRE that solely drives oxygen-regulated expression of the newly identified HIF target gene PAG1. PAG1, a transmembrane adaptor protein involved in Src signalling, was hypoxically induced in various cell lines and mouse tissues. ChIP and reporter gene assays demonstrated that the -82 kb HRE regulates PAG1, but not an equally distant gene further upstream, by direct interaction with HIF. Ablation of the consensus HRE motif abolished the hypoxic induction of PAG1 but not general oxygen signalling. 3C assays revealed that the -82 kb HRE physically associates with the PAG1 promoter region, independent of HIF-DNA interaction. These results demonstrate a constitutive interaction between the -82 kb HRE and the PAG1 promoter, suggesting a physiologically important rapid response to hypoxia.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12820</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/nar/gkv506</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26007655</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Nucleic acids research. - 2015</dc:source>
          <dc:subject xml:lang="en">Adaptor Proteins, Signal Transducing</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Basic Helix-Loop-Helix Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Cell Hypoxia</dc:subject>
          <dc:subject xml:lang="en">Cell Line</dc:subject>
          <dc:subject xml:lang="en">Chromatin</dc:subject>
          <dc:subject xml:lang="en">HeLa Cells</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypoxia-Inducible Factor 1</dc:subject>
          <dc:subject xml:lang="en">Membrane Proteins</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">Phosphoproteins</dc:subject>
          <dc:subject xml:lang="en">Promoter Regions, Genetic</dc:subject>
          <dc:subject xml:lang="en">Response Elements</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:subject xml:lang="en">Transcriptional Activation</dc:subject>
          <dc:subject xml:lang="en">src-Family Kinases</dc:subject>
          <dc:title xml:lang="en">Destruction of a distal hypoxia response element abolishes trans-activation of the PAG1 gene mediated by HIF-independent chromatin looping.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12842</identifier>
        <datestamp>2025-10-24T20:49:47Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Paanalahti K</dc:creator>
          <dc:creator>Wertli MM</dc:creator>
          <dc:creator>Held U</dc:creator>
          <dc:creator>Åkerstedt T</dc:creator>
          <dc:creator>Holm LW</dc:creator>
          <dc:creator>Nordin M</dc:creator>
          <dc:creator>Skillgate E</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">PURPOSE
The estimated prevalence of poor sleep in patients with non-specific chronic low back pain is estimated to 64% in the adult population. The annual cost for musculoskeletal pain and reported poor sleep is estimated to be billions of dollars annually in the US. The aim of this cohort study with one-year follow-up was to explore the role of impaired sleep with daytime consequence on the prognosis of non-specific neck and/or back pain.


METHODS
Secondary analysis of a randomized controlled trial, including 409 patients.


RESULTS
Patients with good sleep at baseline were more likely to experience a minimal clinically important difference in pain [OR 2.03 (95% CI 1.22-3.38)] and disability [OR 1.85 (95% CI 1.04-3.30)] compared to patients with impaired sleep at one-year follow-up.


CONCLUSION
Patients with non-specific neck and/or back pain and self-reported good sleep are more likely to experience a minimal clinically important difference in pain and disability compared to patients with impaired sleep with daytime consequence.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12842</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00586-015-3987-x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/26063054</dc:relation>
          <dc:source>European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. - 2016</dc:source>
          <dc:subject xml:lang="en">Back pain</dc:subject>
          <dc:subject xml:lang="en">Impaired sleep</dc:subject>
          <dc:subject xml:lang="en">Naprapathy</dc:subject>
          <dc:subject xml:lang="en">Neck pain</dc:subject>
          <dc:subject xml:lang="en">Spinal pain</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Back Pain</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Disability Evaluation</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Longitudinal Studies</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Musculoskeletal Manipulations</dc:subject>
          <dc:subject xml:lang="en">Neck Pain</dc:subject>
          <dc:subject xml:lang="en">Pain Measurement</dc:subject>
          <dc:subject xml:lang="en">Prognosis</dc:subject>
          <dc:subject xml:lang="en">Sleep Wake Disorders</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Spinal pain--good sleep matters: a secondary analysis of a randomized controlled trial.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <resumptionToken expirationDate="2026-11-03T07:37:58Z" cursor="0" completeListSize="324439">.eJyN0EFzojAYxvHvkrOzkwBOxZke1tWA7CpNwCTk0omEAksAFVwpnX73Otueq-_9_c0z_zfQZZkGc_hjimzHnboP0LZnFkQPE3BQeQbm1gRUF3XKOzB_A3XWK6169XTKXsoBzEGrymedgvcJ6NJTa8xzecUA9sw5sQYkPfaSWO5Ze8zR2EWam2rZYCRFMGVeYfaVNNrbtr8WCSQjDoSNRchInzD3-EeYKl7mKNzJ5uf_e62FDXmEF2P6d-PQ6hCHfIUInE3p6tBd_896kL8zw5ytF3QSU2dr2FEzM-68voyXkn46MG8cwimTRSiKOlqxXVzjZGPpKBHEyvw1vDplDAuf8sslNlRszRpJKBtSo0rihf21B6dPa87q4F805q977FLl41HyXsk6OMZ-ahF6r0NuOPf2cW71GXgTtJKliLAAa37AKWSR8lm7h8VXn7HcmBlPBenlii1SqCPNmaBxIMMlRVk9BPJux7nl3Nln830f8vgI3j8AF1fq_A.aumPGg.3MSG93aYZEtQC2mGGN-QCFWy4Yc</resumptionToken>
  </ListRecords>
</OAI-PMH>
